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Abstract 
 
Aim 
The aim of our study was to compare toxicities, response rates and survival 
outcomes in patients with HIV-associated lymphoma treated with chemotherapy 
according to whether patients received protease inhibitor (PI) or non-PI based 
combination antiretroviral therapy (cART). 
 
Methods  
A retrospective study, which included HIV-infected patients on cART receiving 
chemotherapy for non-Hodgkin and Hodgkin lymphoma between 2003 and 2010 at a 
single institution. We compared differences in adverse effects between patients on PI 
and non-PI based cART. Differences in response rates, overall survival (OS) and 
disease free survival (DFS) were investigated.  
 
Results 
A total of 53 patients were included, with 47% and 53% were on PI and non-PI based 
cART, respectively.  Median baseline CD4 cell count value for all 53 patients were 
273 cells/μL (range 14-970). Baseline HIV viral load (VL) was undetectable (<50 
copies/mL) in 15 (28%) of patients. PI-based cART was significantly associated with 
more grade 3-4 neurotoxicity  (OR= 11.42, 95% CI 1.7-76.49, p-value=0.012) and 
grade 3-4 infections (OR=14.08, 95% CI 2.13-93.07, p-value=0.006). Patients on 
non-PI based cART were more likely to complete their stage appropriate 
chemotherapy treatment compared to those on PI-based cART (p-value=0.023), but 
there were no differences in response rates, OS or DFS between the two groups. 
 
Conclusion 
This study demonstrated that PI-based cART was significantly associated with more 
treatment related toxicities compared to non-PI based cART in HIV-patients with 
lymphoma undergoing chemotherapy. If appropriate, non-PI based cART should be 
considered during chemotherapy to minimise toxicities.  
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Chapter 1: Introduction and literature review 
1.1  Background 
Human immunodeficiency virus (HIV) and malignancies have been linked since the 
early 1980s, when Kaposi’s sarcoma (KS) was described in young homosexual men 
who also had concomitant symptoms of severe immunosuppression, a condition that 
was subsequently known as acquired immunodeficiency syndrome (AIDS)(1). In 
addition to KS, HIV-infected individuals are also at an increased risk of developing 
high-grade B-cell non-Hodgkin lymphoma (NHL) and invasive carcinoma of the 
cervix(1-3). Hence, KS, NHL and invasive carcinoma of the cervix are known as 
AIDS-defining cancers.  
 
Other cancers like Hodgkin lymphoma (HL) and anal carcinoma, although not 
classified as AIDS-defining cancers, occur at increased frequency in HIV-infected 
patients(2, 4-6). They are referred to as Non-AIDS defining cancers (NADC). 
 
The management of HIV-infected patients with these cancers is frequently 
complicated by treatment-induced immunosuppression (e.g. prolonged neutropenia), 
co-morbid disease (e.g. opportunistic infections) and drug interactions (e.g. 
chemotherapy and antiretroviral therapy)(7).  
 
Malignancy accounts for one third of deaths in patients living with HIV, and HIV-
associated lymphomas are the most common cause of malignancy-related death in 
HIV-infected patients(8).  Most of the HIV-associated lymphomas are high-grade B-
cell lymphomas and characterized by their aggressive nature(9, 10).  They include 
lymphomas that occur in HIV-negative patients as well as others that occur due to 
the HIV-infection and severe immunosuppression.  
 
The most common HIV-associated B-cell non-Hodgkin lymphomas are diffuse large 
B-cell lymphoma (DLBCL), primary central nervous system lymphoma (PCNSL) and 
Burkitt lymphoma (BL). These lymphoma types are included in the World Health 
Organization’s (WHO) classification of HIV-associated lymphomas (11).  
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Classic Hodgkin lymphoma, although occurs less frequently than NHL, is still 
categorized as HIV-associated lymphoma, along with other lymphomas like primary 
effusion lymphoma (PEL) and plasmablastic lymphoma(PBL)(11, 12).  See Table 1-1 
for WHO classification of HIV-associated lymphomas. 
 
Table 1-1 Categories of HIV-associated lymphoma: WHO classification 
Lymphomas also occurring in immunocompetent patients 
 Burkitt lymphoma 
 Classic 
 With plasmacytoid differentiation  
 Atypical 
 Diffuse large B-cell lymphoma 
 Centroblastic 
 Immunoblastic 
 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid 
tissue lymphoma (rare) 
 Peripheral T-cell lymphoma (rare) 
 Classic Hodgkin lymphoma 
Lymphomas occulting more specially in patients who are HIV positive 
 Primary effusion lymphoma 
 Plasmablastic lymphoma of the oral cavity 
Lymphomas occurring in other immunodeficiency states  
 Polymorphic B-cell lymphoma (post transplant lymphoproliferative disorder)  
 
1.2 HIV-associated non-Hodgkin lymphoma (NHL) 
CNS and systemic non-Hodgkin lymphoma have been associated with HIV-infection 
since the beginning of the AIDS epidemic. The incidence of each increases 
dramatically with low CD4-cell counts, high HIV viral load (VL), age and advanced 
immunodeficiency(3). NHL remains the second most common AIDS-defining cancer 
in HIV-infected patients after KS(13).  
 
HIV-infected patients have at least 100-fold increased incidence of NHL compared to 
HIV-negative individuals, the disease is usually widespread and aggressive(14). 
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Furthermore, CNS involvement with lymphoma occurs in up to 20% of patients(15, 
16).  The introduction of combination antiretroviral therapy (cART) has reduced the 
incidence of HIV-associated NHL, although it still remains a major cause of morbidity 
and mortality in HIV-infected patients (16, 17).  DLBCL and BL are the most common 
forms of HIV-associated NHL, about 90% of cases(13). 
 
1.2.1 HIV-associated diffuse large B-cell non-Hodgkin 
lymphoma (DLBCL) 
In the pre-cART era, HIV-associated DLBCL was associated with poor outcomes and 
a median overall survival (OS) of only 6 months(18). This was due to chemotherapy 
failure driven by the high rate of opportunistic infections (OIs) and the high relapse 
rate. Because of AIDS, many HIV-infected patients had poor performance status at 
the start of their chemotherapy, with low CD4 counts of <100 cells/µL and high HIV-
VL, which meant that they could not tolerate the standard and intense dose 
chemotherapy necessary to treat aggressive lymphomas, resulting in very poor 
survival outcomes. It was clear that improvements in survival outcomes would require 
not only antineoplastic intervention, but also control of the underlying HIV infection. 
 
1.2.1.1 Treatment of HIV-DLBCL in the pre-cART era 
In an attempt to reduce infection-related deaths and OIs, earlier chemotherapy 
studies used lower intensity chemotherapy regimens with granulocyte-macrophage 
colony stimulating-factor (GM-CSF) support.  Before the availability of protease 
inhibitors (PIs), Kaplan et al conducted a randomised controlled study which enrolled 
198 HIV-infected patients with previously untreated aggressive B-cell NHL to either 
receive standard dose of m-BACOD regimen (methotrexate, bleomycin, doxorubicin, 
cyclophosphamide, vincristine and dexamethasone) with GM-CSF support or low 
dose m-BACOD with no GM-CSF support. Complete remission (CR) rates were 52% 
in the standard dose arm vs. 41% in the low dose-arm (p=0.56), but the authors 
reported very modest median OS time of 31 weeks vs. 35 weeks in the standard 
dose arm vs. low dose arm(19).  Grade 3-4 toxicities rates were significantly higher in 
the standard dose arm vs. the low dose arm (70% vs. 51%, respectively) (p=0.08). 
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The authors concluded that the low-dose m-BACOD should be used for patients with 
HIV-associated NHL due to the lower toxicity rate but similar OS to the full dose m-
BACOD. After a close examination of the study by Kaplan et al, we can conclude that 
the reported modest survival outcomes were due to the high rate of relapse (23% in 
the low dose-arm and 40% in the standard-dose arm) and the high death rate of 91% 
during a short median follow-up time of 10.5 months. Importantly, HIV progression 
was the primary cause of death in 26% of patients in low-dose arm compared to 30% 
of patients in the standard dose arm. Therefore, the use of low-dose mBACOD may 
have resulted in lower toxicities but no benefits were seen in terms of death rates and 
survival outcomes. 
 
Vaccher et al conducted another study in the pre-cART era, they reported on their 
institution experience after treating 96 patients with HIV-associated NHL between 
1987 and 1993(20). Patients where treated with different combination chemotherapy 
approaches, but the study reported poor outcomes. The observed CR rates of 48% 
were short-lived with OS and disease free survival (DFS) of 7 and 13 months, 
respectively. CD4 cell count of less than 100 cells/µL was a poor prognostic factor.  
Results from the above studies confirmed that severe immune deficiency had an 
important role to play in the response to chemotherapy, and unless the underlying 
HIV-infected is treated, these patients will continue to have poor survival outcomes. 
 
1.2.1.2 Treatment of HIV-DLBCL in the post-cART era  
Since the advent of cART, significant improvements in the median OS of HIV-
infected patients undergoing chemotherapy have been reported (17). Although it may 
be argued that the improvements in outcomes are multi-factorial e.g. the availability 
of granulocyte colony stimulating factor (G-CSF) and broad spectrum anti-infective 
agents, ultimately cART with its effect on preserving the immune function led to 
dramatic improvements in the performance status of HIV-patients, reduction in 
infection rates and reduction of the incidence of NHL(13, 17, 21-24). The positive 
effect of cART on protecting against HIV-related NHL was also remarkable, this 
protective effect was equally evident among both the PIs and the non-nucleoside 
reverse transcriptase inhibitor (NNRTI)-based regimens(13). 
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The use of cART has also led to increased use of standard and intense dose 
chemotherapy and allowed the optimal delivery of chemotherapy, which are 
important factors when treating aggressive lymphomas in the HIV-negative 
setting(25). Furthermore, in a study by Hoffmann et al, the role of cART in controlling 
the HIV viral replication was independently associated with improvements in OS in 
patients with HIV-associated lymphomas(26).  
 
Different chemotherapy regimens have been tested for HIV-associated DLBCL. 
However, there is still some disagreement regarding the optimal regimens. Different 
institutions will use different regimens based on their interpretation of the available 
literature, but will also take their own experiences into consideration when treating 
their patients. The selection of chemotherapy regimens for HIV-associated DLBCL 
was driven by two important therapeutic questions:  
1) Should lower chemotherapy doses be used, in order to reduce immune 
suppression and treatment-related toxicities? 
2) Should rituximab be added to the chemotherapy regimen? 
 
1.2.1.2.1 Low versus standard chemotherapy doses for HIV-DLBCL 
When Fisher et al published their landmark trial in 1993; they showed very positive 
results of CHOP chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine 
and prednisone) for HIV-negative patients with high-grade NHL (27). CHOP-regimen 
became shortly after that the standard treatment approach for DLBCL in the HIV-
negative setting.  This prompted investigators to test CHOP-regimens for HIV-
associated DLBCL. However, similar to the pre-cART era, there was still concerns 
regarding the use of full dose chemotherapy in HIV-patients with lymphomas. For 
that reason, Ratner et al on behalf of the AIDS Malignancy Consortium (AMC), 
conducted a non-randomised prospective study, which enrolled 65 patients with HIV-
associated DLBCL. The first 40 patients entered the study were treated a low-dose 
modified-CHOP while the remaining 25 patients received full doses of CHOP 
combined with G-CSF(28). See Table 1-2 for details of CHOP and low-dose modified 
CHOP regimens.  All patients in the study were on cART, all received same regimen 
(stavudine, lamivudine and indinavir). Patients in the CHOP arm had higher CR rates 
when compared to patients in the low-dose modified CHOP arm (48% vs. 30%, 
respectively, p=0.04). Similar toxicity profile was reported in both arms. 
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Table 1-2 Details of CHOP and modified CHOP (Ratner et al study 2001) 
CHOP (Every 21 days) Low-dose modified CHOP (Every 21 days) 
Cyclophosphamide 750mg/m2 day 1 IV* 
Doxorubicin 50mg/m2   day 1 IV 
Vincristine 1.4mg/m2 (max 2mg) day 1 IV 
Prednisone 100mg PO day 1  day 5     
Cyclophosphamide 375mg/m2   day 1 IV 
Doxorubicin 25mg/m2      day 1 IV 
Vincristine 1.4mg/m2 (max 2mg) day 1 IV 
Prednisone 100mg PO day 1  day 5     
*IV = intravenously  
 
Mounier et al studied the effects of low dose vs. standard dose chemotherapy in HIV-
associated NHL (54% of patients had DLBCL). The authors conducted this 
randomised prospective study (NHL-HIV-93 trial) with a risk-adaptive chemotherapy 
approach(29). They enrolled 485 patients with HIV-associated NHL. Patients were 
assigned to receive chemotherapy after stratification according to an HIV-score 
based on performance status, prior AIDS illness and CD4 count <100 cells/µL (low 
risk= HIV score 0, intermediate risk = HIV-score =1, high risk = HIV score 2-3). Two 
hundred and eighteen low risk patients received either standard dose CHOP or 
ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone), 177 
intermediate risk patients received CHOP or low-dose CHOP, and 90 high risk 
patients received either low dose CHOP or VS (vincristine and steroid).  The CR rate 
was significantly better in the CHOP arm compared to the low-dose CHOP arm 
(p=0.02), but no there was no difference between the CHOP and the low-dose CHOP 
in terms of toxicity. However, ACVBP treatment was associated with more 
haematological toxicity with no benefits in response rates or 5-year OS compared to 
CHOP arm. This study started in 1993 (i.e. before cART) and ended in 1999. 
Therefore, not all patients in the study were on cART. When the authors compared 
survival between patients in the pre-cART and post-cART groups, the use of cART 
was associated with significantly better OS (p<0.001).  
 
Little et al, reported very encouraging results using standard doses of EPOCH 
infusional chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide and 
doxorubicin) infusional chemotherapy for the treatment of HIV-associated NHL (79% 
of patients had DLBCL)(30). The authors in this study used a dose-adjusted 
approach according to the nadir neutrophil counts. Six cycles of EPOCH were 
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administered to 39 patients. CR was achieved in 74% of patients, and at a median 
follow up of 53 months overall survival was 60%. cART was not administered during 
chemotherapy, but patients had to start cART immediately after finishing last cycle of 
DA-EPOCH. Results from this study completely changed the grim picture of the HIV-
associated NHL; they are in fact the best-reported outcomes in this patient population 
to date. This study showed that standard and even more intensified dosing of 
chemotherapy could be administered safely to HIV-patients.  See table 1-3 for details 
of dose adjusted EPOCH chemotherapy.  
 
From the above we can conclude that in the cART era, the administration of standard 
dose chemotherapy became feasible for HIV-patients with DLBCL leading to 
significant improvements in response and overall survival rates. Both CHOP and 
EPOCH chemotherapy regimens are effective therapeutic options in the 
management of HIV-associated DLBCL. The significant improvements that have 
been made in the treatment of HIV-associated DLBCL in the cART era, are mainly 
due to the to higher CD4 cell count at lymphoma diagnosis, and the better delivery of 
full dose chemotherapy regimens in this patient population.  
 
Table 1-3 Dose adjusted EPOCH (DA-EPOCH) 
Drug Dose Route Treatment days 
Infused agents  
Etoposide 50mg/m2/day CIV 1,2,3,4 96hours 
Doxorubicin 10mg/m2/day CIV 1,2,3,4 96hours 
Vincristine 0.4mg/m2/day§ CIV 1,2,3,4 96hours 
Bolus agents - Cyclophosphamide cycle 1 
CD4 count ≥100 cells/µL 375mg/m2 IV 5 
CD4 count <100 cells/µL 187mg/m2 IV 5 
Cyclophosphamide dose - Adjustment after cycle 1    
Nadir ANC* >0.5x 109/L 187mg above previous 
cycle (max 750mg/m2) 
IV 5 
Nadir ANC <0.5 x109/L or 
platelets < 25 x 109/L 
 187mg below previous 
cycle 
IV 5 
Prednisone 60mg/m2/day PO 1,2,3,4,5 
Filgrastim 5mcg/kg/day S.C 6 until ANC>0.5x 109/L 
§ Vincristine dose not capped, *ANC= absolute neutrophil count 
CIV= Continuous intravenous infusion, IV= Intravenous, PO= oral, S.C = subcutaneous  
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1.2.1.2.2 The use of rituximab with chemotherapy for HIV-DLBCL 
On the basis of the excellent results achieved with rituximab, anti-CD20 monoclonal 
antibody therapy, in the HIV-negative patients(31-33), plus the fact that most cases 
of HIV-associated DLBCL are CD20-positive, clinical trials have addressed the 
question of whether the addition of rituximab to CHOP or CHOP-like regimens will be 
beneficial for patients with HIV-associated DLBCL. 
 
Kaplan et al, on behalf of the AMC, conducted a randomised phase III trial(34), which 
included 149 patients with HIV-associated B-cell NHL. Patients were randomized 2:1 
to either receive a minimum of 6 cycles of R-CHOP (rituximab+ CHOP) or CHOP. All 
patients were on cART and all received prophylactic filgrastim.  The CR rate was 
higher in the R-CHOP (57%) compared to the CHOP arm (47%), without reaching 
statistical significance (p=0.147). There were no differences in OS or event free 
survival (EFS) between the two arms. The main difference between the two groups 
was in the treatment-related infectious deaths, which occurred in 15 of the patients in 
the R-CHOP arm (14%) compared to one patient in the CHOP arm (2%) (p=0.035). 
The authors concluded that the addition of rituximab (375mg/m2 on D1) to CHOP-
chemotherapy was not beneficial and was associated with more significant increased 
risk of deaths from infectious complications.  
 
A closer look at the results of the above trial, it is important to note that 9 of the 15 
deaths that occurred in the R-CHOP arms were in patients with CD4 cell count of 
<50 cells/µL. Furthermore, there were more patients with CD4 cell count <50 cells/µL 
in the R-CHOP arm, which put them at high infection risk even when on cART as 
these patients are already heavily immune suppressed. The other shortcoming of the 
trial is that the authors used maintenance rituximab, which has not been shown to be 
useful in the HIV-negative setting in patients with DLBCL. Nearly 40% of the deaths 
reported due to chemotherapy-related neutropenia in the R-CHOP arm occurred 
during or within 6 months of maintenance rituximab.  It is important to note that 
rituximab is associated with grade-4 neutropenia and also late neutropenia in the 
general population(35, 36).  
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Subsequent to the AMC study, Boue et al reported the results of a phase II study that 
included 61 patients with HIV-associated DLBCL(37). All patients were treated with 
R-CHOP every 21 days for up to six cycles. All patients were on cART, G-CSF 
support and pneumocystis jiroveci pneumonia (PJP) prophylaxis. The CR rate was 
67% and 2-year OS and 2-year EFS were 75% and 65%, respectively. The most 
common adverse effects were anaemia (32%) and febrile neutropenia (25%). Only 3 
patients presented with severe sepsis, with one case being fatal. The authors 
suggested that R-CHOP is beneficial and could be administered safely to HIV-
infected patients with DLBCL. 
 
Spina et al reported the results of three phase II trials treating 74 patients with HIV-
associated DLBCL, using rituximab with infusional CDE (cyclophosphamide, 
doxorubicin and etoposide) chemotherapy (R-CDE)(38). All patients were on cART, 
G-CSF support and PJP prophylaxis. Thirty one percent of patients developed an 
infection during their course of treatment, with 10 patients developing opportunistic 
infections. The overall CR rate was 70% and the 2-year OS was 64%.  
 
Ribera et al conducted a phase II study, which included 81 patients with HIV-
associated DLBCL(39). All patients received 6 cycles of R-CHOP, and similar to the 
above studies all patients received cART, G-CSF support and PJP prophylaxis. The 
main adverse effects were neutropenia (48% of cycles) and infections (10% of 
cycles). CR was achieved in 69% of patients, with 3-year OS of 56% and 3-year EFS 
of 77%. Despite the fact that 16 patients (20%) had a CD4 cell count of 50 cells/µL at 
diagnosis, infection-related deaths were only observed in 7 patients. The authors 
concluded that R-CHOP was both effective and safe therapeutic option in HIV-
patients with DLBCL. 
 
The AMC conducted another phase II trial, which randomised patients to receive 
either concurrent rituximab with EPOCH (rituximab given before each EPOCH dose) 
or sequential rituximab with EPOCH (weekly for 6 weeks after completion of all 
EPOCH cycles)(40). The study included a total of 110 patients (54 in the concurrent 
arm and 56 in the sequential arm); most patients (75%) had HIV-associated DLBCL.  
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The rate of cART use was 77% in the concurrent arm vs. 57% in the sequential arm. 
The CR rate was higher in the concurrent arm compared to the sequential arm (65% 
vs. 55%). Despite the high rate of patients with CD4 cell count of <100 cells/µL in 
both arms (31% in each arm), infection-related death was much lower compared to 
what have been reported in the previous AMC trial (a total of 6 infection-related 
deaths). 
 
A pooled retrospective analysis of the both the AMC trials examined whether R-
EPOCH was superior to CHOP with or without rituximab. The authors observed 
improved clinical outcomes for patients who received R-EPOCH compared to those 
who received R-CHOP, including significantly improved EFS and OS(41).  Results for 
all studies using rituximab with chemotherapy for HIV-associated DLBCL are listed in 
Table 1-4.  
 
Table 1-4 Rituximab combined with chemotherapy for patients with HIV-
associated DLBCL 
Author Intervention Sample size CR(%) 2-year OS(%) 
Boue et al, 2006 R-CHOP 
 
61 67 75 
Kaplan et  al, 2005 R-CHOP vs. 
CHOP 
149 58 vs. 47 55 
Spina et al, 2005 R-CDE 
 
74 70 64 
Ribera et al, 2008 R-CHOP 
 
81 69 56* 
Sparano et al, 2010 R-EPOCH vs. 
EPOCH then R 
106 73 vs. 55 70 vs. 67 
*3-year OS 
 
In conclusion, the addition of rituximab to chemotherapy regimens commonly used in 
the management of HIV-associated DLBCL is recommended based on the available 
evidence from all the above trials. Close monitoring of patients receiving rituximab-
based therapy is warranted, especially in patients with CD4 counts below 100 
cells/µL. All patients should be counselled regarding the risks of treatment, and the 
importance of urgent presentation for care in case of occurrence of febrile 
neutropenia. R-EPOCH and R-CHOP appear to effective and safe in the treatment of 
HIV-associated DLBCL. R-EPOCH appears to be superior according to the pooled 
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retrospective analysis of the AMC trials; however, phase III trials are required to 
confirm such results. 
  
1.2.2 HIV-associated Burkitt lymphoma (BL) 
Burkitt lymphoma (BL) is a very aggressive subtype of NHL. The WHO classifies BL 
into three types (endemic, sporadic and immunodeficiency related)(42). The last type 
is the one associated with HIV-infection. NHL accounts for up one third of the HIV-
associated malignancies, and the incidence of BL is up to 10-20% of the HIV-
associated NHL (43-45).  As mentioned before, the lack of cART and low CD4 cell 
count are independent factors for increased risk of developing HIV-associated 
NHL(13). However, the risk of HIV-associated BL appears to be independent of CD4 
cell count, and the impact of cART on the incidence of BL is not clear (12, 46). In 
fact, the incidence of HIV-associated BL have been reported to be the lowest in 
patients with CD4 count <50 cells/µL(47). 
 
1.2.2.1 Treatment of HIV-associated Burkitt lymphoma (BL) 
The management of patients with HIV-associated BL presents few therapeutic 
challenges(48): 
1- The chemotherapy regimens that are used for the treatment of BL in HIV-
negative patients are myelosuppressive intense regimens and can be 
associated with severe treatment related toxicities. Therefore, when used for 
HIV-infected patients with BL, one would expect that treatment-related 
toxicities would be even more profound. 
2- No randomised controlled trials exist for the treatment of patients HIV-
associated BL. There are relatively small numbers of HIV-associated BL 
patients reported in prospective and retrospective cohort studies. 
 
The development and the evolution of BL treatment regimens for HIV-negative 
patients date back to the 1960s &1970s(49). Intensive multi-agent chemotherapy 
built on a backbone of cyclophosphamide, vincristine and methotrexate resulted in 
high CR rates with durable long-term remissions (50, 51). The repeated use of 
intrathecal chemotherapy (IT) has also proven crucial in the prevention of central 
nervous system (CNS) relapse of BL(51). When small numbers of HIV-positive BL 
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patients were included in some of the treatment arms with HIV-negative BL patients, 
high rate of CR where achieved(52, 53). However, there was a trend towards worse 
5-year OS in the HIV patients compared to the HIV-negative patients, mainly due to 
opportunistic infections (OIs) and KS. 
 
Chemotherapy regimens used for HIV-associated BL 
In 2002, Cortes et al investigated the efficacy and tolerability of hyperfractionated 
cyclophosphamide, vincristine, doxorubicin and dexamethasone (hyper-CVAD) 
regimen concomitantly with cART for the treatment of 13 HIV-infected patients, 6 
patients with BL and n=7 with B-cell acute lymphoblastic leukaemia (B-ALL)(54).  
Only 9 out of these 13 patients received cART (7 patients were on cART before 
chemotherapy, one started with 5th cycle and one after chemotherapy was 
completed). All patients received G-CSF support, PJP prophylaxis, antifungal 
prophylaxis with fluconazole and antiviral prophylaxis with aciclovir or valaciclovir. 
The median number of chemotherapy cycles delivered was 6 (range, 3-8). Dose 
reduction or modification was required in 21% of the chemotherapy cycles, and 35% 
of cycles were complicated by fever or infections.  Grade 3-4 haematological 
toxicities were universal among all patients. Six of the 9 patients who were on cART 
at the time of chemotherapy achieved CR and remained alive at the time the study 
was published. All four patients who did not receive cART died, three patients due to 
disease progression.  
 
The same group reported improvements in response rates and OS with the addition 
of rituximab to the hyper-CVAD regimen in 31 patients (n=21 HIV-negative and n=10 
HIV-positive) with BL or B-ALL(55). The CR rate was 86% and 3-year OS was 89%. 
It is important to note that up to 45% of the 31 patients were diagnosed with B-ALL 
as opposed to BL. When reporting on 6 HIV-patients included in the above 
HyperCVAD+ rituximab study, the authors observed 3 deaths due to HIV-related 
malignancy or infection(56).  
 
The success of using CODOX-M/IVAC (dose intense cyclophosphamide, vincristine, 
doxorubicin, high dose methotrexate, high dose ifosfamide, etoposide and high dose 
cytarabine) chemotherapy regimen reported by Magrath et al in the HIV-negative 
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setting(57), has prompted clinicians to investigate the feasibility of the Magrath 
CODOX-M/IVAC regimen in HIV-infected patients with BL.  
 
In 2003, Wang et al reported on the use of CODOX-M/IVAC in HIV-infected patients 
with BL(58). They retrospectively reviewed 14 HIV-infected patients treated for BL 
between 1988 and 2000.  Eight patients were treated with CODOX-M/IVAC and 6 
patients with other less intense regimens; the rates of CR were very similar between 
the two groups (63% vs. 67%, respectively), and the rates 2-year EFS were also 
similar (57% vs. 60%, respectively). This was despite the higher percentage of high-
risk patients in the CODOX-M/IVAC cohort (88% vs. 33%). Toxicities were similar in 
the two groups, except for a higher rate of mucositis in the CODOX-M/IVAC regimen 
compared to the less intense regimen cohort (75% vs. 57%, respectively). It is 
important to note that the methotrexate dose used in the above study was the same 
as that used in the original Magrath regimen (6720mg/m2). When Wang et al 
compared all 14 HIV-BL patients to a cohort of HIV-negative patients (n=24) treated 
with similar fashion over the same period, HIV status did not affect rates of CR or 2-
year EFS. The authors concluded that CODOX-M/IVAC may overcome the high-risk 
features in HIV-BL and did not appear to be more toxic with HIV-BL compared to 
HIV-negative patients with BL. 
 
In an attempt to reduce the neurotoxicity and severe mucositis rates observed with 
the original Magrath protocol, Lacasce et al subsequently modified the CODOX-
M/IVAC regimen by reducing the methotrexate dose to 3000mg/m2, capped the 
vincristine dose, modified the schedule of cyclophophamide, increased the dose of 
doxorubicin and moved methotrexate from D10 to D15(51). This so called “modified 
Magrath” protocol is the accepted new CODOX-M/IVAC that most institutions use for 
patients with BL (both HIV-negative and positive patients), and is the regimen that is 
listed for the treatment of BL on the eviQ NSW cancer institute website(59).  
 
Rodrigo and colleagues retrospectively reviewed the use the modified Magrath 
CODOX-M/IVAC regimen with or without rituximab in 14 HIV-patients with HIV-
BL(60). Ten out of the 14 patients received rituximab with CODOX-M/IVAC. At a 
median follow up of 11.7 months, 86% of patients were alive and in remission. All the 
10 patients who received rituximab were alive and in remission at the time of the 
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publication. The authors concluded that modified Magrath CODOX-M/IVAC (using 
methotrexate 3000mg/m2) with or without rituximab was effective treatment with 
acceptable toxicity for HIV-patients with BL.  Dose adjusted EPOCH was also used in 
HIV-BL. In the study by Sparano et al, which used sequential or concurrent R-
EPOCH, 25% (27) of patients had HIV-related Burkitt or Burkitt-like lymphoma, CR 
occurred in 10 (62.5%) of the 16 patients in the concurrent arm and 9(82%) of the 11 
patients in the sequential arm(40).  
 
Evans et al, reported on their experience using R-EPOCH (n=14) and R-hyper-CVAD 
(n= 7) for patients with HIV-associated BL. CR rate was higher in the R-EPOCH 
cohort compared to the R-hyper-CVAD (71% vs. 43%, respectively)(61). Febrile 
neutropenia was observed in 29% vs. 86% in patients treated with R-EPOCH and R-
hyper-CVAD, respectively. The authors concluded that R-EPOCH was more effective 
and better tolerated than R-hyper-CVAD. Dunleavy et al also reported on the use of 
R-EPOCH in 8 newly diagnosed patients with HIV-associated BL. The authors 
observed excellent outcomes, including 100% CR rate and 96% EFS at 35 
months(62). See Table 1-5 for comparison of studies including patients with HIV-
associated BL. 
 
Table 1-5 Results of studies using chemotherapy for the treatment of patients 
with HIV-associated BL 
Author Intervention Sample size CR(%) OS/EFS 
Cortes et al, 2002 Hyper-CVAD 13 92 48% 2-year OS 
Wang et al, 2003 CODOX-M/IVAC 
MTX*= 6720mg/m2 
8 63 57% 2-year 
EFS 
Rodrigo et al, 2012 CODOX-M/IVAC+/- R 
MTX = 3000mg/m2 
14 86 86% OS at 
11.7 months 
Sparano et al, 2010 R-EPOCH 
Concurrent 
16 63 70% 2-yearOS 
Sparano et al, 2010 R-EPOCH 
Sequential 
11 82 67% 2-year OS 
Evans et al, 2011 R-EPOCH 14 71 NR§ 
Dunleavy et al, 2009 R-EPOCH 8 100 96% EFS at 35 
Months 
*MTX= Methotrexate, §NR= Not reported 
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In conclusion, intensive chemotherapy regimens like CODOX-M/IVAC used for BL in 
the HIV-negative setting could be safely administered to HIV-BL patients. This is due 
to the increased tolerance to treatment as a result of better immune function in the 
cART era. The addition of rituximab to intense chemotherapy regimens appears to be 
safe and is associated with excellent survival outcomes and response rates, which 
are comparable to those observed in HIV-negative patients(60, 63). R-EPOCH also 
seems to be a reasonable option with a good balance between safety and efficacy. 
For patients with HIV-BL who are not able to tolerate CODOX-M/IVAC or those with 
low risk disease, R-EPOCH is considered to be reasonable treatment option. HIV-
patients who have high-risk disease and are able to tolerate intensive chemotherapy, 
CODOX-M/IVAC with or without rituximab should be the standard treatment 
approach. 
 
1.2.3 Central nervous system (CNS) involvement  
CNS involvement in HIV-associated NHL is common, and is associated with poor 
prognosis (64). The incidence of CNS involvement ranges from 10-20% of 
patients(30). The risk of CNS relapse has been investigated in HIV-negative patients 
with lymphoma, which showed that the risk of CNS relapse was 5% when no 
prophylaxis was given using intrathecal (IT) chemotherapy(64). The risk of CNS 
relapse could rise to up to 20% in the presence of other prognostic factors, including 
bone marrow involvement, elevated LDH and stage IV disease. Therefore, CNS 
prophylaxis using intrathecal chemotherapy should be considered for all patients with 
Burkitt lymphoma and DLBCL patients who present with bone marrow, para-nasal, 
testicular, or widespread systemic involvement (65).  IT methotrexate, IT cytarabine 
and IT hydrocortisone are the most commonly used agents for CNS prophylaxis in 
BL and DLBCL patients. 
 
1.2.4 Primary CNS non-Hodgkin lymphoma (PCNSL) 
PCNSL occurs in HIV-infected patients who are severely immunosuppressed, with 
CD4 cell count of <50 cells/µL(66, 67). Main symptoms include headache, lethargy, 
nausea, fatigue, neurological defects, and seizures (68). In the pre-cART era 
prognosis and median OS of PCNSL was very poor, death occurring between few 
weeks and 3 months(69).  
 16 
Expectedly, the incidence of PCNSL has decreased dramatically and the overall 
survival improved significantly since the availability of cART(70). The use of cART in 
conjunction with cranial radiotherapy have been associated with improvements in 
OS, from 1.5 years up to 70 months(69, 71). In a study by Ferreri et al, which used 
systemic chemotherapy with high dose methotrexate and high-dose cytarabine in the 
HIV-negative patients with PCNSL, the rates of CR were 46% with 3-year EFS of 
38%(72). This strategy could potentially be used in HIV-infected patients with 
PCNSL, provided they are well enough to tolerate such high-doses of chemotherapy. 
The main key in improving OS in HIV-associated PCNSL seems to be the immediate 
start or the optimisation of cART, due to its positive effects on improving the immune 
function(70). 
 
1.3 HIV-associated Hodgkin lymphoma (HL) 
Although HL is not considered an AIDS-defining cancer, population-based studies 
have shown a significant increase in the incidence of HIV-associated HL(2, 4, 73-75). 
Grulich et al conducted a meta-analysis of population-based studies and compared 
the incidence of cancer in patients with HIV/AIDS and solid organ transplant 
recipients(2). The risk of HL in patients with HIV was markedly increased, with a 
standard incidence ratio of 11.03 (8.43-14.4) (95% CI). In another prospective cohort 
study of 11,112 HIV-infected patients, the incidence for HL was 14-times higher than 
the general population(74).  
 
In contrast to some types of NHL that are associated with HIV, notably PCNSL, HL 
seems to occur at higher CD4 counts. In fact, the incidence of HL appears to decline 
at CD4 cell count of <200 cells/µL(4, 76).  Interestingly, although the incidence rates 
of AIDS-defining malignancies like KS and NHL have fallen, the incidence of HL in 
HIV-infected patients appeared to have increased according to some reports(77).  
Furthermore, HIV-associated HL is more likely to present as advanced stage disease 
with bone marrow involvement(4, 78). 
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1.3.1 Treatment of HIV-associated HL in the pre-cART era 
Before the introduction of cART, the outcomes of HIV-associated HL were poor.  The 
AIDS Clinical Trials Group (ACTG) conducted a non-randomised prospective study in 
21 HIV-infected patients with HL using ABVD regimen (doxorubicin, bleomycin, 
vinblastine and dacarbazine) and G-CSF(79). Of the 21 patients, only 9 (43%) 
achieved CR. Ten patients (48%) had life-threatening neutropenia, and OIs occurred 
in 6 (29%) patients. The authors reported a modest median OS of 1.5 years.  
In another retrospective study of 114 patients with HIV-associated HL between 1986 
and 1993, the CR rate was 58% with a median OS of only 13 months(80). 
 
1.3.2 Treatment of HIV-associated HL in the post-cART era 
Retrospective and prospective studies have suggested major improvements in 
outcomes of HIV-associated HL in the cART era. Xicoy et al in a retrospective study 
reviewed 62 HIV-positive patients with advanced stage HL who were treated with 
ABVD and cART. The CR rate was 87% and 5-year OS was 76%(81). In a 
prospective phase II study of 59 patients with HIV-associated HL, the use of 
Standford V regimen (doxorubicin, vinblastine, mechlorethamine, vincristine, 
bleomycin, etoposide and prednisone) was associated with a CR rate of 81% and a 
3-year OS and DFS rate of 51% and 68%, respectively. Fifty-two patients (88%) in 
the study were receiving cART concomitantly with chemotherapy(82).  
 
Hartmann et al evaluated the use of the intense BEACOPP regimen (bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) 
in 12 patients with previously untreated HIV-associated HL. Only 5 of the 12 patients 
received concomitant cART. The authors reported 100% CR rate at the end of 
treatment, but with a high rate (12.5%) of opportunistic infections(83). In another 
recent study by Hentrich et al, which was the largest prospective trial ever conducted 
in patients with HIV-associated HL, 108 patients were allocated treatment based on 
stage and risk category(84). Patients with early favourable disease received 2 to 4 
cycles of ABVD plus involved field radiotherapy (RT), patients with early 
unfavourable disease received 4 cycles of BEACOPP or 4 cycles of ABVD followed 
by involved field RT if disease was > 5cm or residual disease was ≥ 2cm. Patients 
with advanced stage HL received disease received 8 cycles of BEACOPP with or 
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without RT. PJP prophylaxis and fluconazole was recommended for patients with 
CD4 count below 200/µL. Primary G-CSF prophylaxis was recommended for patients 
receiving BEACOPP. Most of the patients (94%) were on cART while on treatment. 
The authors reported excellent CR rates of 96%, 100% and 86% for the early 
favourable, early unfavourable and advanced disease, respectively. The overall 2-yr 
progression free survival (PFS) and 2-yr OS were 91.7% and 90.7%, respectively.  
 
A recent retrospective study by Montoto et al, which compared outcomes of HIV-
infected patients and HIV-negative patients treated with ABVD for HL in the cART 
era(85). The total number of patients in the study was 224, of whom 93 were HIV-
positive, and half of them had a CD4 count <200 cells/µL at lymphoma diagnosis. 
Almost all patients (99%) were on cART at the time of chemotherapy. There were no 
significant differences in any of the clinical outcomes between the HIV-positive and 
HIV-negative patients. See Table 1-6 for results of HIV-associated HL studies. 
 
Similar to HIV-associated DLBCL and BL, the advent of cART has completely 
changed the picture for patients with HIV-associated HL. Not only we are observing 
major improvements in the clinical outcomes of HIV-associated HL, these outcomes 
are now parallel to those observed in the HIV-negative population. ABVD regimen 
appears to have the best balance between efficacy and safety; more intense 
regimens like BEACOPP have yielded impressive results, but are generally 
associated with more treatment-related toxicity. 
 
Table 1-6 Results of studies using chemotherapy for the treatment of patients 
with HIV-associated HL 
Author Intervention Sample size CR(%) OS/EFS 
Gerrad et al, 2003 Stanford V 59 81 3-year OS 51% 
3-year DFS 68% 
Hartmann et al, 2003 BEACOPP 12 100 75% OS at 49 months 
Xicoy et al, 2007 ABVD 62 87 5-year OS 76% 
Hentrich et al, 2010 ABVD/BEACOPP 
+/-RT 
108 96-100 2-year PFS 91.7% 
2-year OS 90.7% 
Montoto et al, 2012 ABVD 93 74 5-year OS 81% 
5-year EFS 59% 
RT= Radiotherapy 
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1.4 HIV-associated primary effusion lymphoma (PEL) 
Primary effusion lymphoma (PEL) is a type of B-cell lymphoma that is associated 
with human Herpes virus-8 (HHV-8) infection. PEL accounts for less than 3% of HIV-
associated lymphomas(86). PEL is associated with poor prognosis, and the median 
OS is in the range of 6 months(87, 88). CHOP and DA-EPOCH regimens have been 
used with limited success. Immune reconstitution may play a role, as there have 
been reports of complete remission with the use of cART alone(89).  
 
1.5 HIV-associated plasmablastic lymphoma (PBL) 
PBL is another type of B-cell lymphoma. The prognosis of PBL in the setting of HIV-
infection has been historically poor(90). The impact of cART on PBL is not clear, 
although there are some reports of improved prognosis and survival with cART (91). 
CHOP and CHOP-like regimens may play a role in the treatment of PBL. Patients 
achieving CR could be considered for autologous haematopoietic stem cell transplant 
(ASCT)(91, 92). Other therapies e.g. bortezomib and lenalidomide have been used 
with reports of success(93). 
 
1.6 Relapsed lymphoma  
Relapsed or refractory HIV-associated lymphomas after first-line of chemotherapy 
have poor prognosis(10, 94). Different salvage chemotherapy regimens have been 
used with response rates ranging from 10-30%(94). More encouraging response 
rates of 54% have been reported with platinum-based chemotherapy(95, 96). 
The significant improvements in immune function and the better control of HIV-
infection in the era of cART, along with the fact that HIV-patients are now better able 
to tolerate chemotherapy with results similar to HIV-negative patients, led clinicians 
to consider high dose chemotherapy and ASCT in HIV patients. The thought of 
performing ASCT procedure in HIV-patients, which once unimaginable, has become 
a reality where HIV-patients now routinely undergo ASCT for high risk and relapsed 
HIV-associated lymphomas. Prospective studies of HIV-infected patients undergoing 
ASCT for HIV-associated lymphoma have shown comparable survival outcomes to 
those seen in HIV-negative patients(97-104). Reports of successful allogeneic 
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haematopoietic stem cell transplant have also emerged, although this approach is 
still under investigation (105-108). 
 
1.7 Combination antiretroviral therapy (cART) during 
chemotherapy 
When cART became available, the administration of standard and intensified 
chemotherapy approaches became feasible and the rates of infectious complications 
were markedly reduced. However, due to the potential for drug-drug interactions 
between cART and chemotherapy the following question was posed: 
 Should cART be continued or withheld during chemotherapy? 
 
When considering whether cART should be withheld during chemotherapy, it is 
important to consider the expected degree of immunosuppression to be seen in the 
individual patient. The degree of immunosuppression would in turn affect the risk of 
death from bacterial and opportunistic infections. Furthermore, it is crucial to consider 
the benefits of HIV viral suppression in relation to the overall survival and 
chemotherapy response, and weigh that against the risks of drug interactions 
between cART and chemotherapy(94).   
 
In an attempt to avoid to the potential pharmacokinetic (PK) interaction between 
cART and chemotherapy, Little et al investigated the feasibility of omitting cART 
during the administration of chemotherapy(30).  In this study 6 cycles of EPOCH 
were administered to 39 patients with HIV-associated NHL. cART was not used 
during chemotherapy, but instead it was started immediately after chemotherapy. 
Majority of patients (75%) received all planned 6 EPOCH cycles. The CR rates were 
74%, with even higher CR rates of 87% in patients with CD4 cell count of >100 
cells/µL. While the OS in patients with CD4 cell count of >100 cells/µL was 87% at 56 
months, patients with CD4 cell count of <100 cells/µL had an OS of only 16% at 56 
months. While no OIs occurred during chemotherapy, 3 patients developed OI within 
3 months from finishing chemotherapy. Despite the fact that the authors of the study 
concluded that it may seem reasonable to defer cART until the completion of 
chemotherapy, some clinicians disagree with the authors for the following reasons:  
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1-The outcomes in patients with CD4 <100 cells/µL were quite poor compared to 
those with CD> 100 cells/µL. 
  
2-It might have been possible to avoid the three cases of OIs if cART had not been 
withheld during chemotherapy. 
 
1.7.1. Impact of CART on response rate and overall survival 
Studies highlighting the impact of cART on clinical outcomes of patients undergoing 
chemotherapy for HIV-associated lymphoma are discussed below.  
 
Cortes et al conducted a study which included 13 patients with HIV-associated BL 
who were treated with hyper-CVAD regimen(54). Nine out of the 13 patients received 
cART during chemotherapy. The remaining 4 patients did not receive cART during 
their chemotherapy. The median overall survival for the 9 patients who started cART 
with chemotherapy was 48% at 2 years. Interestingly, all four patients who did not 
receive cART died. 
 
Vaccher et al conducted two sequential prospective trials, which included 104 
patients with intermediate-high grade systemic HIV-related NHL. Patients were 
treated with CHOP chemotherapy plus cART or CHOP without cART(109). The 
investigators reported that patients in the CHOP plus cART arm had fewer OIs and 
significantly less mortality rate compared to the CHOP-only arm (18 vs. 52%, p=0.05) 
and (38 vs. 85%, p=0.001), respectively. 
 
In a retrospective study by Antinori et al, which included 44 patients with HIV-related 
NHL who received CHOP like chemotherapy, the virological response to cART was 
reported to be the only variable independently associated with complete response 
following chemotherapy(110). In another retrospective cohort study by Hoffmann and 
colleagues, which included 203 patients with AIDS-related lymphoma, the response 
to cART during the first 2 years following lymphoma diagnosis was independently 
associated with prolonged survival. In addition, patients receiving cART (n=61) were 
significantly more likely to achieve CR (71% vs. 48%, p=0.006)(26).  
Table 1-7 highlights some of the studies that evaluated the impact of cART on 
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survival outcomes and response rates in patients with HIV-associated lymphomas. 
 
Table 1-7 Studies showing impact of cART on survival outcomes and response 
rates 
Author Patients 
(n) 
Study Design Main Findings 
Cortes et al. 
2002 
13 Prospective study 
Investigating the use of 
hyper-CVAD in BL 
Nine out of 13 patients were on 
cART during chemotherapy. All 
four patients who did not receive 
cART died 
Vaccher et 
al. 
2003 
104 Retrospective analysis of 
two prospective trials in 
patients with HIV-NHL 
Patients on CHOP plus cART had 
fewer opportunistic infections (18 
vs. 52%, p=0.05) and longer OS 
(38 vs. 85%, p=0.001) compared 
to CHOP only arm 
Antinori et 
al. 
2001 
44 Retrospective study in 
patients who received CHOP 
for HIV-related NHL 
Virological response to cART was 
reported to be the only variable 
independently associated with CR 
following chemotherapy 
Hoffmann et 
al. 
2003 
203 Retrospective observational Response to cART was 
associated with prolonged 
survival. Patients receiving cART 
were more likely to achieve CR 
(71% vs. 48%, p=0.006) 
 
Therefore, concomitant administration of cART and chemotherapy has been shown 
to reduce the incidence of opportunistic infections and improves overall survival and 
complete response.  Based on the above information most clinicians nowadays will 
support the continuation of cART during chemotherapy. 
 
1.7.2. cART and chemotherapy  
One of the main challenges that face clinicians is the high likelihood of cART and 
chemotherapy drug interactions (111). Antiretroviral agents that inhibit the 
metabolism of chemotherapy drugs may result in increasing the risk of adverse 
effects, which in turn could lead to life-threatening toxicities and treatment delays.  
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On the other hand, antiretroviral agents that induce the metabolism of chemotherapy 
drugs may reduce their efficacy, and hence compromise treatment outcomes. 
Therefore, the choice of appropriate cART regimen is essential when treating HIV-
associated lymphomas; this is in order to (1) minimise the potential drug-drug 
interactions and related-toxicities, particularly the cytochrome P-450 (CYP450) 
interactions (2) to ensure full efficacy of the chemotherapy drugs (7, 111-115).  
 
1.7.2.1 cART drug metabolism 
Classes of antiretroviral drugs include nucleoside reverse transcriptase inhibitors 
(NRTIs) or nucleotide reverse transcriptase inhibitors (NtRTIs), non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase 
inhibitors (INSTI), entry inhibitors including chemokine-receptor antagonists and 
fusion inhibitors(116). All recommended cART regimens should include three active 
agents from at least two drug classes to prevent resistance, with initial recommended 
regimens including combination of two NRTIs (mostly emtricitabine/tenofovir or 
abacavir/lamivudine) with either NNRTI (mostly efavirenz) or a ritonavir boosted PI 
(mostly atazanavir, darunavir or lopinavir) or a INSTI (raltegravir)(117). 
 
Although, numerous enzyme families have been identified within the CYP450, 
CYP3A4 isoenzyme is involved in the metabolism of many of the available 
antiretroviral agents. There are three ways that antiretroviral therapy interacts with 
the CYP450 enzymes: inhibition, induction, or acting as a substrate(7, 111). Inhibition 
of CYP450 tends to be rapid and can result in immediate increased plasma 
concentration of concomitant drugs that are metabolised via the same isoenzyme. 
Enzyme induction occurs more slowly, and could take few days before resulting in 
increased plasma concentrations of concomitant medications metabolised via the 
same isoenzyme(111). The route of elimination and metabolism of some of the 
commonly used antiretroviral agents are summarised in Table 1-8. 
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 Table 1-8 Metabolism of some commonly used Antiretroviral agents   
Antiretroviral agent Class Metabolism 
Tenofovir (118) Nucleos(t)ide reverse 
transcriptase 
inhibitor (NRTI) 
Minimal systemic metabolism 
(renal excretion 70-80%) 
Emtricitabine (119) 
 
Minimal systemic metabolism. 
(renal excretion 86%) 
Abacavir (120, 121) Hepatic elimination with no known effect 
on CYP450 
Efavirenz (122, 123)  
 
Non-nucleoside 
reverse transcriptase 
inhibitor (NNRTI) 
 
Potent inducer and inhibitor of CYP3A4. 
Efavirenz induces CYP2B6 and UGT1A1. 
Also inhibits CYP2C9 and 2C19. 
Nevirapine (124, 125) Substrate and a potent inducer of 
CYP3A4 and 2B6 enzymes 
Etravirine (126, 127) Weak inducer of the CYP3A4 and 
CYP2B6. Weak inhibitor of CYP2C9 and 
moderate inhibitor of CYP2C19 
Atazanavir (128-130) 
 
 
 
Protease inhibitors 
(PI) 
 
Inhibits CYP3A4 and UGT1A1 
Darunavir (131-133) Primarily metabolised by CYP3A4. 
Inhibits CYP3A4 
Ritonavir (134-137) Potent inhibitor of CYP enzymes in the 
following order 3A4>2D6>2C9>2C19 
Induces:CYP1A2,CYP2B6,CYP2C9/2C19 
and glucoronyl transferases 
Raltegravir (138) Integrase inhibitor 
(INSTI) 
Glucuronidation (UGT1A1) and has no 
inhibitory or inductive potential in-vitro 
UGT= Uridine diphospho-glucuronosyl transferase 
 
1.7.2.2 Potential cART and chemotherapy drug interactions 
 
Nucleoside reverse transcriptase inhibitors 
NRTIs and tenofovir (NtRTI) are not inhibtors, inducers or substrates of the CYP450 
enzymatic complex. PK drug-drug interactions are not expected. However, it is 
important to also consider the pharmacodynamic  (PD) effects of NRTIs. Tenofovir 
could result in added nephrotoxicity with other nephrotoxins(68, 117). Zidovudine is 
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associated with neutropenia and anaemias(68, 117), and hence should be avoided in 
patients undergoing chemotherapy. Stavudine and didanosine are associated with 
peripheral neuropathy which could potentiate the neurotoxicity of some 
chemotherapy agents.(111) 
 
Non-nucleoside reverse transcriptase inhibitors 
As highlighted in Table 1-8, NNRTIs are metabolised via the CYP450 enzyme 
system. Both nevirapine and efavirenz are potent inducers of CYP3A4, which may 
result in increasing the clearance of chemotherapy drugs metabolised by this enzyme 
e.g. etoposide and vinca alkaloids (see Table 1-9). Etravirine, is a second generation 
NNRTI, and it expected to have less interaction potential compared to nevirapine and 
efavirenz as it is a poor inducer of the CYP3A4 and CYP2B6. Rilpivirine is a new 
NNRTI, it is primary metabolised by CYP3A4 as well as CYP2C19 and CYP1A2. It is 
a slight inducer of CYP2B6 and CYP3A4 and a moderate inducer of the CYP2C19. A 
clinically relevant effect seems unlikely with 25mg dose commonly used(127). 
 
Protease inhibitors 
All PIs inhibit CYP3A4, but ritonavir is the most potent inhibitor in the class (139). 
Ritonavir is also a potent inhibitor of the P-glycoprotein (P-gp) efflux pump(111).  
P-gp transports drugs from cells, e.g. from GI cells back into the GI lumen, from the 
brain back into the blood and from the liver and the kidneys into the bile and urine.  
Hence, P-gp plays an important role in the excretion of some chemotherapy drugs 
e.g. vinca alkaloids. Administration of PIs and some chemotherapy agents e.g. vinca 
alkaloid and etoposide may result in decreased clearance of these agents and 
increased toxicities  (see Table 1-9) 
 
Integrase inhibitors 
Raltegravir is primarily metabolised by the UGT1A1 (Uridine diphospho-glucuronosyl 
transferase isoform A1). Raltegravir is not an inhibitor or inducer of the CYP450 and, 
hence is expected to have low potential for chemotherapy drug-drug interactions.  
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Fusion inhibitors 
Enfuvirtide is an amino acid synthetic peptide. No significant drug interactions are 
expected with chemotherapy agents(140). 
 
Chemokine receptor CCR5 antagonists 
Maraviroc is a substrate for CYP3A4 and has no potential to induce or inhibit  
CYP450. Interactions with between maraviroc and chemotherapy agents is 
unlikely(141). 
 
Table 1-9. Potential antiretroviral agents and chemotherapy interactions (115) 
Drug Metabolism Interactions with PIs 
(more with ritonavir) 
Interaction with 
NNRTIs 
Cyclophosphamide 
(142) 
CYP2B6, 2C19 
(active) 
CYP 3A4 (inactive, 
toxic) 
Via CYP2B6 
induction 
CYP3A4 inhibition 
Via CYP2B6 
induction 
 
Etoposide 
 
CYP3A4 
 
Via CYP3A4 
inhibition 
Via CYP3A4 
induction 
Vincristine/vinblastine CYP3A4 
 
via CYP3A4 
inhibition 
Via CYP3A4 
induction 
Doxorubicin CYP450 involved 
in free radical 
generation in vitro. 
 
May reduction via 
CYP2B6 induction to 
free radical and hence 
antineoplastic 
properties 
May reduction 
via CYP2B6 
induction to free 
radical and hence 
antineoplastic 
properties 
Prednisolone CYP3A4 
 
via CYP3A4 
inhibition 
Via CYP3A4 
induction 
=Increase in the concentration of the active metabolite, = decrease in the concentration of active 
metabolite, = Potentially severe increase in the concentration of the active metabolite  
 
1.7.2.3 cART-Chemotherapy drug-drug interactions with non-
Hodgkin lymphoma regimens: 
Vaccher et al conducted a retrospective study, which compared 24 HIV patients on 
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CHOP chemotherapy regimen plus cART vs. 80 patients on CHOP alone.  The 
authors reported more grade 3-4 autonomic neurotoxicity when CHOP was used with 
PIs vs. CHOP alone (17% vs. 0% p= 0.002). Grade 3-4 anaemia was also higher in 
the CHOP plus cART compared to CHOP alone group (33% vs. 7% p=0.001). All the 
patients who developed anaemia in the CHOP plus cART group were on zidovudine 
(ZDV)(109). 
 
Bower et al reviewed 46 HIV-patients with NHL. Patients in the study were treated 
with CDE chemotherapy regimen. A total of 190 cycles of chemotherapy were 
administered.  The authors compared the number of neutropenic episodes in patients 
who received PI-based cART vs. patients on NNRTI-based regimens. More grade 4 
neutropenia, grade 3-4 infections and more delay in the chemotherapy were 
observed in PI-based regimen arm compared to NNRTI-based regimen arm(143). 
 
Leveque et al reported a case of PI-based cART and chemotherapy drug interaction.  
A 37-year old HIV patient with HIV-related Burkitt lymphoma was treated with 
CODOX-M chemotherapy regimen. The patient’s cART consisted of abacavir, 
lamivudine and lopinavir/ritonavir. Vincristine 2mg was administered on D1 and D8 of 
the protocol.  The patient complained of severe abdominal pain and constipation on 
D12, and then went on to develop paralytic ileus that lasted 10 days. The reaction 
was put down to the potential inhibition of the vincristine metabolism by the 
lopinavir/ritonavir and increase in the neurotoxic side effects of the vincristine(144). 
 
A higher incidence of severe (grade 3-4) mucositis was observed in 8 of 12 patients 
with HIV-related NHL treated with CDE and saquinavir based cART compared with 
only 3 out of 25 patients of a prior study of CDE without saquinavir(145). On the other 
hand, Fulco et al retrospectively reviewed 7 HIV-patients with NHL who received 
CHOP or R-CHOP. All patients were on tenofovir+emtricitabine and raltegravir. All 
patients tolerated their chemotherapy regimen well. None had side effects related to 
ART during their chemotherapy(146).  
 
Pharmacokinetic studies that address the issue of cART and chemotherapy drug-
drug interactions are scarce. In one study of 40 patients with HIV-associated NHL 
treated with indinavir-based cART combined with CHOP, the clearance of 
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cyclophosphamide clearance was reduced to 1.5 folds compared to historical 
controls. However, this did not translate into increased toxicities in patients on cART 
(28). In the same study, no effect on the doxorubicin pharmacokinetics was 
observed. In another study by Toffoli et al, PI-based cART had no significant effect 
on doxorubicin pharmacokinetics in 19 patients with HIV-associated NHL treated with 
CHOP with and without cART(147). 
 
1.7.2.4 cART-Chemotherapy drug-drug interactions with Hodgkin 
lymphoma regimens 
 
Cingolani et al retrospectively reviewed 16 HIV patients with HL who were treated 
with ABVD chemotherapy regimen. The authors found that patients who were on PI-
based cART at the time of chemotherapy were more likely to experience severe 
grade 3-4 neutropenia. Furthermore an inverse correlation between the dosage of 
ritonavir and mean nadir neutrophil count was found.  The authors concluded that the 
toxicity was likely due the interaction between PIs and vinblastine, and that the higher 
the ritonavir dose the more profound the interaction would be. It is worthy of note that 
there were no clinically significant interactions between NNRTIs or raltegravir based 
regimens and vinblastine reported in the study.  
 
Another study by Ezzat et al reviewed 36-HIV patients with HL who were treated with 
ABVD or MOPP (mechlorethamine, vincristine, procarbazine, prednisone). The use 
of ritonavir/lopinavir or ritonavir was associated with significant grade 3-4 
neurotoxicities(148). 
 
1.7.2.5 Lessons learnt from the literature review  
 When given with chemotherapy, PI-based regimens appear to be associated with 
more treatment related toxicities compared to NNRTIs and raltegravir based-
regimens. 
 PI-based regimens should be used with extreme caution with vinca alkaloids 
(avoid or chemotherapy dose reduction is warranted). 
 Zidovudine use should be avoided in patients treated with chemotherapy due to 
the increased risk of haematological toxicities (anaemia and neutropenia). 
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 NNRTIs, e.g. efavirenz and nevirapine, have a theoretical potential for drug 
interactions with some chemotherapy agents based on the pharmacokinetic 
profile of these agents. Interactions between chemotherapy agents like 
vinblastine/vincristine and efavirenz /nevirapine have not been studied. Therefore 
more evidence is needed to guide treatment decisions. 
 Raltegravir based regimens appear safe to use, and are well tolerated during 
chemotherapy. However, very limited published data are available regarding the 
use of raltegravir and chemotherapy regimens. 
 
In conclusion, the potential for PK and PD drug interactions between cART and 
chemotherapy is a major concern. These interactions may result in decreased 
plasma concentrations of chemotherapy, which could lead to treatment failure and 
worse survival outcomes.  Such drug interactions may also increase the plasma 
concentrations of chemotherapy, which may result in increased chemotherapy 
toxicity, treatment delays, and ultimately worse survival outcomes. PIs and NNRTIs 
are heavily involved in the CYP450 and other transporter systems e.g. P-gp, and 
may be associated with clinically significant interactions with chemotherapy.  
Better knowledge of cART and chemotherapy drug-drug interactions is therefore 
crucial, especially in the era of increasing burden of non-AIDS defining cancers. 
Studies that describe chemotherapy and cART drug-drug interactions are scarce, 
and those aimed at studying the impact of such drug interactions on survival 
outcomes are lacking. Such studies are important to help establish clear guidelines 
on how HIV-patients with malignancies should be managed, and what would be the 
optimal cART regimen(s) that could be safely administered in HIV-patients 
undergoing chemotherapy. 
 
1.8 Aims, Objectives and Hypothesis 
The aim of our study was to compare toxicities, response rates and survival 
outcomes in HIV-patients with NHL and HL treated with chemotherapy according to 
whether patients received protease inhibitor (PI) or non-PI based cART. 
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The objectives of the study were: 
 
1) To compare the safety of PI-based vs. non-PI-based regimens in patients 
receiving chemotherapy for NHL including BL, DLBCL and other types of NHL. 
2) To compare the safety of PI-based vs. non-PI-based regimens in patients 
receiving chemotherapy for HL. 
3) To evaluate whether any differences in OS, CR rates or safety between the PI 
and non-PI groups may have been due to the potential pharmacokinetic 
interactions between cART and chemotherapy agents. 
4) To develop treatment recommendations and suggestions that would be useful in 
guiding the choice of cART for HIV patients receiving chemotherapy for NHL and 
HL 
 
This study hypothesises that in a population of HIV-infected patients on combination 
antiretroviral therapy who are receiving chemotherapy for HIV-associated lymphomas  
 
H(1) When co-administered with chemotherapy, PI-based regimens are associated 
with more treatment related toxicities compared to non-PI based-regimens. 
 
H(2) When co-administered with chemotherapy, PI-based regimens are associated 
with more chemotherapy dose reductions and/or delays compared to non-PI based 
regimens. 
 
H(3) As a result of chemotherapy dose reductions, delays and/or interruptions, PI-
based regimens are associated with worse response rates, disease free survival and 
overall survival compared to non-PI based regimens. 
 
H(4) NNRTI-based regimens are associated with clinically significant drug interactions, 
which could impact on overall survival, response rates and treatment-related 
toxicities.  
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Chapter 2: Methodology 
This chapter describes the study design and the methodology used to collect and 
analyse the data pertaining to patient demographics, chemotherapy details, 
lymphoma and HIV-characteristics.  
 
2.1 Study design 
This was a retrospective observational single centre study.  
 
2.2 Study population  
This retrospective study included HIV-infected patients who were on cART and 
treated with chemotherapy for NHL and HL from January 1st 2003 to December 31st 
2010 at St Vincent’s Hospital, NSW, Australia. Patients were identified from the 
haematology and immunology departmental databases at St Vincent’s Hospital. All 
patients had biopsy proven lymphoma and were HIV positive at lymphoma diagnosis. 
 
2.2.1 Inclusion criteria:  
 HIV-infected adults who received treatment for NHL with one of the following 
regimens: CHOP, R-CHOP, EPOCH, hyper-CVAD or CODOX-M/IVAC 
chemotherapy from January 1st 2003 until December 31st 2010.           
 HIV-infected adults who received treatment for HL with ABVD chemotherapy 
regimen from January 1st 2003 until December 31st 2010.  
 Patient on cART during one or more chemotherapy cycles for the treatment of 
HIV-associated lymphoma. 
 
2.2.2 Exclusion criteria: 
 Children and/or young patients <18 years. 
 HIV-infected patients who did not receive cART during chemotherapy.  
 HIV-infected patients who did not receive chemotherapy treatment for their 
lymphoma. 
 HIV-infected patients diagnosed with primary CNS lymphoma. 
 HIV-infected patients with a haematological malignancy other than lymphoma. 
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2.3 Ethics approval 
The Human Research and Ethics Committee (HREC) at St Vincent’s Hospital (SVH) 
approved the study protocol in May 2012 (Reference SVH file number 12/066) 
(Appendix 1). The HREC approved the study as a Low and Negligible Risk (LNR) 
research to be conducted at SVH. 
 
2.4 Data collection 
Data collection was performed using a data collection form (Appendix 2). The 
collected data was then recorded in a Microsoft Office Excel worksheet. 
Clinical characteristics and details of therapy were obtained by retrospective review 
of inpatient and outpatient progress notes, paper and electronic drug charts, 
chemotherapy manufacturing database, pharmacy-dispensing records and 
computerised pathology database.  
 
Clinical characteristics collected during the study are outlined below: 
2.4.1 Demographic data  
 Date of birth and gender. 
 Weight, height and body surface area (BSA). 
 
2.4.2 HIV-related characteristics  
 Date of HIV diagnosis 
 HIV acquisition risk (male to male sexual contact [MSM], heterosexual contact, 
injecting drug use, occupational exposure) 
 Duration of HIV-infection prior to lymphoma diagnosis 
 History of prior AIDS illness 
 CD4 cell count and HIV-VL at lymphoma diagnosis, 1-3 months, 6-9 months and 
12-15 months post chemotherapy  
 Details of cART at lymphoma diagnosis and post chemotherapy 
 Details of cART interruptions during chemotherapy, if any. 
 Co-infections (hepatitis-B and hepatitis-C). 
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 History of prior neuropathy, including cause. 
 Details of prophylactic therapy administered during chemotherapy for PJP, viral, 
fungal, Mycobacterium avium complex (MAC), cytomegalovirus infections (CMV). 
 
2.4.3 Lymphoma-related characteristics  
 Age at lymphoma diagnosis 
 Type of lymphoma (Hodgkin, Burkitt, diffuse large B-cell or other lymphoma)  
 Ann-Arbor staging of lymphoma 
 Presence of B-symptoms 
 CNS involvement 
 Bone marrow involvement  
 Extranodal sites involvement 
 Lactate dehyrogenase (LDH) elevated or normal at lymphoma diagnosis 
 Eastern Cooperative Oncology Group (ECOG) performance score  
 Hasenclever International Prognostic Score (IPS) for Hodgkin lymphoma 
(149)(age < or ≥45 years, gender, albumin normal or <40g/L, haemoglobin < or ≥ 
105g/L, stage of lymphoma, leukocytosis WBC = 15 x 109/L or more, lymphopenia 
< 0.6 x 109/L or < 8% of WBC count). 
o Good risk 
o Fair risk 
o Poor risk  
 Magrath scoring criteria for Burkitt lymphoma(57, 150).  
o Low risk if normal LDH, Ann Arbor stage I-II, ECOG performance status 0 
to 1, number of extra nodal sites involved ≤1. 
o  All other patients were considered high risk. 
 The age-adjusted International Prognostic Index (age adjusted-IPI) score(151) 
was used for patients with diffuse large B-cell lymphoma (ECOG performance 
score, LDH, stage of lymphoma). 
o Low IPI score  
o Low-intermediate IPI score  
o High-intermediate IPI score  
o High IPI score  
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 Details of chemotherapy regimen used, doses and number of cycles given. 
 Details of intrathecal and radiotherapy used. 
 Dose reductions in chemotherapy, delays and completion of stage-appropriate 
therapy. 
 Reasons for delays or reduction in chemotherapy doses 
 Details of dose and chemotherapy regimen intensification. 
 Treatment –related toxicities. 
 Details of G-CSF use. 
 Response to therapy at the end of treatment. 
 Date of last follow-up, and if alive-date last censored. 
 Date of relapse, if applicable. 
 Cause and date of death, if applicable.  
 
2.5 Study Definitions 
Combination antiretroviral therapy (cART)  
Defined as a regimen that is composed of three antiretroviral agents from at least two 
drug classes. cART regimens that contained PIs, irrespective of whether they also 
contained NNRTIs and/or INSTI, were classified as PI-based cART otherwise the 
regimen was classified as non-PI based cART.  
 
Patients needed to be on cART concomitantly with chemotherapy. If the patient was 
not on cART prior to starting chemotherapy, then cART needed to have started by 
cycle 2 of chemotherapy. cART had to be co-administered with least one 
chemotherapy cycle. Interruption of cART was defined as discontinuation of all 
antiretroviral agents lasting for at least 3 days. 
 
Adherence to cART was assessed by reviewing the St Vincent’s Hospital pharmacy 
records for dates of cART dispensing, and progress notes entries by clinicians or 
nursing staff, including HIV- Clinical Nurse Consultants (CNC).  
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Chemotherapy related definitions 
 Chemotherapy dose reduction was defined as omission or dose reduction of 
any medication included in the chemotherapy regimen. 
 Chemotherapy regimen change was defined as the substitution of any 
medication included in the chemotherapy regimen by another agent.  
 Chemotherapy delay was defined as failure to administer the chemotherapy on 
the scheduled date due to patient being unfit and/or unable to have planned 
treatment.  
 Stage appropriate chemotherapy was defined according to National 
Comprehensive Cancer Network (NCCN) clinical practice guidelines for the 
management of NHL and HL(152, 153). This was also confirmed with the 
clinician’s entry in the progress notes and the chemotherapy drug chart regarding 
the intended course of chemotherapy. 
 For HL, stage-appropriate therapy was defined as completion of 4 or more 
chemotherapy cycles for Ann Arbor stage I or II favourable disease, four or more 
chemotherapy cycles with radiotherapy for stage I or II unfavourable disease, and 
six or more chemotherapy cycles for stage III or IV disease. 
 For BL, stage-appropriate therapy was defined as completion of at least 3 
chemotherapy cycles. 
 For DLBCL and other lymphomas, stage appropriate therapy was defined as 
completion of 3 or more chemotherapy cycles with radiotherapy or six or more 
chemotherapy cycles for Ann Arbor stage I-II disease, and six or more 
chemotherapy cycles for stage III-IV disease. 
Chemotherapy doses and schedules in the study were: 
1- ABVD (154): One cycle was defined as = doxurubicin 25mg/m2 (IV), bleomycin 
10000 IU/m2 (IV), vinblastine 6mg/m2 (IV), dacarbazine 375mg/m2 (IV) days 1 & 15 
every 28 days.  
2- CHOP ± rituximab(155, 156): One cycle=cyclophosphamide 750mg/m2 day 1 
(IV), doxorubicin 50mg/m2  day 1 (IV), vincristine 1.4mg/m2 (max 2mg) day 1 (IV), 
prednisone 100mg PO day 1 through to day 5 ± rituximab 375mg/m2 day 1 (IV). Each 
cycle was repeated every 14 (R-CHOP-14) or 21 days (R-CHOP21). 
3- EPOCH regimen: see Table 1-3 for EPOCH chemotherapy details.  
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4- CODOX-M/IVAC(57): One cycle consists of CODOX-M/IVAC arms 
 CODOX-M arm: cyclophosphamide 800mg/m2 (IV) on days 1 and 2, 
doxorubicin 50mg/m2 on day 1, vincristine 1.4mg/m2 IV on days 1 and 8, 
methotrexate (MTX) 6720mg/m2 *on day 10. 
*The haematology unit at SVH amended the MTX dose in the above protocol 
to 1000mg/m2 on day 10, due to high rates of severe mucositis in HIV-infected 
patients(157). This change of practice has been in place since 2007 until the 
time of writing this review. 
Alternating with 
 IVAC arm: cytarabine 2000mg/m2 (IV) every 12 hours on days 1 and 2, 
ifosfamide 1500mg/m2 (IV) given with mesna on days 1 to 5, etoposide (IV) 
60mg/m2 on days 1 to 5. 
5- Hyper-CVAD(158, 159): One cycle consists of hyper-CVAD A+ hyper-CVAD B 
 Hyper-CVAD part A: cyclophosphamide 300mg/m2 BD (IV) day 1 to 3, mesna 
600mg/m2/day (IV) day 1 to 3, mesna PO 80mg TDS day 4, dexamethasone 
40mg PO/IV day 1 to 4, 11 to 14, vincristine 2mg IV days 4,11 every 21 days. 
Alternating with  
 Hyper-CVAD part B: methotrexate (MTX) 1000mg/m2 IV day 1 and cytarabine 
3000mg/m2 (IV) BD days 2,3 every 21 days. 
 CNS prophylaxis or treatment using intrathecal chemotherapy was 
administered according to chemotherapy protocol and clinician’s discretion  
 Chemotherapy related-adverse events were graded based on the National 
Cancer Institute  (NCI) common toxicity criteria(160).  
 
Response assessment and follow up 
Response to treatment was determined by restaging after two, four or six 
chemotherapy cycles, according to the risk of disease. Response to treatment was 
documented in progress notes or correspondence letters. 
Complete remission (CR) was defined as the disappearance of all evidence of 
lymphoma maintained for at least 4 weeks following the completion of therapy. 
Unconfirmed complete remission (CRu) was defined as the presence of a residual 
mass of ≤2.5 cm that remained unchanged over at least 3 months. 
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Partial remission (PR) was defined as reduction in all disease manifestations by at 
least 50% reduction compared to initial manifestation. 
Disease progression (PD) was defined as more than 25% increases in the size of 
lymphoma lesions 
Overall survival (OS) was defined as the time from diagnosis to the time of death of 
any cause. Patients still alive were censored at last date of contact/follow-up. 
Disease free survival (DFS) was defined as the time period following chemotherapy 
during which there are no signs of cancer recurrence. 
 
2.6 Statistical analysis 
All statistical analyses were conducted using SPSS® for Mac, version 20.0.  
All p values were two-sided. P values of 0.05 or less were considered statistically 
significant. Median and range were used to describe continuous variables. 
 
Each of the different lymphoma groups were initially analysed separately due to the 
differences in treatment approach, prognosis and survival outcomes. The differences 
in adverse effects between patients in the PI and the non-PI based cART groups 
were compared using Fisher’s exact test for categorical variables, Fisher’s exact test 
was chosen over Chi-Square test as the majority of the cell count values were less 
than 5. The Mann-Whitney U test was used for non-parametric variables. Descriptive 
comparison was also used when appropriate to compare differences between the PI 
and the non-PI groups. 
 
Difference in response rates and survival were investigated. The probability of DFS 
and OS survival was determined using the Kaplan-Meier method, and the differences 
in survival were assessed by the log-rank test.  
 
The difference between the median CD4 cell counts at diagnosis and post 
chemotherapy within the lymphoma groups, and in patients on PI and non-PI cART 
were compared using Wilcoxon signed rank and Kruskal Wallis tests. Univariate 
logistic regression analysis was used to test for factors associated with achieving 
complete or unconfirmed complete remissions (CR/CRu) for patients with HIV-
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associated DLBCL. The precision of the odds ratio (OR) was determined by 
calculating a 95% confidence interval (95%CI).  
 
Univariate logistic regression was used to test for factors associated with following 
outcomes in a pooled analysis of all patients with HIV-associated lymphoma: 
 Developing grade 3-4 neurotoxicity 
 Developing grade 3-4 infections 
 Developing grade 3-4 haematological toxicity  
 Completion of stage appropriate chemotherapy treatment.  
 
Multivariate logistic regression models were used to allow the effect of the cART 
regimen on the outcomes to be assessed while adjusting for other variables. In our 
multivariate models we adjusted for variables that were significant (p≤0.05) in the 
univariate analysis. We also adjusted for the type of chemotherapy regimen used 
when testing the association between the cART regimen and grade 3-4 toxicities, this 
due to the difference in the neurotoxic and the myelosuppressive potential between 
the different chemotherapy regimens.  In our univariate and multivariate analysis we 
coded our variables to have two categories. Only two variables had more than two 
categories in our analyses:  
1- Lymphoma type was divided to three categories:  
 DLBCL+ other NHL lymphoma (reference category) 
 HL,BL 
2- Chemotherapy regimen was divided to three categories 
 ABVD (reference category) 
 CODOX-M/IVAC  
 CHOP, R-CHOP, EPOCH. 
 
Where categorical variables had more than two categories a global test of 
significance was used to assess the strength of association.  The precision of the OR 
was determined by calculating a 95%CI. The Hosmer and Lemeshow goodness-of-fit 
test was used to assess multivariate model fit, a non-significant result implied a good 
model fit. Cox proportional hazards model was used to estimate the hazard ratio 
(HR) for overall survival (OS) in univariate analysis for all patients with HIV-
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associated lymphoma grouped together. The precision of the HR was determined by 
calculating a 95%CI. 
 
Chapter 3: Results 
Sixty-three patients with HIV and lymphoma were identified between 2003 and 2010 
A-Excluded patients: 
1-Patients not on cART during chemotherapy (n=7) 
 Four patients with diffuse large B-cell lymphoma 
 One patient with Burkitt lymphoma 
 One patient with plasmablastic lymphoma  
 One patient with primary CNS lymphoma 
2- Patients who did not receive chemotherapy (n=1)  
 One patient with Hodgkin lymphoma who was on cART, but died from 
pneumonia prior to starting chemotherapy 
3- Patients with a diagnosis other than lymphoma (n=1) 
 One patient with a diagnosis of multiple myeloma/Castleman’s disease  
4- Patients with primary CNS lymphoma (n=1) 
 One patient with primary CNS lymphoma and advanced multi-resistant 
HIV. Patient was on cART at lymphoma diagnosis and received 3 cycles of 
methotrexate 1g/m2 and one session of cranial radiotherapy, which was 
poorly tolerated and patient was palliated. 
Total number of patients excluded from the analysis n= 10 patients 
 
B- Included patients: 
 16 patients with Hodgkin lymphoma 
 13 patients with Burkitt lymphoma 
 20 patients with diffuse large B-cell lymphoma  
 4 patients, with other lymphoma (one with anaplastic lymphoma, two with 
plasmablastic lymphoma and one with primary effusion lymphoma)  
Total number of patients included in the analysis n= 53 patients 
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 Percentages of the different lymphoma types among the 53 patients included 
in the analysis are shown in Figure 3-1. 
 
 
Figure 3-1 Percentages of lymphoma types among HIV-infected patients 
included in the analysis 
 
3.1 Hodgkin lymphoma (HL) data analyses 
 
3.1.1 Patient baseline characteristics  
Characteristics of 16 patients diagnosed with biopsy proven HIV-associated HL are 
shown in Table 3-1. The median age at HL diagnosis was 44 (range, 34-59) years. 
All patients were males; male-to-male sexual contact (MSM) was the risk for HIV 
acquisition in100% of the patients.  HIV characteristics included a median CD4 cell 
count at HL diagnosis (n= 16) of 233.5 (range, 14-970) cells/µL, and the median HIV 
viral load (n=16) was undetectable <50  (range, <50 to 481,000) copies/mL. In all 
patients, the HIV diagnosis was made prior to the lymphoma diagnosis. The median 
duration of HIV infection prior to the HL diagnosis was 13.5 (range, 2-24) years. No 
difference in HIV duration prior to lymphoma diagnosis between the PI and the non-
PI group (p=0.27,Mann-Whitney U test) 
 
Baselines characteristics of patients receiving PI- based cART were compared with 
patients on non-PI based cART (see Table 3-1). HIV and lymphoma-related baseline 
characteristics were similar across both PI and non-PI groups. There was a higher 
Hodgkin 
lymphoma; 
30.2% 
Burkitt 
lymphoma 
24.5% 
Diffuse large B 
cell lymphoma; 
37.8% 
Other lymphoma 
7.5% 
Lymphoma type 
n=53  
Hodgkin lymphoma 
Burkitt lymphoma 
Diffuse large B cell 
lymphoma 
Other lymphoma 
n= number of patients  
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rate of prior AIDS illness in the PI-group but the difference was marginally 
insignificant (50% vs. 0%, p=0.09, Fisher’s exact test).  
Prior AIDS diagnosis were: n=1 MAC infection, n=2 PJP infection, n= 1 KS, n=1 CMV 
retinitis and n=1 oesophageal candidiasis. 
Table 3-1 Baseline characteristics of 16 patients with HIV-associated HL 
 Total n 
(%) 
PI-based 
cART n(%) 
Non-PI based 
cART n(%) 
P-
value 
No. Patients  16 10 6  
Median [range] age at HL 
diagnosis  
44 [34-59] 49 [40-59] 42.5 [34-59] 0.35§ 
 ≤ 44 9 (56) 4 (40) 5 (83)  
 > 44 7 (44) 6 (60) 1 (17)  
Gender 
Male 16 10 6  
HIV risk  
Male to male sexual (MSM) 16 10 6  
Prior AIDS 
No 11 (69) 5 (50) 6 (100) 0.09* 
Yes 5 (31) 5 (50) 0 (0) 
Median [range] CD4 cell 
count at HL diagnosis.  
233.5 [14-
970] 
190.5 [14-
768] 
296 [117-970] 0.43§ 
>200 cells/µL 10 (62.5) 5 (50) 1 (17)  
≤200 cells/µL 6 (37.5) 5 (50) 5 (83)  
≤100 cells/µL 2 (12.5) 2 (20) 0 (0)  
HIV viral load (VL) at diagnosis copies/mL 
≤50 (undetectable)  11 (69) 6 (60) 5 (83) 0.59* 
>50 5 (31) 4 (40) 1 (17)  
Hepatitis B co-infection 
Known negative 12 (75) 8 (80) 4 (67) 0.6* 
Known positive 4 (25) 2 (20) 2 (23) 
Hepatitis C co-infection 
Known negative 16 10 6  
Known positive 0 0 0  
HL stage 
I-II 7 (44) 4 (40) 3 (50) 1* 
III-IV 9 (56) 6 (60) 3 (50) 
Hasenclever IPS score 
Good risk (0-1) 6 (37) 3 (30) 3 (50) 0.8* 
Fair risk (2-3) 3 (19) 2 (20) 1 (17) 
Poor risk (4-7) 7 (44) 5 (50) 2 (23) 
ECOG PS 
0-1 12 (75) 7 (70) 5 (83) 1* 
≥2 4 (25) 3 (30) 1 (17) 
B-symptoms 
Yes 12 (75) 7 (70) 5 (83) 1* 
No 4 (25) 3 (30) 1 (17) 
LDH 
Normal 7 (44) 4 (40) 3 (50) 1* 
Elevated 9 (56) 6 (60) 3 (50) 
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Bone marrow involvement 
Yes 6 (37.5) 3 (30) 3 (50) 0.6* 
No 10 (62.5) 7 (70) 3 (50) 
Extranodal involvement  
Yes 8 (50) 5 (50) 3 (50) 1* 
No 8 (50) 5 (50) 3 (50) 
*P-value determined using Fisher’s exact test  §P-value determined using Mann-Whitney U test 
3.1.2 Combination antiretroviral therapy (cART) 
Only one patient (6%) was cART naïve at HL diagnosis, all other 15 patients were on 
cART at the time of HL diagnosis. Median duration on cART prior to lymphoma 
diagnosis (n=15) was 36 (range, 17-144) months. At the time of chemotherapy 10 
patients (62.5%) were on PI-based cART and 6 patients (37.5%) were on non-PI 
based cART. In the non-PI group, 5 patients were on NNRTI-based cARTand one 
patient was on INSTI (raltegravir)-based cART. See Table 3-2 for cART details.   
Six patients experienced cART holidays prior to lymphoma diagnosis, 4 patients 
(40%) in the PI group and 2 (33%) in non-PI group. Median cART holiday-period prior 
to HL diagnosis was 9.5 (range, 6-84) months.   
 
Table 3-2 Combination antiretroviral therapy details for 16 patients with HIV-
associated HL 
Patient no. cART regimen Regimen type 
HL-1 FTC/TDF+NVP NNRTI-based = non-PI based 
HL-2 TDF+3TC+EFV NNRTI-based = non-PI based 
HL-3 3TC/ABC+EFV NNRTI-based = non-PI based 
HL-4 FTC/TDF+ NVP NNRTI-based = non-PI based 
HL-5 DRV/r (twice daily)+ETR+RAL PI-based 
HL-6 LPV/r+TDF+T20 PI-based 
HL-7 ABC+ATV/r+TDF PI-based 
HL-8 d4T+ NVP+3TC+LPV/r PI-based 
HL-9 LPV/r+3TC+ddI 400mg PI-based 
HL-10 TDF+3TC+ EFV NNRTI-based = non-PI based 
HL-11 DRV/r (once daily)+TDF/FTC PI-based 
HL-12 DRV/r (once daily)+TDF/FTC PI-based 
HL-13 ABC+TDF+ddI 250mg+NFV PI-based 
HL-14 LPV/r+ 3TC/ABC PI-based 
HL-15 RAL+3TC/ABC Raltegravir-based = non-PI based 
HL-16 LPV/r+ 3TC+TDF PI-based 
Key to abbreviations: FTC= emtricitabine, TDF= tenofovir, NVP= nevirapine, 3TC= lamivudine, 
EFV= efavirenz, ABC=abacavir, DRV/r= ritonavir-boosted darunavir, ETR= etravirine, RAL= 
raltegravir, LPV/r= ritonavir-boosted lopinavir, T20= enfuvirtide, ATV/r= ritonavir-boosted atazanavir, 
d4T= stavudine, ddI= didanosine, NFV= nelfinavir 
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3.1.3 Chemotherapy and radiotherapy 
All 16 patients received ABVD chemotherapy for their HL. Two patients (12.5%) 
received local radiotherapy after their ABVD chemotherapy. No intrathecal 
chemotherapy was used for any of the patients. A total of 76 cycles of chemotherapy 
of ABVD was given to the 16 patients in our HL cohort. Of the 76 ABVD cycles, 46 
cycles (60.5%)were given to patients on PI-based cART regimen and 30 cycles 
(39.5%) to patients on non-PI based cART regimen. 
 
3.1.4 Antimicrobial prophylaxis during chemotherapy 
Prophylaxis for PJP was documented in 13 (81%) patients (all received 
sulfamethoxazole/trimethoprim 800mg/160mg three times weekly or 400mg/80mg 
once daily). Eight patients (50%) received prophylaxis for herpes simplex virus (HSV) 
and/or varicella zoster virus (VZV) (with valaciclovir 500mg daily or 500mg twice 
daily). Four patients (25%) received fungal prophylaxis  (n=3 with fluconazole 100-
200mg daily, and n=1 with nilstat 1mL four times daily). Two patients (12.5%) 
received MAC prophylaxis (with azithromycin 1200mg weekly). Both patients had a 
CD4 cell count <100 cells/µL at HL diagnosis. 
 
3.1.5 G-CSF prophylaxis during chemotherapy 
Fifteen patients (94%) received G-CSF prophylaxis during chemotherapy. G-CSF 
support was given as secondary prophylaxis (i.e. after a prior episode of febrile 
neutropenia and/or prolonged neutropenia) In 7 patients (44%) of the 15 patients.   
G-CSF support was given as primary prophylaxis in the remaining 8 patients 
(53.3%). One patient in the non-PI group did not require G-CSF (primary or 
secondary). See Table 3-3 for details of G-CSF prophylaxis.  
 
Table 3-3 G-CSF prophylaxis in the PI-based vs. non-PI based groups in 
patients with HIV-associated Hodgkin lymphoma 
*P-value determined using Fisher’s exact test.  
G-CSF use  PI-based 
 cART n (%) 
Non-PI based 
cART n (%) 
P-value 
Primary G-CSF 
prophylaxis 
4 (40) 4 (66.7) 0.28* 
 
Secondary  
G-CSF prophylaxis 
6 (60) 1 (16.7) 
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3.1.6 Treatment-related toxicities  
3.1.6.1 Neurotoxicity  
Neurotoxicity (NT) of any grade occurred in 8 (50%) patients, and of these 8 patients, 
5 experienced grade 3-4 NT.  Peripheral neuropathy was the most common 
neurotoxicity in 6 of the 8 patients with any grade NT. Two patients of the 5 patients 
experiencing grade 3-4 NT, developed autonomic neuropathy presenting as severe 
constipation and faecal loading. Both patients were on a PI-based regimen, namely 
ritonavir-boosted lopinavir based regimen.  
 
Overall, more patients in the PI group had neurotoxicity compared to the non-PI 
group. Seven patients (70%) of the 10 patients in the PI group had any grade 
neurotoxicity compared to one patient (17%) of the 6 patients in the non-PI group 
(p=0.12, using Fisher’s exact test). It is important to note that the patient with NT in 
the non-PI group had pre-treatment neuropathy from the use of didanosine as part of 
his previous cART regimen 
 
Five patients (50%) in the PI group had grade 3-4 NT compared to none in the non-
PI group (p=0.09, Fisher’s exact test). The use of ritonavir was associated was a 
statistically significant occurrence of any grade NT and grade 3-4 NT (Fisher’s exact 
test, p=0.04 and p=0.03, respectively). 
 
3.1.6.2 Haematological toxicity  
Grade 3-4 haematological toxicities occurred in 31 (41%) ABVD cycles from a total of 
76 ABVD cycles administered to 16 patients with HIV-associated HL. Grade 3-4 
haematological toxicities were significantly more common in patients on PI-based 
regimen compared to those on non-PI based regimens; 26 (56.5%) of 46 cycles 
when prescribed PI-based regimen and 5 (17%) of 30 cycles when prescribed non-PI 
based regimen (p= 0.001, Fisher’s exact test)  
The median nadir neutrophil values during all chemotherapy cycles in patients 
receiving PI-based cART was significantly lower compared to patients on a non-PI 
based cART. Results shown in Table 3-4. 
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Table 3-4. Median nadir neutrophil count in patients with HIV-associated 
Hodgkin lymphoma on PI-based and non-PI based cART 
 PI-based cART 
Median (range) 
Non-PI cART 
Median (range) 
P-value 
Nadir neutrophil count x 
109/L 
0.15 [0-1] 0.95 [0.1-2.2] 0.015 § 
§P-value determined using the Mann-Whitney U test  
 
Grade 3-4 anaemia were recorded in 3 (4%) of the 76 cycles of ABVD; 3 (6.5%) of 
the 46 ABVD cycles episodes were in the PI group compared to none of the 30 
ABVD cycles in the non-PI group.  
 
3.1.6.3 Infections 
Grade 3-4 infections requiring hospitalization and the administration of the IV 
antibiotics were recorded for 10(13%) of the 76 cycles of ABVD; 10 (22%) of 46 
ABVD cycles episodes were in the PI group vs. none of the 30 ABVD cycles in the 
non-PI group (p=0.005, Fisher’s exact test). Expectedly, the median number of days 
on G-CSF used for the management of febrile neutropenia for patients in the PI 
group was greater compared to the non-PI group; 7 (range, 5-11) days vs. 0 days, 
respectively. (p=0.034, Mann-Whitney U test) 
 
3.1.6.4 Other adverse effects 
Grade 1-2 mucositis occurred in 3 patients (19%) of the 16 patients, all 3 patients 
were in the PI-group compared to none in the non-PI group. Two patients (one in 
each of the PI-group and non-PI groups) experienced changes in their respiratory 
function test, which resulted in the cessation of bleomycin. No evidence for long-term 
respiratory toxicity was evident during follow-up of both patients. Apart from changes 
in respiratory function tests, another two patients experienced allergic reactions to 
bleomycin (rigors, fevers and sweats), which led to the cessation of bleomycin.   
 The first patient was in the PI group; the bleomycin was omitted after the first 
chemotherapy cycle. 
 The second patient was in the non-PI group; bleomycin was changed to 
etoposide IV 100mg/m2 on day1+ day15 after the second chemotherapy cycle. 
 
 46 
One patient in the PI group developed severe pancreatitis after the 3rd cycle of 
chemotherapy, which led to the cessation of both the chemotherapy and cART. The 
patient was on abacavir 600mg+ tenofovir+ nelfinavir+ didanosine (250mg daily). 
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3.1.7 Chemotherapy dose reductions and/or changes due to toxicity 
Eight (50%) of the 16 patients had their chemotherapy reduced or changed during 
their course of treatment. Of these 8 patients, 2 were in the non-PI group compared 
to 6 patients in the PI-group (p=0.6, Fisher’s exact test). Table 3-5 illustrates 
chemotherapy dose reductions and/or changes in both the PI & non-PI groups. 
Vinblastine dose reductions or omissions were reported in 6 patients (37.5%), 5 
patients (50%) in the PI-group compared to one patient (17%) in the non-PI group 
(p=0.3, Fisher exact test). Vinblastine was changed to etoposide 100mg/m2 IV on 
day1+ day15 in 5 patients, all in the PI-group. 
 
Table 3-5. Dose reductions and/or changes in chemotherapy in patients with 
HIV-associated Hodgkin lymphoma  
Patient 
no.  
cART regimen  Details of changes and/or reductions in chemotherapy 
HL-5 
 
(PI-based) 
 
DRV/r (twice 
daily)+ETR+RAL 
Bleomycin omitted after cycle 4 due to changes in lung 
function test. Vinblastine changed to etoposide from cycle 5 
due to constipation and peripheral neuropathy. 
HL-6  
 
(PI-based) 
 
LPV/r+TDF+T20 
Vinblastine changed to etoposide from cycle 3 due to 
severe constipation, faecal loading and peripheral 
neuropathy. 
HL-7 
 
(PI-based) 
 
ABC+ATV/r+TDF 
Vinblastine changed to etoposide from cycle 4 due to 
peripheral neuropathy. 
HL-8 
 
(PI-based) 
 
d4T+ 
NVP+3TC+LPV/r 
Bleomycin omitted after cycle 1 due to allergic reaction. 
HL-9 
 
(PI-based) 
 
LPV/r+3TC+ddI 
Vinblastine changed to etoposide from cycle 4 because of 
severe constipation, faecal loading and peripheral 
neuropathy. 
HL-14 
 
(PI-based) 
 
LPV/r+ 3TC/ABV 
Vinblastine changed to etoposide from cycle 3 due to 
peripheral neuropathy 
HL-3 
 
(non-PI based) 
 
3TC/ABC+EFV 
Bleomycin changed to etoposide from cycle 2 due to drug 
reaction fevers, sweats and rigors with bleomycin 
HL-10 
 
(non-PI based) 
 
TDF+3TC+ EFV 
Bleomycin after cycle 3 omitted due to changes in lung 
function test. Vinblastine 50% dose reduction from cycle 4 
due to peripheral neuropathy. 
Key to abbreviations: DRV/r= ritonavir-boosted darunavir, ETR= etravirine, RAL= raltegravir, LPV/r= 
ritonavir-boosted lopinavir, TDF= tenofovir, T20= enfuvirtide, ABC= abacavir, ATV/r= ritonavir-boosted 
atazanavir, d4T= stavudine, NVP= nevirapine, 3TC= lamivudine, ddI= didanosine, EFV= efavirenz 
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3.1.8 Full dose chemotherapy from start of treatment 
Four patients (25%) did not receive full-dose (100%) intensity chemotherapy from the 
start of treatment. All the remaining 12 patients received full dose intensity 
chemotherapy from the start of their HL treatment. Table 3-6 outlines treatment 
details for the four patients. 
 
Table 3-6 Reasons for not receiving 100% dose intensity of ABVD 
chemotherapy from the start of treatment 
Patient no. cART regimen Reasons for not receiving 100% dose intensity 
of ABVD chemotherapy from the start of HL 
treatment  
HL-7 (PI-based) 
ATV/r+ ABC+TDF 
BSA= 2.3 m2. ABVD dose capped at 2m2 for all 
chemotherapy cycles. 
HL-9 (PI based) 
LPV/r+3TC+ddI  
Doxorubicin was reduced by 50% for 1st cycle due 
to high bilirubin. Then dose increased to 100% 
dose intensity from cycle 2.  
HL-14 (PI-based) 
LPV/r+ 3TC/ABC 
BSA= 2.71 m2. ABVD capped at 2m2 for all 
chemotherapy cycles. 
HL-15 (non-PI based) 
RAL+3TC/ABC 
BSA= 2.05 m2. ABVD dose capped at 2m2 for all 
chemotherapy cycles.  
Key to abbreviations: ATV/r= ritonavir-boosted atazanavir, ABC=abacavir, TDF= tenofovir, LPV/r= 
ritonavir-boosted lopinavir,3TC= lamivudine , ddI= didanosine, RAL= raltegravir,  
 
3.1.9 Chemotherapy delays 
More chemotherapy delays were observed in the PI-group. Chemotherapy delays 
occurred in 10(13%) of total 76 cycles of ABVD administered; 9(19.6%) of 46 cycles 
in the PI-group compared to 1(3%) of 30 cycles in the non-PI group. P-value was 
marginally insignificant (p=0.08, Fisher’s exact test).  See Figure 3-2 for reasons for 
delays in chemotherapy. The Median number of delay-days in chemotherapy 
administration in the PI-group was higher compared to the non-PI group, but the 
difference did not reach statistical significance; 7 (range, 4-14) days in the PI-group 
compared to 5 days in the non-PI group (p=0.09, Mann-Whitney U test). 
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Figure 3-2 Reasons for delays in chemotherapy administration in patients with 
HIV-associated Hodgkin lymphoma (n=16) 
 
 
Table 3-7. Reasons for not completing full course of ABVD chemotherapy  
(N=5, all on PI-based regimens) 
Patient 
no. 
No. of planned 
Chemotherapy 
cycles 
No. of actual 
chemotherapy 
Cycles given 
Reasons for not 
completing full 
course of 
chemotherapy 
Additional 
Treatment given 
HL-9 6 5 Constipation, 
peripheral neuropathy 
and lethargy 
Nil 
HL-11 4 3 Significant nausea 
and vomiting, fatigue, 
and three episodes of 
febrile neutropenia 
Local 
radiotherapy to 
inguinal lesion 
HL-12 6 5 Febrile neutropenia 
and peripheral 
neuropathy 
Nil 
HL-13 4 3 Severe pancreatitis 
after cycle 3 of 
chemotherapy 
Nil 
HL-16 4 3 Significant nausea 
and vomiting and 
neutropenic sepsis 
Local field 
radiotherapy 
Febrile 
neutropenia/neut
ropenic sepsis 
50% 
Nausea and 
vomiting 20% 
Severe 
constipation and 
faecal loading 
20% 
Non febrile 
myelosuppression
, 10% 
Febrile 
neutropenia/neutropenic 
sepsis 
Nausea and vomiting  
Severe constipation and faecal 
loading 
Non febrile myelosuppression 
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3.1.10 Completion of stage appropriate chemotherapy 
Five patients did not complete their full planned chemotherapy course; all five 
patients were in the PI group 5 (50%) compared to none in the non-PI group (p=0.09, 
using Fisher’s exact test). Reasons for not completing full course of stage 
appropriate chemotherapy treatment are shown in Table 3-7. 
 
3.1.11 cART interruption during chemotherapy 
cART interruptions were recorded in two patients: 
 First patient ceased his cART regimen (lopinavir/ritonavir+ lamivudine and 
tenofovir) after two cycles of his ABVD chemotherapy because of worsening 
nausea and vomiting. His cART was resumed after the completion of 
chemotherapy with same regimen.  
 
 Second patient, developed severe pancreatitis after 3rd cycle of chemotherapy, 
which led to the cessation of both the cART and chemotherapy. Patient’s cART 
regimen at the time was abacavir+tenofovir+nelfinavir and didanosine 250mg 
daily. Patient resumed his cART four months after the completion of 
chemotherapy with same previous cART regimen but without didanosine i.e. 
abacavir+tenofovir and nelfinavir. The patient’s cART was again changed 12 
months later to abacavir/lamivudine+ tenofovir+ raltegravir+ darunavir and 
ritonavir. 
 
All the other patients maintained their same cART regimens during their 
chemotherapy and for at least 6 months after completion of their chemotherapy.  
No adherence issues to cART regimens during chemotherapy were identified for any 
of the other patients included in the HL analysis. 
 
3.1.12 CD4 cell count and HIV-viral load (VL) after chemotherapy 
Median CD4 cell count and HIV-VL results at HL diagnosis, 1-3 months post 
chemotherapy, 6-9 months post chemotherapy and 12-15 months post 
chemotherapy are shown in Tables 3-8 & 3-9. The median CD4 cell count at HL 
diagnosis was the lowest in comparison to the median CD4 cell count values post 
chemotherapy. 
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CD4 cell counts at 1-3 months post chemotherapy continued to increase steadily to 
higher values at 6-9 months and 12-15 months post chemotherapy. When comparing 
the median CD4 cell count values after chemotherapy, the median value at 1-3 
months post chemotherapy was significantly lower compared to those at 6-9 months, 
and 12-15 months post chemotherapy (Wilcoxon test, p= 0.049 and p= 0.006, 
respectively).  
 
Table 3-8 Median CD4 cell count at diagnosis and post chemotherapy  
CD4 cell count 
(cells/µL) 
 at HL diagnosis 
CD4 cell count 
(cells/µL) 
 1-3 months post 
chemotherapy  
CD4 cell count 
(cells/µL) 
 6-9 months post 
chemotherapy 
CD4 cell count 
(cells/µL) 
12-15 months post 
chemotherapy 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
16 233.5 
[14-970] 
15 372 
[10-748] 
14 393 
[18-961] 
14 463 
[30-978] 
 
Table 3-9 Median HIV viral load (VL) at diagnosis and post chemotherapy  
HIV-VL 
 (copies/mL) 
at HL diagnosis 
HIV-VL (copies/mL) 
1-3 months post 
chemotherapy 
HIV-VL (copies/mL) 
6-9 months post 
chemotherapy 
HIV-VL 
(copies/mL) 
12-15 months post 
chemotherapy 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
16 <50 
[<50-
481000] 
15 <50 
[<50-
265000] 
14 <50 
[<50-
22600] 
14 <50 
[<50-
81000] 
 
When comparing the median CD4 cell count values post chemotherapy across PI 
and non-PI groups, the value at 1-3 months post chemotherapy was significantly 
lower in the PI-group compared to the non-PI group (p=0.05, Kruskal Wallis test). 
There was no statistically significant differences in the median CD4 cell count values 
at 6-9 months and 12-15 months post chemotherapy between the two groups. See 
Figure 3-3 
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Figure 3-3 Median CD4 cell count post chemotherapy in PI and non-PI groups 
in HL patients (PI-based regimen = 10, non-PI based regimen= 6) 
 
 
Figure 3-3 P-value is significant (p=0.05) for difference in median CD4 count 1-3 months post 
chemotherapy, P-value is non-significant for median CD4 count at 6-9 months and at 12-15 months 
post chemotherapy 
3.1.13 Clinical outcomes 
Response rates  
The overall response rate at the end of treatment for the HL cohort was 100%.  All 16 
patients achieved complete remission (CR) or unconfirmed complete remission 
(CRu), 14 (87.5%) patients achieved CR and 2 (12.5%) patients achieved CRu.  
 
Overall Survival (OS)  
All patients (100%) were alive at the last date censored. Median OS was 62 (range, 
32-121) months.  
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Relapses and disease free survival (DFS): 
Median DFS was 58 (range, 30-111) months. Two relapses occurred, both in were 
the PI group compared to no relapses in the non-PI group. There was no evidence 
of a difference in DFS between the PI and the non-PI group using the Kaplan-Meier 
method and the significance in survival by the log-rank test (p=0.2). See Figure 3-4 
for Kaplan Meier DFS curves. 
 
Relapse details: 
1- First patient, relapsed at 30 months post HL treatment, patient underwent 
salvage chemotherapy with BEACOPP chemotherapy followed by autologous 
haematopoietic stem cell transplant (ASCT). Patient achieved remission and is 
still well, alive and disease free at 93 months post initial lymphoma diagnosis. 
2- Second patient relapsed at 70 months post HL treatment, received salvage 
chemotherapy with BEACOPP chemotherapy. Patient achieved remission, and is 
alive and disease free at 121 months post initial lymphoma diagnosis. 
It is worthy of note that the 2 patients who relapsed were among the 5 patients who 
did not complete their stage appropriate chemotherapy due to side effects. 
The two relapsed patients also shared the following: 
 CD4 count of <100 cells/µL at diagnosis. 
 Prior AIDS illness. 
 Experienced cART holidays prior to lymphoma diagnosis. 
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Figure 3-4 Kaplan Meier analysis of disease free survival for patients with HIV-
associated HL (n= 16) 
 
 
3.2 Burkitt lymphoma (BL) data analyses 
 
3.2.1 Patient baseline characteristics  
Characteristics of 13 patients diagnosed with biopsy proven HIV associated-BL are 
shown in Table 3-10. The median age at BL diagnosis was 45 (range, 27-72) years.  
Most patients were males 12 (92%), and one female (8%). MSM was the most 
common risk factor for HIV acquisition in 10 (77%) of the patients. Other HIV 
exposure risks included: n=1 intravenous injection drug use, n=1 heterosexual 
contact and n=1 occupational exposure. HIV characteristics included a median CD4 
cell count at BL diagnosis (n= 13) of 330 (range, 28-620) cell/µL and median HIV-VL 
(n=13) of 4159 (range, <50 to >750,000) copies/mL. Only one patient had 
undetectable HIV-VL (≤50 copies/mL) at BL diagnosis. 
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HIV diagnosis was made prior to the lymphoma diagnosis in 12 patients (92%), and 
in one patient (8%) HIV diagnosis was incidental during lymphoma workup. The 
median duration of HIV infection prior to lymphoma diagnosis was 8 (range, 0-24) 
years. 
 Prior AIDS illnesses occurred in 2 patients (15%), both were in the PI group 
compared to none in the non-PI group (67% vs.0%, p=0.038, using Fisher’s exact 
test). Prior AIDS illnesses were: KS in one patient, and CMV retinitis & oesophageal 
candidiasis in the other patient. Baselines characteristics in patients receiving PI- 
based cART were compared with those on non-PI based cART (see Table 3-10). 
 
Table 3-10. Baseline characteristics of patients (n=13) with HIV-associated 
Burkitt lymphoma 
 
 
Total n (%) PI-based  
cART n(%) 
Non-PI based 
 cART n(%) 
P-
value 
No. Patients  13 3 10 ‘  
Median age [range] at BL 
diagnosis.  
45 [27-72] 56 [44-64] 43.5 [27-72] 0.2§ 
≤45 5 (38) 1 (33) 4 (40)  
>45 8 (62) 2 (67) 6 (60)  
Gender 
Male 12 (92) 3 (100) 9 (90)  
Female 1 (8) 0 (0) 1 (10)  
HIV risk  
Male to male sexual 
contact 
10 (76.9) 2 (67) 8 (80)  
Heterosexual contact 1 (7.7) 0 1 (10)  
Injecting drug use 1 (7.7) 1 (33) 0 (0)  
Occupational exposure 1 (7.7) 0 1 (10)  
Prior AIDS  
No 11 (85) 1 (33) 10 (100) 0.038* 
Yes 2 (15) 2(67) 0 (0) 
Median CD4 cell count 
[range] at BL diagnosis  
330 [28-620] 304 [28-391] 340 [246-620] 0.47§ 
>200 cells/µL 12 (92) 2 (67) 10 (100)  
≤200 cells/µL 1 (8) 1 (33) 0 (0)  
≤100 cells/µL 1 (8) 1 (33) 0 (0)  
HIV viral load (VL) at diagnosis  
<50 (undetectable)  1(8) 0(0) 1(10) 1* 
>50 12 (92) 3 (100) 9 (90)  
Hepatitis B co-infection 
Known negative 6 (46) 2 (67) 4 (40) 0.56* 
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Known positive 
 
7 (54) 1 (33) 6 (60) 
Hepatitis C co-infection 
Known negative 11 (85) 2 (67) 9 (90) 0.42* 
Known positive 2 (15) 1 (33) 1 (10) 
BL stage 
I-II 0(0) 0(0) 0 (0) 1* 
III-IV 13 (100) 3 (100) 10 (100) 
Magrath score 
Low risk  4 (31) 1 (33) 3 (30) 1* 
High risk  9 (69) 2 (67) 7 (70) 
ECOG PS  
0-1 6 (46) 1 (33) 5 (50) 1* 
>2 7 (54) 2 (67) 5 (50) 
B-symptoms 
Yes 12 (92) 3 (100) 9 (90) 1* 
No 1 (8) 0 (0) 1 (10) 
LDH 
Normal 3 (23) 0 (0) 3 (30) 0.53* 
Elevated 10 (77) 3 (100) 7 (70) 
Bone marrow involvement 
Yes 4 (31) 1 (33) 3 (30) 1* 
No 9 (69) 2 (67) 7 (70) 
CNS involvement  
Yes 3 (23) 1 (33) 2 (20) 1* 
No 10 (77) 2 (67) 8 (80) 
Extranodal involvement 
Yes 8 (62) 3 (100) 5 (50) 0.23* 
No 5 (38) 0 (0) 5 (50) 
§P-value determined using Mann-Whitney U test  *P-value determined using Fisher’s exact test 
 
3.2.2 Combination antiretroviral therapy 
Five (38.5%) of 13 patients were cART naïve at BL diagnosis.  All other 8 patients 
were on cART at the time of BL diagnosis. Median duration on cART prior to BL 
diagnosis for the remaining 8 patients was 42 (range, 11-180) months.  Two patients 
had cART holidays prior to lymphoma diagnosis; one patient was in the PI group, 
with a period of 6 months off cART. The other patient was in the non-PI group, with a 
period of 66 months off cART. All 13 patients were on cART during all cycles of 
chemotherapy, except for one patient who started cART by the second cycle of 
chemotherapy regimen (CODOX-M/IVAC). None of the patients changed their cART 
regimen during chemotherapy.  
 
Three patients (23%) were receiving PI-based cART at the time of chemotherapy, 
and 10 patients (77%) were on non-PI based cART (see Table 3-11 for cART 
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details). 
All three patients in the PI group were on ritonavir-boosted lopinavir cART, with one 
patient on both atazanavir and ritonavir-boosted lopinavir cART. In the non-PI group, 
8 patients were on efavirenz-based cART and 2 patients on nevirapine-based cART. 
 
Table 3-11 Combination antiretroviral therapy details for Burkitt lymphoma 
patients  
Patient no. cART regimen Regimen type 
BL-1 LPV/r+ 3TC+TDF+ATV PI-based 
BL-2 TDF+3TC+ NVP NNRTI-based = non-PI based 
BL-3 
3TC/ABC+EFV+RAL 
NNRTI-based + raltegravir = non-PI 
based 
BL-4 TDF+FTC+ EFV NNRTI-based = non-PI based 
BL-5 TDF+3TC+ EFV NNRTI-based = non-PI based 
BL-6 NVP+TDF+ddI 250mg NNRTI-based = non-PI based 
BL-7 TDF+3TC+ EFV NNRTI-based = non-PI based 
BL-8 LPV/r+ 3TC/ABC PI-based 
BL-9 TDF+FTC+ EFV NNRTI-based = non-PI based 
BL-10 3TC/ABC+EFV NNRTI-based = non-PI based 
BL11 LPV/r +FTC/TDF PI-based 
BL-12 TDF/FTC+ EFV NNRTI-based = non-PI based 
BL-13 TDF/FTC+ EFV NNRTI-based = non-PI based 
Key to abbreviations: LPV/r= ritonavir-boosted lopinavir, 3TC= lamivudine, TDF= tenofovir, 
ATV= atazanavir, NVP= nevirapine, ABC=abacavir, EFV= efavirenz, RAL= raltegravir, 
ddI=didanosine, FTC=emtricitabine 
 
3.2.3 Chemotherapy 
A total of 38 chemotherapy cycles were administered during the course of treatment 
of 13 patients with BL. Eight chemotherapy cycles (21%) of the total 38 cycles were 
administered to patients in the PI-group compared to 30 cycles (79%) in the non-PI 
group.  The main chemotherapy regimen used was CODOX-M/IVAC in 34 (89.5%) of 
the 38 cycles (16 cycles of CODOX-M/IVAC with high dose methotrexate of 
6720mg/m2 and 18 cycles of CODOX-M/IVAC with high dose methotrexate of 
1000mg/m2). EPOCH chemotherapy was used in 4 (10.5%) of the 38 cycles. See 
Table 3-12 for the distribution of chemotherapy regimens between patients in the PI 
and the non-PI groups.  All patients received intrathecal (IT) chemotherapy as part of 
CODOX-M/IVAC protocol (IT cytarabine, IT methotrexate and IT hydrocortisone). 
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Table 3-12 Chemotherapy treatment details for Burkitt lymphoma patients 
(n=13) 
 
3.2.4 Antimicrobial prophylaxis during chemotherapy 
All thirteen patients received PJP prophylaxis (n=11 sulfamethoxazole/trimethoprim 
800mg/160mg three times weekly or 400mg/80mg once daily, n=2 received dapsone 
100mg thrice weekly). Twelve patients (92%) received prophylaxis for herpes simplex 
virus (HSV) and/or varicella zoster virus (VZV) (valaciclovir 500mg twice daily or 
acyclovir 200mg three times daily). 
All thirteen patients (100%) received fungal prophylaxis  (n=10 with fluconazole 100-
200mg daily and n=3 with itraconazole 200mg twice daily). One patient received 
MAC prophylaxis with azithromycin 1200mg weekly. Same patient also received 
CMV prophylaxis with valganciclovir 900mg daily. The patient had a CD4 count of 28 
cells/µL at BL diagnosis. 
 
3.2.5 G-CSF prophylaxis during chemotherapy 
All patients received primary G-CSF prophylaxis during their chemotherapy. 
Filgrastim 5mcg/kg/day was used as prophylaxis in all patients. 
 
3.2.6 Treatment-related toxicities and infections 
3.2.6.1 Neurotoxicity 
Neurotoxicity (NT) of any grade occurred in 6 patients (46%) in the BL cohort, and of 
these 6 patients, 3 experienced grade 3-4 NT. When comparing the incidence of NT 
among patients on PI and non-PI based regimens, there were more rates of any 
Regimen Total number 
of cycles 
Number of cycles 
administered  
 PI-based group 
Number of cycles 
administered  
non-PI based group 
EPOCH 4 3 1 
CODOX-M/IVAC 
(MTX 1g/m2) 
18 3 15 
CODOX-M/IVAC 
(MTX 6.72g/m2) 
16 2 14 
Total 38 8 30 
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grade NT and grade 3-4 NT in the PI group compared to the non-PI group but the 
differences were marginally insignificant (Fisher’s exact test, 100% vs. 30%, p=0.07 
and 67% vs. 10% p=0.10, respectively).  
 
Grade 3-4 NT in two patients in the PI-group manifested as severe autonomic 
neuropathy with severe constipation and bowel obstruction. The first patient was on 
ritonavir-boosted lopinavir and received CODOX-M/IVAC chemotherapy for BL 
treatment. The second patient was on ritonavir-boosted lopinavir as well as 
atazanavir as part of the same cART regimen and received EPOCH chemotherapy. 
The patient went on to develop paralytic ileus as a complication of the constipation 
and the bowel obstruction. Grade 3-4 NT in one patient non-PI group also manifested 
as severe bowel obstruction and paralytic ileus. The patient cART regimen consisted 
of efavirenz, tenofovir/emtricitabine. However, It is important to note that the patient 
suffered from pre-treatment neuropathy and was on itraconazole for fungal 
prophylaxis concurrently with the CODOX-M/IVAC treatment. 
 
3.2.6.2 Haematological toxicity  
Grade 3-4 haematological toxicities occurred in 35 (92%) of the 38 chemotherapy 
cycles. No differences in grade 3-4 haematological toxicities or grade 3-4 anaemia 
were observed between the PI and the non-PI group. Haematological toxicities 
occurred in all 8 chemotherapy cycles (100%) in the PI group vs. 27 (90%) of 30 
cycles in the non-PI group. Grade 3-4 anaemia occurred in 3 (37.5%) of the 8 cycles 
in the PI group vs. 6 (20%) of 30 cycles in the non-PI group. 
 
3.2.6.3 Infections 
Grade 3-4 infections were observed in 24 episodes during the 38 chemotherapy 
cycles; 14 episodes (58%) were culture negative febrile neutropenia (FN) and 10 
episodes (42%) were bacterial infections.  
Four FN episodes were in the PI group vs. 10 in the non-PI group. Three bacterial 
infections episodes were in the PI group vs. 7 in the non-PI group. There was no 
difference in terms of the median number of days on G-CSF for the management of 
febrile neutropenia between the PI and the non-PI group. Ten (range, 8-15) days in 
the PI-group compared to 8 (range, 7-27) days in the non-PI group (p=0.4, Mann 
Whitney U test). 
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3.2.6.4 Mucositis 
All grades mucositis occurred in a total of 9 patients (69%) of 13 patients.  Any grade 
mucositis developed in all 3 patients (100%) in the PI group and 6 (60%) patients 
from the non-PI group (p=0.5, Fisher’s exact test). Grade 3-4 mucositis occurred in a 
total of 7 patients (54%), 3 patients (100%) in the PI group and 4 (40%) patients in 
the non-PI group (p=0.2, Fisher’s exact test). 
 
3.2.6.5 GI-toxicities 
Grade 3-4 nausea and vomiting were observed in two patients in the PI group and 
one patient in the non-PI group. Grade 3-4 diarrhoea occurred in one patient in the 
PI-group compared to none in the non-PI group. 
 
3.2.6.6. Other toxicities 
 Grade 3-4 increased liver enzymes were noted in two patients, both in the non-PI 
group. First patient was on efavirenz+tenofovir/emtricitabine and the second 
patient on efavirenz+ lamivudine/abacavir.  
 One patient in the non-PI group developed cardiac problems, presenting as 
supraventricular tachycardia (SVT), which responded to adenosine IV treatment. 
 One patient in the non-PI group developed skin reaction, which was suspected to 
be due to methotrexate.  
 One patient in the non-PI group developed haemorrhagic cystitis after cycle 2 of 
IVAC possibly due to cyclopshophamide.  
 Transient renal impairment, presenting as doubling of serum creatinine, was seen 
in one patient after 3rd high dose methotrexate cycle, the patient was on a non-PI 
based therapy that included lamivudine+efavirenz and tenofovir. See Table 3-13 
for a summary of all treatment-related toxicities. 
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Table 3-13 Treatment-related toxicities in 13 HIV-associated Burkitt lymphoma 
patients 
Treatment-related toxicity Total no. of 
episodes 
PI-based 
cART 
n= episodes 
non-PI based 
cART 
n= episodes 
Grade 1-2 neurotoxicity 6 3 3 
Grade 3-4 neurotoxicity 3 2 1 
Grade 3-4 haematological toxicity 35 8 27 
Grade 3-4 culture negative febrile 
neutropenia 
14 4 10 
Documented bacterial infection  10 3 7 
All infections/febrile neutropenia 24 7 17 
Grade 1-2 mucositis 9 3 6 
Grade 3-4 mucositis 7 3 4 
Grade 3-4 Nausea and vomiting 6 5 1 
Grade 3-4 diarrhoea 2 2 Nil 
Grade 3-4 ALT/AST elevation^ 2 Nil 2 
Cardiac arrythmias  1 Nil 1 
Haemorrhagic cystitis  1 Nil 1 
Skin reaction 1 Nil 1 
Renal impairment/elevation in 
serum creatinine 
1 Nil 1 
^AST/ALT = liver transaminases 
 
3.2.7 Treatment related-deaths 
One patient in the PI group died as a result of neutropenic sepsis in the context of 
prolonged neutropenia after the third cycle of chemotherapy. This patient was on a 
PI-based cART that included atazanavir 300mg daily+ lopinavir/ritonavir 
300mg/75mg twice daily + lamivudine 300mg daily and tenofovir 300mg daily. 
 
3.2.8 Chemotherapy dose reductions and/or changes due to toxicity 
Seven (54%) of the 13 patients had their chemotherapy reduced or changed during 
their chemotherapy course. Two patients (67%) were in the PI group and 5 patients 
(50%) in the non-PI group. Table 3-14 illustrates chemotherapy dose reductions 
and/or changes in both the PI & non-PI groups. 
 
3.2.9 Full dose chemotherapy from start of treatment 
Four patients (31%) did not receive full-dose (100%) intensity chemotherapy from the 
start of their treatment. Table 3-15 outlines treatment details for the four patients. 
Table 3-14 Chemotherapy dose reductions and/or changes for BL patients  
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Key to abbreviations: LPV/r= ritonavir-boosted lopinavir, 3TC= lamivudine, TDF= tenofovir, ATV= 
atazanavir, NVP= nevirapine, ddI=didanosine, EFV= efavirenz, FTC=emtricitabine,  
 ABC=abacavir, RAL= raltegravir 
 
Table 3-15 Reasons for not receiving 100% dose intensity chemotherapy from 
the start of treatment 
Patient no. cART regimen Reasons for not receiving 100% 
dose intensity of chemotherapy from 
the start of BL treatment  
BL-3 (non-PI-based) 
3TC/ABC+EFV+RAL 
BSA= 2.12 m2. CODOX-M/IVAC dose 
capped at 2m2  
BL-5 (non-PI based) 
TDF+3TC+ EFV 
BSA = 2.2 m2. CODOX-M/IVAC dose 
capped at 2m2 
BL-9 (non-PI based) 
TDF/FTC+ EFV 
BSA= 2.14 m2. CODOX-M/IVAC 
capped at 2m2  
BL-12 (non-PI based) 
TDF/FTC+ EFV 
Cytarabine was reduced to 1g/m2 BD 
from cycle 1 due to age (>65 years)  
Key to abbreviations: 3TC= lamivudine, ABC=abacavir, EFV= efavirenz, RAL= raltegravir, TDF= 
tenofovir, FTC=emtricitabine 
 
Patient no. & 
Chemotherapy 
regimen (n=7) 
cART agents Details of changes and/or reductions in 
chemotherapy 
BL-1 
EPOCH Q3 weeks 
LPV/r+ 
3TC+TDF+ATV 
(PI-based regimen)  
Vincristine changed to vinblastine from 3rd 
chemotherapy cycle due to autonomic 
neuropathy & paralytic ileus 
BL-6 
CODOX-M 
(6.72g/m2)/IVAC 
NVP+TDF+ddI  
(non-PI based 
regimen) 
Methotrexate reduced to 1g/m2 from 2nd 
chemotherapy cycle due to severe mucositis 
BL-7 
CODOX-M 
(6.72g/m2)/IVAC 
 
TDF+3TC+ EFV 
(non-PI based 
regimen) 
 
Methotrexate reduced to 1g/m2 due to severe 
mucositis and vincristine changed to 
vinblastine due to peripheral neurotoxicity 
from 2nd cycle  
BL-4 
CODOX-M 
(6.72g/m2)/IVAC 
 
TDF/FTC+ EFV 
(non-PI based 
regimen) 
 
Vincristine omitted from 2nd cycle due to 
severe constipation, bowel obstruction and 
paralytic ileus with first cycle of 
chemotherapy  
BL-11 
CODOX-M 
(6.72g/m2)/IVAC 
LPV/r+FTC/TDF 
(PI-based regimen) 
Vincrsitine changed to vinblastine 
from 2nd chemotherapy cycle due to 
significant constipation and bowel obstruction 
BL-3 
CODOX-M 
(1g/m2)/IVAC 
3TC/ABC+EFV+RAL 
(non-PI based 
regimen) 
Methotrexate further reduced to 1g total dose 
from cycle two of chemotherapy 
BL-12 
CODOX-M 
(1g/m2)/IVAC 
 
TDF/FTC+ EFV 
(non-PI based 
regimen) 
 
Methotrexate changed to 
 500mg/m2 from last cycle due to rash. 
Vincristine changed to vinblastine due to 
peripheral neurotoxicity from 2nd cycle.  
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3.2.10 Chemotherapy delays 
Chemotherapy delays occurred in 16 (42%) of total 38 cycles. There were 3 more 
significant chemotherapy delays in the PI-based cART group compared to the non-PI 
cART group; 6(75%) of 8 cycles in the PI-group compared to 10(33%) of 30 cycles in 
the non-PI group (p=0.05, Fisher’s exact test).  Median number of chemotherapy 
delay-days in the PI-group was 26 (range, 7-44) days compared to 17 in the non-PI 
group (range, 7-25) days  (p=0.18, Mann-Whitney U test). Reasons for delay in 
chemotherapy administration are shown in Figure 3-5. 
 
Figure 3-5 Reasons for delay in chemotherapy administration in patients with 
HIV-associated Burkitt lymphoma (n=13) 
 
3.2.11 Completion of stage appropriate chemotherapy 
Three patients  (23%) did not complete their full planned course of chemotherapy, 
n=2 in the PI group and n=1 in the non-PI group, Details of reasons for not 
completing full course of stage appropriate chemotherapy treatment are shown in 
Table 3-16. 
 
 
 
 
 
 
Febrile 
neutropenia/neu
tropenic sepsis, 
31% 
Infection with 
normal 
neutrophils, 
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mucositis, 25% 
Autonomic 
neuropathy, 
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Non febrile 
myelosupression
, 13% 
Febrile 
neutropenia/neutropenic 
sepsis 
Infection with normal 
neutrophils 
Severe mucositis 
Autonomic neuropathy 
Non febrile 
myelosupression 
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Table 3-16 Reasons for not completing full course of chemotherapy for 
patients with HIV-associated Burkitt lymphoma 
Patient no. No. of planned 
Chemotherapy 
cycles 
No. of actual 
chemotherapy 
Cycles given 
Reasons for not 
completing full course of 
chemotherapy 
BL-1 
(PI-based 
group) 
6 cycles of EPOCH 3 cycles Patient died of neutropenic 
sepsis after cycle 3 of 
EPOCH 
BL-2 
(Non-PI 
based group) 
2 cycles of CODOX-
M/IVAC 
(Patient had EPOCH 
as first cycle) 
Did not get IVAC 
arm of cycle 2 of 
CODOX-M/IVAC 
Neutropenic sepsis and 
progressive weakness 
BL-11 
(PI-based 
group) 
3 cycles of CODOX-
M/IVAC 
Completed 2 
cycles only 
Marked cytopenias, febrile 
neutropenia and severe 
pneumococcal infection 
 
3.2.12 cART interruption during chemotherapy 
cART interruption for more than 3 days during chemotherapy occurred in five 
patients, n=2 in the PI-group and n=3 in the non-PI group. The median duration of 
cART interruption during chemotherapy was 6 (range 4-13) days. Reasons for cART 
interruption were mainly due to severe mucositis, poor oral intake and GI-toxicities 
like nausea and vomiting. No adherence issues to cART regimens during 
chemotherapy were identified for any of the other patients included in the BL 
analysis. 
 
3.2.13 CD4 cell count and HIV VL during and after chemotherapy 
Median CD4 cell count and HIV-viral load results at BL diagnosis, 1-3 months post 
chemotherapy, 6-9 months post chemotherapy and 12-15 months post 
chemotherapy are shown in Tables 3-17 & 3-18.  The median CD4 cell count at BL 
diagnosis was the highest in the comparison to median CD4 cell count values post 
chemotherapy. 
 
CD4 cell counts continued to decrease steadily at 1-3 months and 6-9 months post 
chemotherapy. This decrease was statistically significant from baseline value at BL 
diagnosis compared to that at 1-3 months and 6-9 months post chemotherapy 
(Wilcoxon test, p= 0.05 and p= 0.007, respectively). There was no difference 
between the median CD4 cell count at BL diagnosis and 12-15 months post 
chemotherapy (p=0.2, Wilcoxon test).  
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Table 3-17 Median CD4 cell count at diagnosis and post chemotherapy for BL patients 
CD4 cell count 
(cells/µL) 
 at BL diagnosis 
CD4 cell count 
(cells/µL) 
 1-3 mths post 
chemotherapy 
CD4 cell count 
(cells/µL) 
 6-9 mths post 
chemotherapy 
CD4 cell count 
(cells/µL) 
12-15 mths post 
chemotherapy 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
13 330 
[28-620] 
11 220 
[76-528] 
12 162.5 
[32-400] 
11 272 
[30-541] 
 
Table 3-18 Median HIV-viral load (VL) at diagnosis and post chemotherapy for 
BL patients 
HIV-VL 
 (copies/mL) 
 at BL diagnosis 
HIV-VL 
(copies/mL) 
 1-3 mths post 
chemotherapy  
HIV-VL (copies/mL) 
 6-9 mths post 
chemotherapy 
HIV-VL 
(copies/mL) 
12-15 mths post 
chemotherapy 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
13 4159 
[<50-
>750000] 
11 <50 
[<50-
650] 
12 <50 
[<50-
34100] 
11 <50 
[<50-
>750000] 
 
When comparing the median CD4 cell count post chemotherapy in the PI and non-PI 
groups, we found no statistically significant differences in the median CD4 count at 1-
3 months, 6-9 months and 12-15 months post chemotherapy. See figure 3-6. 
 
Figure 3-6 Median CD4 cell count post chemotherapy in PI and non-PI groups 
in BL patients (Non-PI based regimen= 3, PI-based regimen=3) 
 
Figure 3-6. No significant differences in median CD4 count at 1-3 months, 6-9 months or 12-15 
months post chemotherapy.  
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3.2.14 Clinical outcomes 
Response rates 
One patient could not be evaluated for treatment response due to early death after 
cycle 3 of chemotherapy due to neutropenic sepsis.  Twelve out of 13 patients were 
evaluable at the end of their treatment.  All twelve patients achieved a complete 
response  (CR) at the end of their chemotherapy course.  
 
Autologous haematopoietic stem cell transplant (ASCT) 
Four patients underwent ASCT for BL 1-6 months after finishing chemotherapy 
treatment.  Two of the four patients who underwent ASCT are still alive, well and in 
remission at 78 and 68 months post ASCT. The other two patients died, one with 
lymphoma relapse at 15 months post ASCT, and the other patient was in remission 
but died 10 months post ASCT secondary to zidovudine (ZDV) adverse event (lactic 
acidosis and pancreatitis). ZDV was initiated four months prior to death.  
 
Survival and causes of death 
At a median follow up of 53 (range 3-86) months, 10 (77%) of the 13 patients are 
alive and in remission. There were 3 deaths, at 3, 22 and 27 months from the time of 
lymphoma diagnosis.  Causes for death at 3, 22, and 27 months were neutropenic 
sepsis, lymphoma relapse and drug adverse event, respectively.  
 
The death that occurred at 3 months was in the PI group, and the other two deaths 
were in patients who were on non-PI regimen during BL chemotherapy treatment. 
There was no difference in OS between the patients in PI and the non-PI groups 
using Kaplan-Meier curve and log-rank test (p=0.54).  See Figure 3-7.  
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Figure 3-7 Kaplan-Meier overall survival curves for HIV-associated Burkitt 
lymphoma patients (n=13) 
 
 
 
 
3.3 Diffuse large B-Cell lymphoma (DLBCL) data analyses 
 
3.3.1 Patient baseline characteristics 
 
Characteristics of 20 HIV-infected patients diagnosed with DLBCL are shown in 
Table 3-19. The median age at DLBCL diagnosis was 42 (range, 26-59) years. 
Most patients were males 19 (95%), and one female (5%). MSM was the most 
common risk for HIV acquisition in 19(95%) of the patients, and in one patient (5%) 
heterosexual contact was the risk for HIV acquisition. 
 
HIV characteristics included a median CD4 cell count at DLBCL diagnosis (n= 20) of 
208.50 (range, 28-484) cells/µL, and a median HIV viral load (n=20) of 67,000 
(range, <50 to 833,400) copies/mL. In 18 patients (90%), the HIV diagnosis was 
made prior to the lymphoma diagnosis, and in two patients (10%) HIV diagnosis was 
made at the time of lymphoma diagnosis. The median duration of HIV prior to 
lymphoma diagnosis was 9 (range, 0-20) years. 
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Prior AIDS illness occurred in 5 patients (25%) of the 20 patients. Prior AIDS 
illnesses reported in the 20 DLBCL patients are listed below: 
1- KS in two patients 
2- Pulmonary TB in one patient 
3- PJP in one patient  
4- Chronic anal herpes simplex ulcers in one patient. 
 
Baselines characteristics in patients receiving PI-based cART were compared with 
patients on non-PI based cART (see Table 3-19). There were no statistically 
significant differences in HIV and lymphoma baseline characteristics between the two 
groups, including median CD4 cell count (P=0.72, Mann-Whitney U test) and HIV-VL 
at lymphoma diagnosis. There were also no significant differences in lymphoma data, 
including Ann Arbor lymphoma stage, age-adjusted IPI score, bone marrow 
involvement and CNS involvement. 
 
Table 3-19 Baseline characteristics of 20 HIV-associated diffuse large B-cell 
lymphoma patients 
Characteristics Total n (%) PI-based  
cART n(%) 
Non PI-based 
 cART n(%) 
P-
value 
No. Patients  20 10 10  
Median age [range] at 
DLBCL diagnosis.  
42 [26-59] 36.5 [26-59] 43 [36-58] 0.34§ 
≤42 10 (50) 6 (60) 4 (40)  
>42 10 (50) 4 (40) 6 (60)  
Gender 
Male 19 (95) 9 (90) 10 (100)  
Female 1 (5) 1 (10) 0 (0)  
HIV risk 
Male to male sexual contact 19 (95) 9 (90) 10 (100)  
Heterosexual contact 1 (5) 1(10) 0 (0)  
Prior AIDS 
No 15 (75) 6 (60) 8 (80) 1* 
Yes 5 (25) 3 (30) 2 (20) 
Median CD4 cell count 
[range] at DLBCL diagnosis.  
208.5 
[28-484] 
200.5 
[28-450] 
208.5 
[28-484] 
0.49§ 
>200 cells/µL 10 (50) 5 (50) 5 (50)  
≤200 cells/µL 10 (50) 5 (50) 5 (50)  
≤100 cells/µL 4 (20) 3 (30) 1 (10)  
HIV viral load (VL) at diagnosis 
≤50 (undetectable)  3 (15) 2 (20) 1 (10) 1* 
>50 17 (85) 8 (80) 9 (90)  
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§P-value determined using Mann-Whitney U test   *P-value determined using Fisher’s exact test 
 
3.3.2 Combination antiretroviral therapy 
Nearly half the patients, 9 (45%) of 20 patients were cART naïve at DLBCL 
diagnosis. Median duration on cART prior to DLBCL diagnosis for the remaining 11 
patients was 24 (range, 3-156) months. Of the 11 patients who were not cART naïve 
at lymphoma diagnosis, only 9 patients were taking their cART at the time of DLBCL 
diagnosis. 
 
HIV duration prior to 
lymphoma diagnosis 
    
Median duration (years) 9 (0-20) 11.25 (4-19) 5.5 (0-20) 0.47§ 
 
cART naïve at lymphoma diagnosis 
No 11 (55) 7 (70) 4 (40) 0.37* 
Yes 9 (45) 3 (30) 6 (60) 
Hepatitis B co-infection     
Known positive 7 (35) 4 (40) 3 (30) 1* 
Known negative 13 (65) 6 (60) 7 (70) 
Hepatitis C co-infection     
Known positive 3 (15) 0 (0) 3 (30) 0.2* 
Known negative 17 (85) 10 (100) 7 (70) 
Ann arbor DLBCL stage     
I-II 8 (40) 4 (40) 4 (40) 1* 
III-IV 12 (60) 6 (60) 6 (60)  
Age adjusted (IPI) score      
0-1 6 (30) 3 (30) 3 (30) 1* 
2 5 (25) 2 (20) 3 (30)  
3 9 (45) 5 (50) 4 (40)  
B-symptoms     
Yes 12 (60) 7 (70) 5 (50) 0.65* 
No 8 (40) 3 (30) 5 (50)  
LDH     
Normal 2 (10) 2 (20) 0 (0) 0.47* 
Elevated 18 (90) 8 (80) 10 (100)  
Bone marrow involvement     
Yes 5 (25) 2 (20) 3 (30) 0.63* 
No 14 (70) 8 (80) 6 (70)  
Unknown 1 (5) 0 (0) 1 (10)  
CNS involvement      
Yes 5 (25) 3 (30) 2 (20) 1* 
No 15 (75) 7 (70) 8 (80)  
Extranodal involvement     
Yes 13 (65) 6 (60) 7 (70) 1* 
No 7 (35) 4 (40) 3 (30)  
Rituximab in chemotherapy     
Yes 8 (40) 3 (30) 5 (50) 0.65* 
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cART drug holidays were reported in 7 patients; 4 patients in the PI group and 3 
patients in non-PI group. Median cART holiday period was 14 (range-2-36) months.  
Twenty DLBCL patients included in the analysis were equally divided between PI and 
non-PI based regimens, 10 patients in each group. One patient changed their cART 
regimen after 1st cycle of chemotherapy from lamivudine, stavudine and nelfinavir 
(PI-based regimen) to efavirenz, tenofovir and lopinavir/ritonavir (PI-based regimen). 
This change was due to virological failure/resistance.  See table 3-20 for cART 
details. 
 
Table 3-20 Combination antiretroviral therapy details for diffuse large B-cell 
lymphoma patients 
Patient no. cART regimen Regimen type 
DLBCL-1 3TC+TDF+EFV NNRTI-based = non-PI based 
DLBCL-2 LPV/r+ 3TC+TDF PI-based 
DLBCL-3 EFV+TDF+ddI 250mg NNRTI-based = non-PI based 
DLBCL-4 LPV/r + 3TC/ABC PI-based 
DLBCL-5 3TC+d4T+EFV NNRTI-based = non-PI based 
DLBCL-6 RTV+TPV+T20+3TC+ ddI 
400mg 
PI based 
DLBCL-7 LPV/r+SQV+TDF PI-based 
DLBCL-8 TDF/FTC+ EFV NNRTI-based = non-PI based 
DLBCL-9 ABC/3TC+ EFV NNRTI-based = non-PI based 
DLBCL-10 3TC+d4T+NFV switched 
to  
LPV/r+TDF+EFV 
PI-based 
DLBCL-11 LPV/r+ 3TC/ABC PI-based 
DLBCL-12 3TC/ABC+ NVP NNRTI-based = non-PI based 
DLBCL-13 TDF/FTC+ EFV NNRTI-based = non-PI based 
DLBCL-14 TDF/FTC+ATV/r PI-based 
DLBCL-15 3TC/ABC+ NVP NNRTI-based = non-PI based 
DLBCL-16 RAL+NVP+ABC NNRTI-based = non-PI based 
DLBCL-17 LPV/r+3TC+FPV PI-based 
DLBCL-18 TDF/FTC+ LPV/r PI-based 
DLBCL-19 LPV/r+ 3TC+TDF PI-based 
DLBCL-20 RAL+ETR+TDF/FTC NNRTI+ raltegravir-based = non-PI 
based 
Key to abbreviations 3TC= lamivudine, TDF= tenofovir, EFV=efavirenz, LPV/r= ritonavir-boosted 
lopinavir, ddI= didanosine, ABC= abacavir, d4T= stavudine, RTV= ritonavir, TPV= tipranavir, T20= 
enfuvirtide, SQV= saquinavir, NFV=nelfinavir, NVP= nevirapine, FTC= emtricitabine, ATV/r= ritonavir-
boosted atazanavir, RAL= raltegravir, FPV= fosamprenavir, ETR= etravirine. 
 
 
 
 
 71 
3.3.3 Chemotherapy and radiotherapy 
All 20 patients received chemotherapy for their DLBCL. A total of 105 chemotherapy 
cycles were administered, 53 cycles of EPOCH, 44 cycles of R-CHOP and 8 cycles 
of other regimens.  See table 3-21 for breakdown of chemotherapy regimens 
between patients in the PI and the non-PI group.  
 
Table 3-21 Chemotherapy treatment details for diffuse large B-cell lymphoma 
patients (n=20) 
Chemotherapy 
regimen 
Total no. of cycles No. of cycles 
administered 
PI group 
No. of cycles 
administered 
Non-PI group 
EPOCH 53 39 14 
R-CHOP 44 18 7 
Other  8 1 7 
Total 105 58 47 
 
Details of ‘other’ chemotherapy regimens (total 8 cycles) 
1- One patient in the non-PI group initially received one cycle of CODOX-M 
(methotrexate 6720mg/m2) for what was initially thought to be Burkitt lymphoma, 
diagnosis was subsequently changed to DLBCL and the patient went on to have 5 
more cycles of EPOCH. 
2- One patient in the PI group finished 6 cycles of EPOCH, but had refractory 
lymphoma with CNS involvement at the end of treatment and received one cycle 
of CODOX-M (methotrexate 6720mg/m2). 
3- One patient in the non-PI group received 3 cycles of R-CHOP then switched to 
CODOX-M/IVAC due to persistent lymphoma with CNS lymphoma involvement. 
Patient completed two cycles of CODOX-M (methotrexate 1000g/m2) and IVAC. 
4- One patient in the non-PI group received 3 cycles of EPOCH then treatment was 
escalated to hyper-CVAD due to refractory lymphoma. Patient received one 
cycle of hyper-CVAD. 
5- One patient in the non-PI group received EPOCH for 1st cycle then switched to 
hyper-CVAD due to refractory lymphoma with CNS involvement. Patient received 
three cycles of hyper-CVAD. 
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A total of 13 patients (65%) received intrathecal chemotherapy, predominantly IT 
methotrexate, n= 6 in the PI group and n=7 in the non-PI group.  Only one patient, in 
the non-PI group, received palliative cranio-spinal radiotherapy for CNS lymphoma 
involvement.  
 
3.3.4 Antimicrobial prophylaxis during chemotherapy 
All 20 patients received PJP prophylaxis (n=16 sulfamethoxazole/trimethoprim 
800mg/160mg three times weekly or 400/80mg once daily, n= 2 received atovaquone 
750mg twice daily, n=1 received dapsone 100mg thrice weekly, n=1 received 
nebulised pentamidine once a month).  
 
Thirteen patients (65%) received prophylaxis for herpes simplex virus (HSV) and/or 
varicella zoster virus (VZV) (n=12 valaciclovir 500mg daily to twice daily n=1 
famciclovir 500mg daily). Ten patients (50%) received fungal prophylaxis  (n=9 with 
fluconazole 100-200mg daily and n=1 with itraconazole 200mg twice daily). 
 
Two patients (10%) received MAC prophylaxis (with azithromycin 1200mg weekly).  
One patient had CD4 cell count of 56 cells/µL and the other had a CD4 cell count of 
128 cells/µL at DLBCL diagnosis. One patient (5%) received CMV prophylaxis with 
valganciclovir 900mg daily; the patient had a CD4 cell count of 56 cells/µL at DLBCL 
diagnosis and developed early CMV colitis during chemotherapy. 
 
3.3.5 G-CSF prophylaxis during chemotherapy 
All patients (100%) received G-CSF primary prophylaxis during their chemotherapy. 
Filgrastim 5mcg/kg/day was used as prophylaxis in 14(70%) patients. Pegfilgrastim 
was used in 6 (30%) patients.  
 
3.3.6 Treatment-related toxicities 
3.3.6.1 Neurotoxicity  
Neurotoxicity (NT) of any grade occurred in 9 (45%) patients, and of these 9 patients, 
4 experienced grade 3-4 NT. Peripheral neuropathy was the most common form of 
neurotoxicity developing in 6 of the total 9 patients with NT. 
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Six patients (67%) in the PI group developed any grade neurotoxicity compared to 
three patients (33%) in the non-PI group (p=0.37, using Fisher’s exact test). There 
were more rates of grade 3-4 NT observed in the PI group compared to the non-PI 
group, 4 patients in the PI-group compared to none in the non-PI group, but the 
difference was marginally insignificant (40% vs. 0%, p=0.087, Fisher’s exact test).  
 
Three out of the 4 patients in the PI-group who experienced grade 3-4 NT developed 
autonomic neuropathy, presenting as severe constipation and bowel obstruction. 
One of the patients developed ileus and bowel perforation that required urgent 
laparotomy. The fourth patient who experienced grade 3-4 NT presented with severe 
peripheral neuropathy after the 4th chemotherapy cycle. All four patients with grade 3-
4 NT in the PI group were on ritonavir-boosted lopinavir and EPOCH chemotherapy 
concurrently. 
 
Important remarks with regards to NT in the DLBCL cohort: 
1- Three of the 9 patients who developed NT had pre-treatment neuropathy 
secondary to their HIV-infection and/or the use of first generation NRTIs 
(stavudine and didanosine). Two patients with were in the PI group and one was 
in the non-PI group.  
2- The patient who developed bowel perforation requiring urgent laparotomy also 
had lymphoma involvement of the bowel, and hence the bowel perforation could 
be due to lymphoma lysis with the chemotherapy treatment and/or a result of the 
severe constipation and the development of ileus. Patient’s cART regimen was 
lopinavir/ritonavir 400mg/100mg BD+ abacavir 600mg daily and lamivudine 
300mg daily. 
3- One of the patients who developed severe constipation and bowel obstruction 
was on ritonavir-boosted lopinavir and saquinavir. Patient’s cART regimen was 
lopinavir/ritonavir 300mg/75mg twice daily + saquinavir 1000mg twice daily and 
tenofovir 300mg daily. 
4- One of the patients in the non-PI group who developed grade 2-peripheral 
neuropathy was on itraconazole for fungal prophylaxis during his chemotherapy. 
His cART regimen was stavudine 40 twice daily+ lamivudine 300mg once daily 
and efavirenz 600mg once daily.  
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3.3.6.2 Haematological toxicity 
Grade 3-4 haematological toxicities occurred in 57 (53%) of the total 105 
chemotherapy cycles; 27 (46.5%) of 58 cycles when prescribed PI-based regimen 
and 30 (64%) of the 47 cycles when prescribed non-PI (p= 0.12, Fisher’s exact test).   
Grade 3-4 anaemia occurred in 9 (8.5%) of the total 105 chemotherapy cycles; 6 
(10%) of the 58 cycles when prescribed PI-based regimen and 3 (6%) of the 47 
cycles when prescribed non-PI regimen (p=0.7, Fisher’s exact test). 
One patient suffered from prolonged grade 3-4 neutropenia, which lasted for 4 
months after finishing chemotherapy. Patient received R-CHOP for his DLBCL and 
was on a non-PI based regimen (lamivudine/abacavir+ nevirapine). The patient also 
developed lower limb cellulitis in the context of the prolonged neutropenia, but the 
infection subsequently responded well to intravenous antibiotics. 
 
3.3.6.3 Infections 
Grade 3-4 infections requiring hospitalization and the administration of the IV 
antibiotics were observed in 21(20%) of the 105 chemotherapy cycles; 11(19%) of 58 
cycles episodes were in the PI group vs. 10 (21%) of 47 cycles in the non-PI group 
(p=0.8, Fisher exact test). There was no difference in terms of the median number of 
days on G-CSF prescribed for the management of febrile neutropenia between the PI 
group and the non-PI groups (Mann-Whitney U test, 7.5 vs.10 days, p=0.72, 
respectively). 
 
Opportunistic infections occurred in two patients, both were in the PI-group:  
 The first patient developed CMV colitis with the first cycle of chemotherapy. 
Patient had a low CD4 cell count of 56 cells/µL and HIV-VL of > 750,000 
copies/mL at lymphoma diagnosis.  
 The second patient developed progressive multifocal leukoencephalopathy 
(PML) after 2nd cycle of chemotherapy, which resulted in treatment 
discontinuation and palliation.  Patient had a CD4 cell count of 128 cells/µL 
and HIV-VL of 216,000 copies/mL at lymphoma diagnosis.  
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3.3.6.4 Other treatment-related toxicities 
Grade 3-4 mucositis occurred in 2 (10%) of the 20 patients, both patients were in the 
PI group. Grade 3-4 diarrhoea developed in 2 (20%) of the 20 patients, one patient in 
each of the PI and the non-PI groups. Grade 3-4 nausea and vomiting developed in 3 
(15%) of the 20 patients, two in the non-PI and one patient in the PI group.  
Grade 3-4 ALT/AST (liver transaminases) elevations occurred in two patients, both 
were in the non-PI group, with one patient developing jaundice and liver failure. The 
first patient was on efavirenz+ tenofovir/emtricitabine, and the second patient was on 
etravirine + raltegravir and tenofovir/emtricitabine.  
 
3.3.7 Chemotherapy dose reductions and/or changes due to toxicity 
Six patients (30%) had their chemotherapy reduced and/or changed during their 
course of treatment. Of these six patients, two patients were in the non-PI group 
compared to four patients in the PI-group (p=0.63, Fisher’s exact test). See Table 3-
22 for chemotherapy dose reductions and/or changes (all changes and/or reductions 
were related to vincristine). 
 
3.3.8 Chemotherapy delays 
Chemotherapy delays occurred in 17(16%) of total 105 cycles; 9(15.5%) of 58 cycles 
in the PI-group compared to 8 (17%) of 47 cycles in the non-PI group (p=1, Fisher’s 
exact). Median number of chemotherapy delay-days in the PI-group was 20 (range, 
7-34) days compared to 10(range 7-26) days in the non-PI group (p=0.86, Mann-
Whitney U test). Reasons for chemotherapy delays are mentioned in Figure 3-8. 
 
3.3.9 Completion of stage appropriate chemotherapy 
Eight patients (40%) did not complete their full planned course of chemotherapy. 
Four patients were in each of the PI group and the non-PI groups.  Details of  
reasons for not completing full course of stage appropriate chemotherapy treatment 
are shown in Table 3-23. 
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Table 3-22 Chemotherapy dose reductions and/or changes for 20 patients with 
HIV-associated DLBCL 
Patient no.  
& chemotherapy 
regimen n=6 
cART agents  Details of changes and/or reductions 
in chemotherapy 
DLBCL-3 
EPOCH 
TDF+ddI+EFV 
(non-PI based 
regimen) 
Vincristine changed to vinblastine 
6mg/m2 from 4th chemotherapy cycle due 
to peripheral neuropathy 
DLBCL-4 
EPOCH  
LPV/r+ 3TC/ABC 
(PI-based regimen) 
Vincristine changed to vinblastine 
6mg/m2 from 4th chemotherapy cycle due 
to peripheral neuropathy 
DLBCL-5 
EPOCH x 1 cycle then 
hyper-CVAD x 3 cycles 
d4T+3TC+ EFV 
(non-PI based 
regimen) 
Vincristine changed to vinblastine 
6mg/m2 due to peripheral neuropathy 
after cycle 2 of hyper-CVAD 
DLBCL-10 
EPOCH 
LPV/r+TDF+EFV 
(PI-based regimen) 
Vincristine changed to vinblastine 
6mg/m2 from 4th chemotherapy due to 
peripheral neuropathy and constipation. 
DLBCL-11 
EPOCH 
LPV/r+ 3TC/ABC 
(PI-based regimen) 
 
Vincristine changed to vinblastine 
6mg/m2 after cycle 1 due to peripheral 
neuropathy and constipation. Vinblastine 
dose was further reduced by 25% from 
3rd chemotherapy cycle due to 
haematological toxicity 
DLBCL-14 
R-CHOP 
 
TDF/FTC+ATV/r 
(PI-based regimen) 
 
Vincristine dose reduced by 50% to 1mg 
from 5th chemotherapy cycle due to 
peripheral neuropathy 
Key to abbreviations TDF= tenofovir, ddI= didanosine, EFV=efavirenz, LPV/r= ritonavir-boosted 
lopinavir, 3TC= lamivudine, ABC= abacavir, d4T= stavudine, FTC= emtricitabine, ATV/r= ritonavir-
boosted atazanavir 
 
Figure 3-8 Reasons for delays in chemotherapy administration in patients with 
HIV-associated diffuse large B-cell lymphoma (n=20) 
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Table 3-23 Reasons for not completing full course of chemotherapy for HIV-
associated diffuse large B-cell lymphoma 
Patient 
no. & 
cART 
group 
No. of planned 
Chemotherapy 
cycles 
No. of actual 
chemotherapy 
Cycles given 
Reasons for not 
completing full course 
of chemotherapy 
Additional 
Treatment 
given 
DLBCL-3 
Non-PI 
group 
6 cycles of 
EPOCH 
4 Issues with 
chemotherapy tolerance, 
diarrhoea and weight 
loss  
Nil 
DLBCL-6 
PI group 
6 cycles of 
EPOCH 
2 
 
PML infection after cycle 
2 of treatment 
Nil 
DLBCL-7 
PI-group 
6 cycles of 
EPOCH 
3 Neutropenic sepsis and 
severe bowel  
obstruction 
Nil 
DLBCL-8 
Non-PI 
group 
3 cycles of 
HyperCVAD  
1 Liver dysfunction and  
jaundice after  
hyper-CVAD 
Nil 
DLBCL-10 
PI-group 
6 cycles of 
EPOCH 
5 Neurotoxicity and 
neutropenic sepsis 
Nil  
DLBCL-12 
Non-PI 
group 
6 cycle of  
R-CHOP 
5 Neutropenic sepsis and 
febrile neutropenia with 
chemotherapy PET scan 
negative after cycle 5. 
Team decided to 
discontinue treatment 
Nil 
DLBCL-19 
PI-group 
3 cycles of 
CODOX-M 
1  Died after treatment 
escalation with one cycle 
of CODOX-M. Severe 
mucositis and sepsis 
Nil 
DLBCL-20 
Non-PI 
group 
3 cycles of 
CODOX-
M/IVAC 
2  Died after treatment 
escalation with two 
cycles of CODOX-
M/IVAC. Severe 
mucositis and sepsis 
Carnio-spinal 
radiotherapy  
Key to abbreviations: PML= progressive multifocal leukoencephalopathy 
 
3.3.10 cART interruption during chemotherapy 
All 20 patients were on cART during all cycles of chemotherapy, except for one 
patient who ceased cART  (efavirenz+ tenofovir + didanosine) after the second cycle 
of chemotherapy due to nausea and diarrhoea. Patient re-started cART 3 months 
after the chemotherapy was completed. Sub-optimal adherence to cART during 
chemotherapy was suspected in two patients, both patients were in the PI-group. The 
first one patient died from progressive lymphoma at the end of treatment, while the 
second patient achieved CR at the end of treatment. It is important to note that the 
HIV-VL in the second patient was undetectable at 6 months follow-up, which may 
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indicate improvement in adherence to cART post chemotherapy. 
 
3.3.11 CD4 cell count and HIV VL during and after chemotherapy 
Median CD4 cell count and HIV-VL results at DLBCL diagnosis, 1-3 months, 6-9 
months and 12-15 months post chemotherapy are shown in Tables 3-24 & 3-25.   
The median CD4 cell count at DLBCL diagnosis was the lowest in comparison to the 
median CD4 cell count values post chemotherapy. 
 
CD4 cell counts at 1-3 months post chemotherapy continued to increase steadily to 
higher values 12-15 months post chemotherapy. This increase in the CD4 cell count 
was marginally insignificant when comparing the median CD4 cell count values at 1-3 
months to that at 12-15 months post chemotherapy (Wilcoxon test, p= 0.06). 
 
Table 3-24 Median CD4 cell count at diagnosis and post chemotherapy for 
DLBCL patients 
CD4 cell count 
(cells/µL) 
 at DLBCL 
diagnosis 
CD4 cell count 
(cells/µL) 
 1-3 mths post 
chemotherapy  
CD4 cell count 
(cells/µL) 
 6-9 mths post 
chemotherapy 
CD4 cell count 
(cells/µL) 
12-15 mths post 
chemotherapy 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
20 208.5 
[28-484] 
7 280 
[14-373] 
11 285 
[20-786] 
8 486 
[366-
724] 
 
Table 3-25 Median HIV-viral load (VL) at diagnosis and post chemotherapy for 
DLBCL patients 
HIV-VL  
(copies/mL) 
 at DLBCL 
diagnosis 
HIV-VL 
 (copies/mL) 
 1-3 mths post 
chemotherapy  
HIV-VL  
(copies/mL) 
 6-9 mths post 
chemotherapy 
HIV-VL 
 (copies/mL) 
12-15 mths post 
chemotherapy 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
No. of 
patients 
Median 
[Range] 
20 67000 
[<50-
833400] 
7 <50 
[<50-
>100000] 
11 <50 
[50-
9600] 
8 <50 
[30-100] 
 
When comparing the median CD4 cell count values post chemotherapy across PI 
and non-PI groups, there was no significant differences in CD4 cell recovery at 1-3 
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months, 6-9 months or 12-15 months post chemotherapy (Kruskal Wallis test). See 
Figure 3-9. 
 
Figure 3-9 Median CD4 cell count post chemotherapy in PI and non-PI groups 
in DLBCL patients (PI-based regimens=10, non-PI based regimens = 10) 
 
Figure 3-9 No significant differences in median CD4 cell count at 1-3 months, 6-9 months or 12-15 months 
post chemotherapy. 
3.3.12 Clinical outcomes 
Response rates and deaths 
At the end of treatment 19 of the 20 patients were evaluable for response, 13 out of 
19 patients (68%) achieved CR/CRu and 6 patients (31.5%) had progressive 
disease. One patient was not evaluated (NE) because of the diagnosis of PML 
infection after receiving 2 cycles of chemotherapy. Patient was palliated and died 4 
months from lymphoma diagnosis. All 6 patients with progressive disease died. See 
table 3-26 for response to HIV-associated diffuse large B-cell lymphoma 
treatment in patients on PI and non-PI based cART regimens.  
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Table 3-26 Response to HIV-associated diffuse large B-cell lymphoma 
treatment in patients on PI and non-PI based cART regimens 
 Response at end of chemotherapy Total 
CR/CRu (n) PD (n) NE (n) 
ART 
regimen 
PI-based regimen  6 3 1 10 
Non-PI-based regimen  7 3 0 10 
Total 13 6 1 20 
Key to abbreviations CR= Complete remission, CRu=unconfirmed complete remission, PD= 
Progressive disease, NE= Not evaluated 
 
Overall Survival (OS) 
Twelve patients, 6 patients in each of the PI and the non-PI groups, out of a total of 
20 patients were alive at the last date censored (60%). Median OS was 26.5 (range, 
4-104) months. There was no statistical difference in OS between the PI and the non-
PI group using the Kaplan-Meier method and the long-rank test (p=0.72). See Figure 
3-10. 
 
Figure 3-10 Kaplan-Meier survival curves for HIV-associated diffuse large B-cell 
lymphoma patients (n=20) 
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Disease free survival (DFS) 
Median DFS time was 42 (range, 11-101) months. Two patients relapsed at 11 and 
83 months post lymphoma treatment, one patient in each of the non-PI and the PI-
groups. The patient in the non-PI group did not receive any further treatment and 
died. The patient in the PI-group received salvage chemotherapy and achieved CR 
and is still alive and well at 104 months follow-up time. There was no statistical 
difference in DFS between the PI and the non-PI group using the Kaplan-Meier 
method and the long-rank test (p=0.35).  
 
3.3.13 Factors associated with achieving of complete (CR) and 
unconfirmed complete remission (CRu) in DLBCL patients 
Univariate logistic regression analysis was conducted to test for factors associated 
with achieving CR and CRu in DLBCL patients. Bone marrow and CNS involvement 
of lymphoma were significant factors associated with decreased odds of achieving 
CR/CRu (OR=0.068,95% CI= 0.005-0.86, p=0.038) and (OR= 0.068, 95%CI 0.005-
0.78, p=0.032) respectively. Completion of stage appropriate chemotherapy was a 
significant factor associated with increased OR for achieving CR/CRu (OR= 8.88, 
95% CI, 1.03-67.14, P= 0.046). All other tested factors did not reach statistical 
significance. See Tables 3-27 A&B. 
 
3.4 Other lymphoma data analyses:  
 
3.4.1 Baseline Characteristics 
 
A total of four patients with ‘other lymphoma’ were analysed separately  
 Two patients with plasmablastic lymphoma (PBL) 
 One patient with anaplastic lymphoma 
 One patient with primary effusion lymphoma (PEL).  
 
Characteristics of four HIV-infected patients diagnosed with other lymphomas are 
shown in Tables 3-28 & 3-29. In all 4 patients, the HIV diagnosis was made prior to 
the lymphoma diagnosis. Prior AIDS diagnoses occurred in one patient were KS and 
PJP. 
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Table 3-27 (A) Univariate analysis for achieving CR/CRu (HIV-related data) 
Variable  No. of patients  Odds 
Ratio 
95% CI P-value 
Age, years      
≤45 14 7.33 0.87-6.13 0.066 
>45 6 (ref)*   
CD4 count cells/µL     
>200  10 1.55 0.24-9.91 0.64 
≤200 10 (ref)   
Prior AIDS     
No 15 1.33 0.16-10.74 0.78 
Yes 5 (ref)   
Undetectable VL at 
DLBCL diagnosis 
   
 
 
No 17 0.91 0.068-12.32 0.94 
Yes 3 (ref)  ` 
cART naive at diagnosis  
 
   
No 11 0.87 0.13-5.57 0.88 
Yes 9 (ref)   
HIV duration prior  
to diagnosis, years 
20 0.87 0.73-1.04 0.135 
Hep-B co-infection     
No 13 1.68 0.25-11.33 0.59 
Yes 7 (ref)   
PI-based cART     
Yes 10 0.643 0.1-4.09 0.64 
No 10 (ref)   
cART holidays prior 
to DLBCL diagnosis 
 
 
   
No 7 2.25 0.14-33.93 0.55 
Yes 4 (ref)   
*(ref)= reference category 
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Table 3-27(B) Univariate analysis for achieving CR/CRu (lymphoma-related 
data) 
Variable  No. of patients  Odds Ratio 95% CI P-value 
Ann Arbor lymphoma stage     
I-II 8 7 0.64-75.73 0.109 
III-IV 12 (ref)*   
LDH     
Elevated 18 N/A N/A 0.999 
Normal 2 (ref) N/A  
B-symptoms     
Yes 12 0.14 0.13-1.54 0.109 
No 8 (ref)   
CNS involvement     
Yes 5 0.63 0.005-0.78 0.032 
No 15 (ref)   
Bone marrow involvement§     
Yes 5 0.038 0.005-0.86 0.038 
No 14 (ref)   
Extranodal involvement     
No 7 5.14 0.47-55.64 0.178 
Yes 13 (ref)   
EGOC performance status     
0-1 11 5.62 0.74-42.35 0.094 
>2 9 (ref)   
Age adjusted IPI score     
0-1 6 N/A N/A 0.857 
2 5 1.85 0.2-17.2 0.2 
3 9 (ref)   
Chemotherapy delays     
Yes 13 1.56 0.21-11.36 0.659 
No 7 (ref)   
Completion of stage 
appropriate chemotherapy 
 
 
 
 
 
 
  
Yes 12 8.33 1.03-67.14 0.046 
No 8 (ref)   
Rituximab given     
No 12 0.467 0.065-3.34 0.448 
Yes 8 (ref)   
*(ref)= reference category 
§ If assessed  
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Table 3-28 HIV-related characteristics of patients with ‘other lymphoma’ 
Key to abbreviations MSM= male to male sexual contact, KS= Kaposi’s sarcoma, PJP= 
Pneumocystis jiroveci pneumonia, LPV/r= ritonavir-boosted lopinavir, EFV= efavirenz, TDF= tenofovir, 
ddI= didanosine, FTC= emtricitabine, ATV/r ritonavir-boosted atazanavir 
 
Table 3-29 Lymphoma-related characteristics of HIV-patients with ‘other 
lymphoma 
 
Key to abbreviations: EGOC PS= Eastern Cooperative Oncology Group performance status, CR= 
complete remission, PD= progressive disease 
 
3.4.2 Combination antiretroviral therapy 
Only one patient was cART naïve at lymphoma diagnosis. All other three patients 
who were on cART prior to lymphoma diagnosis experienced cART drug holidays.  
Three patients were on cART during all cycles of chemotherapy, and in one patient 
the cART was initiated by the second chemotherapy cycle. Two patients were on PI-
based cART and two were on non-PI based cART. See table 3-28 for cART details. 
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3.4.3 Chemotherapy 
Details of chemotherapy regimen used and the number of cycles administered are 
highlighted in Table 3-29.  Two patients received EPOCH chemotherapy and two 
received CHOP chemotherapy. A total of 21 chemotherapy cycles were 
administered, 12 EPOCH and 9 CHOP cycles. 
 
3.4.4 Antimicrobial prophylaxis during chemotherapy 
All four patients received PJP prophylaxis (n=4 sulfamethoxazole/trimethoprim 
800mg/160mg three times weekly). Three patients received prophylaxis for herpes 
simplex virus (HSV) and/or varicella zoster virus (VZV) (all with valaciclovir 500mg 
daily).  Three patients received fungal prophylaxis  (with fluconazole 100-200mg 
daily)  
 
3.4.5 G-CSF prophylaxis during chemotherapy 
All patients received G-CSF prophylaxis during their chemotherapy. Two patients 
received primary G-CSF prophylaxis and two received secondary G-CSF 
prophylaxis. Filgrastim 5mcg/kg/day was used as prophylaxis in all patients.  
 
3.4.6 Treatment-related toxicities and infections 
3.4.6.1 Neurotoxicity  
Neurotoxicity (NT) occurred in two patients. One patient on efavirenz+ 
tenofovir+emtricitabine regimen developed grade 3-4 peripheral neuropathy. The 
other patient developed grade 3-4 autonomic neurotoxicity presenting as severe 
constipation with development of anal fistula, the patient was on PI-based regimen 
(lopinavir/ritonavir + efavirenz+ tenofovir and didanosine).  
 
3.4.6.2 Haematological toxicity 
Grade 3-4 haematological toxicities occurred in 4 (38%) of the total 21 chemotherapy 
cycles. More significant grade 3-4 toxicities were reported in the PI group; 7 (78%) of 
9 cycles when prescribed PI-based regimen and one (8%) of the 12 cycles when 
prescribed non-PI (p= 0.02, Fisher’s exact test). Grade 3-4 anaemia occurred in 2 of 
the 9 cycles when prescribed PI-based regimen and none of the 12 cycles when 
prescribed non-PI.  
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3.4.6.3 Infections 
Grade 3-4 infections requiring hospitalization and the administration of the IV 
antibiotics were observed in 4(19%) of the 21 chemotherapy cycles. All 4 episodes 
occurred in patients on PI-based cART. The total number of days on G-CSF that was 
used for the febrile neutropenia (FN) management in the PI group was 26 days. 
Patients in the non-PI group did not require G-CSF for FN management.  
 
3.4.6.4 other toxicities: 
Grade 3-4 gastrointestinal (GI) toxicities presenting as nausea, vomiting and 
diarrhoea occurred only in one patient in the PI-group. 
 
3.4.7 Chemotherapy dose reductions/changes due to toxicity 
Vincristine was omitted from the 5th and 6th cycle of EPOCH in one patient on non-PI 
based cART due to grade 3-4 peripheral neuropathy.  
 
3.4.8 Chemotherapy delays 
Chemotherapy delays occurred in 3 (16%) of total 21 cycles. All delays were in the 
PI-group. The total number of delay-days in chemotherapy administration in the PI-
group was 26 days. 
 
3.4.9 Completion of stage appropriate chemotherapy 
One patient in the PI-group did not complete the full planned course of 
chemotherapy. The patient completed 3 out of 6 planned CHOP chemotherapy 
cycles, the patient experienced marked cytopenias and myelosuppression, was 
unable to tolerate his fourth cycle and died due to disease progression.  
 
3.4.10 Full dose chemotherapy from start of treatment 
Two patients (50%) did not receive full-dose (100%) intensity chemotherapy from the 
start of their treatment. The remaining two patients received full intensity 
chemotherapy from the start of their treatment. 
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Table 3-30 Reasons for not receiving full intensity chemotherapy for HIV-
patients with ‘other lymphoma’ 
Patient no. cART regimen Reasons for not receiving 100% dose intensity of 
chemotherapy from the start of lymphoma 
treatment  
2 Non-PI-based 
TDF/FTC+ EFV 
Dose capped at 2m2 for all EPOCH chemotherapy 
cycles (BSA= 2.06 m2) 
3 Non-PI based 
TDF/FTC+ EFV 
Dose capped at 2m2 for all CHOP chemotherapy 
cycles (BSA =2.1 m2) 
 
3.4.11 CD4 and HIV viral load post chemotherapy  
CD4 cell count and HIV-viral load results at lymphoma diagnosis, 1-3 months post 
chemotherapy, 6-9 months post chemotherapy and 12-15 months post 
chemotherapy are shown in Tables 3-31 & 3-32.   
 
Table 3-31 CD4 cell count at diagnosis and post chemotherapy  
Patient CD4 count 
cells/µL at 
lymphoma 
diagnosis 
CD4 count 
cells/µL at 1-3  
mths post  
chemotherapy 
CD4 count at 
cells/µL at 6-9  
mths post  
chemotherapy 
CD4 count 
cells/µL at 12-
15 mths post  
chemotherapy 
1 150 39 150 228 
2 112 143 75 Unknown 
3 392 352 450 590 
4 21 Deceased Deceased Deceased 
 
Table 3-32 HIV viral load at diagnosis and post chemotherapy   
Patient HIV-viral 
load copies/mL 
 at lymphoma 
diagnosis 
HIV-viral load 
copies/mL 
at 1-3 mths post 
chemotherapy 
HIV-viral load 
copies/mL 
at 6-9 mths post 
chemotherapy 
HIV-viral load 
copies/mL at 12-
15 mths post 
chemotherapy 
1 25,900 220 110 <50 
2 3,700 1700 700 Unknown 
3 13,700 <50 <50 <50 
4 139,800 Deceased Deceased Deceased 
 
3.4.12 Clinical outcomes 
Response rates 
Three patients achieved CR at the end of their treatment and one patient had 
progressive disease after 3 cycles of chemotherapy, see Table 3-29.  
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Overall survival 
Three (75%) of the four patients were alive and well at the last date censored. 
Median follow-up time was 53.5 (range, 3-101) months. One patient in the PI-group 
died from disease progression at 3 months from the date of his lymphoma diagnosis. 
 
Disease free survival 
One of the three patients, who achieved CR, relapsed at 7 months post treatment. 
Patient was in the non-PI arm. He then received salvage chemotherapy with hyper-
CVAD and underwent ASCT in Feb 2009. The patient relapsed again in Dec 2009 
and received more salvage chemotherapy and then underwent allogeneic stem cell 
transplant in April 2010. To date the patient is alive and well post allogeneic stem cell 
transplant.  
 
3.5 Pooled analyses of HIV-associated lymphoma patients 
3.5.1 Baseline characteristics  
HIV-related baseline characteristics of all patients with HIV-associated lymphoma are 
shown in Table 3-33. The median CD4 cell count of patients with BL diagnosis was 
the highest compared to patients in the other lymphoma groups but the difference 
was not statistically significant (p=0.58 for BL vs. HL, p=0.1 for BL vs. DLBCL, and  
p= 0.6 for BL vs. ‘other lymphoma’, Wilcoxon test). The median CD4 cell count was 
lowest in patients with ‘other lymphoma’ diagnosis but the difference was not 
statistically significant  (p= 0.12 for ‘other lymphoma’ vs. HL, p= 0.6 for ‘other 
lymphoma’ vs. DLBCL, and p= 0.6 for ‘other lymphoma’ vs. BL, Wilcoxon test). 
 
There were more patients with undetectable HIV-VL at lymphoma diagnosis in the HL 
group (69%) compared to patients in the other lymphoma groups (15%, 8%, 0% in 
DLBCL, BL and “other lymphoma’, respectively). (P= 0.002 for HL vs. DLBCL, 
p=0.002 for HL vs. BL and p= 0.026 for HL vs. ‘other lymphoma, Fisher’s exact test). 
 
Lymphoma-related baseline characteristics of all patients with HIV-associated 
lymphoma are shown in Table 3-34.  HIV-associated lymphoma cases frequently 
presented with advanced disease, elevated LDH, B-symptoms, extranodal 
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involvement and Bone marrow involvement. CNS involvement was seen DLBCL and 
BL patients only, with no CNS cases in HL and ‘other lymphoma’ patients. 
 
Table 3-33 HIV-related baseline characteristics of patients with HIV-associated 
lymphoma 
 All  
(n=53) 
HL 
 (n=16) 
All NHL 
 (n=37) 
DLBCL 
 (n=20) 
BL  
(n=13) 
Other 
 (n=4) 
Age (yrs)  
Median [range] 
44 
[26-72] 
44 
[34-59] 
43 
[26-72] 
36.5 
[26-59] 
45 
[27-72] 
45 
[42-51] 
Gender       
Male 51  
(96%) 
16 
(100%) 
41  
(95%) 
19  
(95%) 
12  
(92%) 
4 
(100%) 
Female  2 (4%) 0 2 (5%) 1 (5%) 1 (8%) 0 
HIV duration prior 
to lymphoma dx  
Median [range] 
yrs 
11.5 
[0-24] 
13.5 
[2-24] 
11.25 
[0-20] 
9 
[0-20] 
8 
[0-24] 
15.8 
[2.5-20] 
CD4 count at 
lymphoma dx 
Median [range] 
273 
[14-970] 
233.5 
[14-970] 
280 
[21-620] 
208.5 
[28-484] 
330 
[28-620] 
131 
[21-
371] 
>200 cells/µL 33 (62%) 10 (63%) 23 (62%) 10 (50%) 12 (92) 1 (25%) 
≤200 cells/µL 20 (38%) 6 (38%) 14 (38%) 10 (50%) 1 (8%) 3 (75%) 
≤100 cells/µL 8 (15%) 2 12.5%) 6 (16%) 4 (20%) 1 (8%) 1 (25%) 
cART regimen       
PI-Based    25 
(47%) 
10 
(62.5%) 
15  
(40%) 
10  
(50%) 
3  
(23%) 
2  
(50%) 
Non-PI based  28 
(53%) 
6 
(37.5%) 
22  
(60%) 
10  
(50%) 
10  
(77%) 
2  
(50%) 
HIV-VL at lymphoma dx copies/mL    
<50 (undetectable)  15 (28%) 11 (69%) 4 (11%) 3 (15%) 1 (8%) 0 
>50  38  
(72%) 
5  
(31%) 
33  
(89%) 
17  
(85%) 
12  
(92%) 
4 
(100%) 
Prior AIDS       
No 39 (74%) 11 (69%) 28 (76%) 14 (70%) 11 (85%) 3 (75%) 
Yes 14 (26%) 5 (31%) 9 (24%) 6 (30%) 2 (15%) 1 (25%) 
Hep-B co-infection      
Known negative 35  
(66%) 
12  
(75%) 
23  
(62%) 
13  
(65%) 
6  
(46%) 
4 
(100%) 
Known positive 18 (34%) 4 (25%) 14 (38%) 7 (35%) 7 (54%) 0 
Hep-C co-infection       
Known negative 48  
(90% 
16 
(100%) 
32  
(86%) 
17  
(85%) 
11  
(85%) 
4 
(100%) 
Known positive 5 (9%) 0 5 (14%) 3 (15%) 2 (15%) 0 
Key to abbreviations: All= all lymphoma patients, HL= Hodgkin lymphoma, All NHL= non-Hodgkin 
lymphoma (DLBCL+BL+other), DLBCL= diffuse large B-cell lymphoma, BL= Burkitt lymphoma, other= 
other lymphoma, dx= diagnosis. 
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Table 3-34 Lymphoma-related baseline characteristics of patients with HIV-
associated lymphoma 
* If assessed 
Key to abbreviations: All= all lymphoma patients, HL= Hodgkin lymphoma, All NHL= non-Hodgkin 
lymphoma (DLBCL+BL+other), DLBCL= diffuse large B-cell lymphoma, BL= Burkitt lymphoma, other= 
other lymphoma, BM= Bone marrow. 
 
3.5.2 Treatment-related toxicity 
3.5.2.1 Grade 3-4 neurotoxicity  
By univariate analysis, the OR of developing grade 3-4 neurotoxicity was significantly 
increased with the following factors: age > 45 years, the use of PI-based cART, the 
use of lopinavir/ritonavir. No significant association was found between developing 
grade 3-4 neurotoxicity and efavirenz, raltegravir, tenofovir or didanosine use. See 
Table 3-35 for variables tested in the univariate analysis.  
 
 
  
 All 
(n=53) 
HL 
(n=16) 
All NHL 
(n=37) 
DLBCL 
(n=20) 
BL 
(n=13) 
Other 
lymphoma 
(n=4) 
Ann Arbor stage 
I-II 17 (32%) 7 (44%) 10 (27%) 8 (40%) 0 2(50%) 
III-IV 36 (68%) 9 (56%) 27 (73%) 12 (60%) 13 (100%) 2(50%) 
EGOC PS 
0-1 31 (58%) 12 (75%) 19 (51%) 11 (55%) 6 (46%) 2 (50%) 
≥2 22 (42%) 4 (25%) 18 (49%) 9  (45%) 7 (54%) 2 (50%) 
B-symptoms 
Yes 39 (74%) 12 (75%) 27 (73%) 12 (60%) 12 (92%) 3 (75%) 
No 14 (26%) 4 (25%) 10 (27%) 8  (40%) 1 (8%) 1 (25%) 
LDH 
Normal 14 (26%) 7 (44%) 7 (19%) 2 (10%) 3 (23%) 2 (50%) 
Elevated 39 (74%) 9 (56%) 30 (81%) 18 (90%) 10 (77%) 2 (50%) 
BM involvement* 
No 35 (66%) 10 (62%) 25 (68%) 14 (70%) 9 (69%) 2 (50%) 
Yes 17 (32%) 6 (38%) 11 (30%) 5 (25%) 4 (31%) 2 (50%) 
CNS involvement 
No 45 (85%) 16 (100%) 29 (78%) 15 (75%) 10 (77%) 4 (100%) 
Yes 8 (15%) 0 8 (22%) 5 (25%) 3 (23%) 0 
Extranodal involvement 
No 22 (42%) 8 (50%) 14 (38%) 7 (35%) 5 (38%) 2 (50%) 
Yes 31 (58%) 8 (50%) 23 (62%) 13 (65%) 8 (62%) 2 (50%) 
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Table 3-35 Grade 3-4 neurotoxicity (univariate analysis) 
Variable  No. patients  Odds Ratio 95% CI P-value 
Lymphoma type     
HL 16 1.36 0.33-5.55 0.665 
BL 13 0.9 0.18-4.4 0.896 
DLBCL+other 24 (ref)*  0.865 
Age     
>45 years 19 5.22 1.41-19.31 0.013 
≤45 years 34 (ref)   
CD4 cell count     
>200 cells/µL 33 0.74 0.21-2.59 0.645 
≤200 cells/µL 20 (ref)   
HIV duration prior 
to lymphoma dx (yrs) 
53 1.04 
(ref) 
0.95-1.14 0.302 
cART regimen     
PI-based  25 12 2.33-61.75 0.003 
Non-PI based 28 (ref)   
Lopinavir/ritonavir in 
cART 
17 11.4 2.76-47.23 0.001 
No lopinavir/ritonavir 36 (ref)   
Efavirenz in cART 21 0.518 0.13-1.94 0.329 
No efavirenz 32 (ref)   
Tenofovir in cART 35 1.4 0.37-5.3 0.62 
No tenofovir 18 (ref)   
Raltegravir in cART 5 N/A N/A 0.999 
No raltegravir 48 (ref)   
Didanosine in cART 6 1.45 0.23-8.99 0.684 
No didanosine 47 (ref)   
EGOC PS     
0-1 31 0.92 0.27-3.19 0.905 
≥2 22 (ref)   
Chemotherapy regimen     
ABVD 16 (ref)  0.344 
EPOCH/CHOP/CHOP-R 21 1.1 0.27-4.43 0.89 
CODOX-M/IVAC/Hyper-
CVAD 
16 0.31 0.05-1.94 0.213 
Pre-treatment neuropathy     
No 48 0.5 0.074-3.35 0.476 
Yes 5 (ref)   
*(ref)= reference category 
 
In the multivariate analysis models, use of PI-based cART and use of 
lopinavir/ritonavir were found be significantly associated with increased OR of 
developing grade 3-4 NT, after adjusting for age and the chemotherapy regimen type 
(Tables 3-36). Hosmer and Lemeshow test was not significant for any of the 
multivariate models i.e. the models fits the observed data well. 
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Table 3-36 Grade 3-4 neurotoxicity (multivariate analysis) 
Variable  No. of patients Odds Ratio 95% CI P-value 
Age     
>45 years 19 6.32 1.2-31.2 0.023 
≤45 years 34 (ref)*   
Chemotherapy 
regimen 
    
ABVD 16 (ref)  0.66 
EPOCH/CHOP/CHOP-
R 
21 2.1 0.34-12.63 0.418 
CODOX-
M/IVAC/Hyper-CVAD 
16 1.03 0.10-10.32 0.98 
cART regimen     
PI-based  25 11.42 1.7-76.49 0.012 
Non-PI based 28 (ref)   
Age     
>45 years 19 6.21 1.21-31.72 0.028 
≤45 years 34 (ref)   
Chemotherapy 
regimen 
    
ABVD 16 (ref)  0.554 
EPOCH/CHOP/CHOP-
R 
21 1.26 0.198-8.04 0.806 
CODOX-
M/IVAC/Hyper-CVAD 
16 0.41 0.47-3.63 0.424 
Lopinavir/ritonavir in 
cART 
17 10.32 2.12-50.17 0.004 
No lopinavir/ritonavir 36 (ref)   
*(ref)= reference category 
 
3.5.2.2 Grade 3-4 infections  
By univariate analysis, the OR of developing grade 3-4 infections was significantly 
increased with lymphoma type, worse EGOC performance status, lopinavir/ritonavir 
use in cART and the chemotherapy regimen used. The association was marginally 
insignificant for PI-based cART. See Table 3-37 for variables tested in the univariate 
analysis. By multivariate analysis, use of PI-based cART and use lopinavir/ritonavir 
was significantly associated with increased OR of developing grade 3-4 infections 
after adjusting for lymphoma type, EGOC performance status and chemotherapy 
regimen type (see Table 3-38). Hosmer and Lemeshow test was not significant for 
any of the multivariate models i.e. the models fits the observed data well. 
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Table 3-37 Grade 3-4 infections (univariate analysis) 
 
Variable  No. of patients  Odds Ratio 95% CI P-value 
Lymphoma type     
DLBCL+other 24 (ref)*  0.033 
HL 16 0.42 0.11-1.56 0.201 
BL 13 8.57 0.95-77 0.055 
Age     
>45 years 19 2.48 0.73-8.45 0.144 
<45 years 34 (ref)   
CD4 cell count     
>200 cells/µL 33 0.73 0.23-2.3 0.593 
≤200 cells/µL 20 (ref)   
HIV-VL at lymphoma  
dx copies/mL 
   
Undetectable  <50  15 0.308 0.089-1.06 0.062 
>50 38 (ref)   
EGOC PS     
0-1 31 (ref) 1.49-19.92 0.01 
≥2 22 5.46   
cART naïve at dx     
Yes 17 2.9 0.79-10.64 0.107 
No 36 (ref)   
cART regimen     
PI-based  25 2.57 0.818-8.08 0.106 
Non-PI based 28 (ref)   
Lopinavir/ritonavir in 
cART 
17 4.66 1.14-19.07 0.032 
No lopinavir  36 (ref)   
Efavirenz in cART 21 0.576 0.18-1.77 0.337 
No efavirenz 32 (ref)   
Tenofovir in cART 35 0.457 0.13-1.55 0.211 
No tenofovir 18 (ref)   
Raltegravir in cART 5 0.4 0.061-2.62 0.34 
No raltegravir 48 (ref)   
Didanosine in cART 6 1.35 0.22-8.16 0.739 
No didanosine 47 (ref)   
Primary G-CSF 
prophylaxis 
    
Yes 43 1.02 0.25-4.15 0.97 
No 10 (ref)   
Rituximab given      
Yes 8 0.607 0.134-2.75 0.518 
No 45 (ref)   
Chemotherapy 
regimen 
    
ABVD 16 (ref)  0.021 
EPOCH/CHOP/CHOP-
R 
21 1.83 0.48-6.9 0.37 
CODOX-
M/IVAC/Hyper- 
CVAD 
16 25 2.6-240.33 0.005 
*(ref)= reference category, dx= diagnosis  
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Table 3-38 Grade 3-4 infections (Multivariate analysis) 
Variable  No. of patients  Odds Ratio 95% CI P-value 
Lymphoma type     
DLBCL+other 24 (ref)  0.004 
HL 16 0.009 0.001-0.392 0.014 
BL 13 1.207 0.048-30.13 0.909 
EGOC PS     
0-1 31 0.29 0.043-1.96 0.206 
≥2 22 (ref)   
cART regimen     
PI-based  25 14.08 2.13-93.07 0.006 
Non-PI based 28 (ref)   
 
ABVD 16 (ref)  0.025 
EPOCH/CHOP/CHOP-R 21 0.02 0.001-0.614 0.025 
CODOX-M/IVAC/Hyper-
CVAD 16 N/A N/A N/A 
Lymphoma type     
DLBCL+other 24 (ref)  0.013 
HL 16 0.027 0.001-0.867 0.041 
BL 13 1.09 0.04-29.16 0.909 
EGOC PS     
0-1 31 4.07 0.82-20.14 0.085 
≥2 22 (ref)   
Lopinavir/ritonavir in 
cART  25 9.15 1.71-48.89 0.01 
No lopinavir/ritonavir  28 (ref)   
Chemotherapy regimen     
ABVD 16 (ref)  0.047 
EPOCH/CHOP/CHOP-R 21 0.035 0.001-0.95 0.047 
CODOX-M/IVAC/Hyper-
CVAD 16 N/A N/A N/A 
*(ref)= reference category 
 
3.5.2.3 Grade 3-4 haematological toxicity (HT) 
By univariate analysis, the risk of developing grade 3-4 HT was not significantly 
associated with any of the variables tested (see Table 3-39). Bone marrow 
involvement and elevated LDH were associated with increased OR of grade 3-4 HT 
but the difference was only marginally insignificant.  
 
Multivariate analysis was attempted and after adjusting for bone marrow involvement, 
and elevated LDH, none of the cART variables were significant for developing grade 
3-4 haematological toxicity. 
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Table 3-39 Grade 3-4 haematological toxicity (univariate analysis) 
Variable  No. patients  Odds Ratio 95% CI P-value 
Lymphoma type 
DLBCL+other 24 (ref)*  0.384 
HL 16 0.188 0.018-2 0.166 
BL 13 N/A N/A 0.999 
Age     
>45 years 19 N/A N/A 0.998 
<45 years 34 (ref)   
CD4 cell count     
>200 cells/µL 33 0.52 0.051-5.4 0.59 
≤200 cells/µL 20 (ref)   
HIV-VL at lymphoma Dx copies/mL 
Undetectable  <50  15 0.108 0.01-1.13 0.064 
>50 38 (ref)   
EGOC PS     
0-1 31 0.44 0.04-4.58 0.496 
≥2 22 (ref)   
LDH     
Normal 14 0.096 0.009-1.023 0.052 
Elevated 39 (ref)   
Bone marrow involvement 
Yes 18 0.5 0.06-3.88 0.507 
No 34 (ref)   
Extranodal involvement 
Yes 31 4.73 0.45-48.9 0.192 
No 22 (ref)   
cART regimen     
PI-based  25 N/A N/A 0.99 
Non-PI based 28 (ref)   
Ritonavir in cART 24 N/A N/A 0.99 
No ritonavir 29 (ref)   
Lopinavir in cART 17 N/A N/A 0.99 
No lopinavir  36 (ref)   
Efavirenz in cART 21 0.194 0.019-2 0.168 
No efavirenz 32 (ref)   
Tenofovir in cART 35 2.06 0.26-16 0.489 
No tenofovir 18 (ref)   
Raltegravir in cART 5 0.267 0.022-3.19 0.297 
No raltegravir 
 
48 (ref)   
Didanosine in cART 6 N/A N/A 0.99 
No didanosine 47 (ref)   
Primary G-CSF prophylaxis 
Yes 43 5.12 0.62-41.9 0.12 
No 10 (ref)   
Chemotherapy regimen 
ABVD 16 (ref)  0.449 
EPOCH/CHOP/CHOP-R 21 4.6 0.43-49.2 0.2 
CODOX-M/IVAC/Hyper-
CVAD 
16 N/A N/A 0.99 
*(ref) Reference category  
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Table 3-40 Completion of stage appropriate chemotherapy (univariate analysis) 
 
Variable No. patients Odds Ratio 95% CI P-value 
Lymphoma type     
DLBCL+other 24 (ref)  0.67 
HL 16 1.32 0.34-5.05 0.685 
BL 13 2 0.43-9.25 0.375 
Age     
>45 years 19 0.49 0.15-1.62 0.24 
≤45 years 34 (ref)   
CD4 cell count     
>200 cells/uL 33 5.5 1.57-19.16 0.007 
≤200 cells/uL 20 (ref)   
HIV-VL at lymphoma dx copies/mL 
Undetectable  <50  15 2.33 0.56-9.71 0.244 
>50 38 (ref)   
Prior AIDS     
Yes 13 0.11 0.02-0.45 0.002 
No 40 (ref)   
EGOC PS     
0-1 31 1.99 0.61-6.4 0.24 
>2 22 (ref)   
cART regimen     
PI-based  25 0.23 0.06-0.81 0.023 
Non-PI based 28 (ref)   
Ritonavir in cART 24 0.3 0.09-1.02 0.056 
No ritonavir 29 (ref)   
Lopinavir in cART 17 0.33 0.16-1.84 0.332 
No lopinavir  36 (ref)   
Efavirenz in cART 21 4.66 1.1-19.07 0.032 
No efavirenz 32 (ref)   
Tenofovir in cART 35 0.3 0.07-1.23 0.095 
No tenofovir 18 (ref)   
Raltegravir in cART 5 2 0.2-19.3 0.55 
No raltegravir 48 (ref)   
Didanosine in cART 6 0.19 0.03-1.17 0.074 
No didanosine 47 (ref)   
Primary G-CSF prophylaxis 
Yes 43 0.88 0.19-3.96 0.87 
No 10 (ref)   
Chemotherapy regimen 
ABVD 16 (ref)  0.98 
EPOCH/CHOP/CHOP-R 21 0.9 0.22-3.66 0.89 
CODOX-M/IVAC/Hyper-
CVAD 16 1 0.22-4.45 1 
*(ref)= reference category 
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3.5.3 Completion of stage appropriate chemotherapy 
By univariate analysis, prior AIDS illness and PI-based cART were significantly 
associated with decreased OR of completion of stage appropriate chemotherapy. 
On the other hand, a CD4 count of > 200 cells/µL and efavirenz use were 
significantly associated with increased OR of completing stage appropriate 
chemotherapy. Didanosine was associated with decreased OR of completion of 
stage appropriate chemotherapy but the association was marginally insignificant 
(p=0.074). See Table 3-40 on page 95. 
 Multivariate analysis was attempted, and after adjusting for CD4 cell count and prior 
AIDS illness, none of the cART variables were significant for completing stage 
appropriate chemotherapy. 
 
3.5.4 CD4 cell count recovery after chemotherapy  
When comparing the median CD4 cell count post chemotherapy in PI and non-PI 
groups in all patients with HIV-associated lymphomas, there was no statistically 
significant differences in CD4 cell recovery at 1-3 months, 6-9 months or 12-15 
months post chemotherapy between the two groups (Kruskal Wallis test). See Figure 
3-11.  
 
3.5.5 Clinical outcomes for patients with HIV-associated lymphoma 
Response, overall survival and relapse rates for all patients with HIV-associated 
lymphomas are summarised in Table 3-41.  The OS rate for all 53 patients with HIV-
associated lymphomas was 77%. CR/CRu and relapse rates at the end of treatment 
for 51 evaluable patients were 86% and 12%, respectively. The OS rate for all 
patients with NHL (including DLBCL, BL and ‘other lymphoma’ patients) was 67.5%. 
The CR/CRu and relapse rates at the end of treatment for 35 evaluable patients were 
65% and 10.5%, respectively.  
 
3.5.6 Survival analysis for HIV-associated lymphoma patients  
Cox proportional hazards model was used to assess OS for all patients with HIV-
associated lymphomas in univariate analysis. Bone marrow involvement was 
significantly associated with worse OS, while completing stage appropriate 
chemotherapy treatment was significantly associated with better OS. The type of 
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cART regimen use, whether PI or non-PI based, was not associated with a significant 
effect on OS. See Table 3-42 for all variables tested. 
 
Figure 3-11 Median CD4 cell count post chemotherapy in PI and non-PI groups 
in all patients with HIV-associated lymphoma (PI-based regimen= 25, Non-PI 
based regimen= 28) 
 
 
Figure 3-11 No significant differences in median CD4 cell count at 1-3 months, 6-9 months or 12-15 months 
post chemotherapy. 
 
Table 3-41 Complete response rates, overall survival and relapses for patients 
with HIV-associated lymphoma 
 All  
 
HL 
 
All NHL 
  
DLBCL 
 
BL  
 
Other 
  
CR/CRu 44/51 
(86%) 
16/16  
(100%) 
28/35 
(80%) 
13/19  
(68%) 
12/12 
(100%) 
3/4  
(75%) 
OS 41/53 
(77%) 
16/16 
(100%) 
25/37 
(67.5%) 
12/20  
(60%) 
10/13 
(77%) 
3/4 
(75%) 
Relapse 6/51 
(12%) 
2/16 
(12.5%) 
4/35 
(11%) 
2/19 
(10.5%) 
1/12 
(8%) 
1/4  
(25%) 
Key to abbreviations: CR/CRu= Complete and unconfirmed complete remission at the end of 
treatment, OS= Overall survival at last date censored 
Error Bars 95% CI 
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Table 3-42 Overall Survival (univariate analysis) 
Variable  No. patients  Hazard Ratio 95% CI P-value 
Lymphoma type     
DLBCL+other 24 (ref)*  0.66 
HL 16 N/A N/A 0.957 
BL 13 0.54 0.147-2.01 0.363 
Age     
>45 years 19 1.37 0.43-4.31 0.59 
<45 years 34 (ref)   
CD4 count     
>200 cells/uL 33 0.35 0.11-1.12 0.78 
≤200 cells/uL 20 (ref)   
HIV-VL at  dx (copies/mL) 
Undetectable  <50  15 0.2 0.027-1.604 0.132 
>50 38 (ref)   
Prior AIDS     
Yes 13 2.84 0.9-8.98 0.075 
No 40 (ref)   
cART regimen     
PI-based  25 1.26 0.4-3.92 0.685 
Non-PI based 28 (ref)   
EGOC PS     
0-1 31 0.46 0.14-1.45 0.188 
≥2 22 (ref)   
Ann Arbor stage     
I-II 17 0.38 0.085-1.76 0.22 
III-IV 36 (ref)   
LDH     
Normal 14 0.24 0.03-1.88 0.175 
Elevated 39 (ref)   
B-symptoms     
No 14 0.52 0.11-2.39 0.4 
Yes 39 (ref)   
CNS involvement     
Yes 9 2.72 0.81-9.09 0.102 
No 44 (ref)   
Bone marrow involvement    
Yes 18 3.53 1.03-12.07 0.044 
No 34 (ref)   
Extranodal 
involvement     
Yes 31 1.53 0.46-5.11 0.482 
No 22 (ref)   
Completion of stage appropriate chemotherapy 
Yes 36 0.188 0.05-0.62 0.007 
No 17 (ref)   
Chemotherapy 
delays     
Yes 31 2.4 0.65-8.9 0.188 
No 22 (ref)   
*(ref) = reference category, dx= diagnosis  
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Chapter 4: Discussion 
HIV-infected patients receiving chemotherapy are at an increased risk of treatment-
related complications due to the increased risk of myelosuppression and the 
additional CD4 cell count loss associated with chemotherapy(161). The risk of 
infections in these patients is also increased due to the prolonged neutropenia 
associated with both chemotherapy and the HIV infection(162-164) and the co-
morbid conditions e.g. opportunistic infections(165). 
 
With the advent of cART, there has been a dramatic shift in the survival outcomes of 
HIV-associated lymphomas(39, 40, 46, 84, 85).  The use of cART concomitantly with 
chemotherapy for HIV-associated lymphomas has been associated with superior 
response rates and survival outcomes compared to chemotherapy alone(21, 54, 81, 
109, 166). However, the high likelihood of cART and chemotherapy pharmacokinetic 
(PK) and pharmacodynamic (PD) drug-drug interactions is regarded as a potential 
hazard(7, 115).  Such drug interactions may be associated with an increased or 
decreased efficacy of chemotherapy, which could potentially lead to detrimental 
toxicities or treatment failure. Minimising and managing these drug interactions are 
becoming increasingly important as HIV-infected patients live longer, and as the 
incidence of non-AIDS defining cancers continue to increase(167, 168).  
 
Antiretroviral agents like PIs and NNRTIs are metabolised via CYP-450 system, and 
therefore may be associated with clinically significant drug interactions with 
chemotherapy. Literature reports, including PK studies, which describe cART and 
chemotherapy drug-drug interactions are very limited. Furthermore, data regarding 
the effect of the different cART regimens on response rates and survival outcomes of 
HIV-infected patients who are receiving chemotherapy are at best scarce. 
 
We were only able to identity one study in patients with HIV-associated lymphoma 
which compared response rates and survival outcomes across different PI and non-
PI based regimens. In this recent study by Wong et al, the authors retrospectively 
reviewed a total of 34 patients with HIV-associated DLBCL from three hospitals in 
Canada, 65% of patients were receiving PI-based cART and 35% were receiving 
non-PI based cART. The authors observed higher CR/CRu rates in the PI group 
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compared to the non-PI group (77% vs. 58%, respectively), but the difference was 
not statistically significant (p=0.21). Similar 2-year OS survival was observed in the PI 
and non-PI group (65% vs. 63%)(169).  
 
In the light of all the above, we undertook a retrospective review of patients with HIV-
associated lymphoma who were on cART during their chemotherapy treatment, at a 
single academic Hospital, over an 8-year period from 1st of January 2003 until 31st of 
December 2010.  The advantages of conducting this study were: to report on the 
tolerability of PI and non-PI based cART during chemotherapy, to shed some light on 
the clinical significance of the expected drug interactions between cART and 
chemotherapy, and to report on the impact of such drug interactions on survival 
outcomes. This would hopefully provide clinicians with some answers regarding what 
would be the optimal cART regimen(s) to choose when treating patients who are 
receiving chemotherapy for HIV-associated lymphoma. 
 
4.1 HIV-associated Hodgkin lymphoma results  
In our retrospective review we identified 16 patients with HIV-associated HL who 
were on cART during chemotherapy. Ten patients were on PI-based cART (62.5%) 
and 6 patients on non-PI based cART (37.5%). HIV and lymphoma-related baseline 
characteristics were similar across both the PI and non-PI groups, including median 
CD4 cell count and age at lymphoma diagnosis .All patients in the HL cohort received 
ABVD chemotherapy. 
 
HL diagnosis in our study cohort appeared to occur at higher CD4 counts. Ten 
patients (62.5%) had a CD4 cell count of >200 cells/µL at HL diagnosis. Furthermore, 
HIV RNA suppression was evident in 11 patients with undetectable HIV-VL (<50 
copies/mL) at lymphoma diagnosis. This observation supports literature reports, 
which showed that the incidence of non-AIDS defining cancers like HL are still on the 
rise despite good control of HIV-infection(4, 76, 170).  
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Our results also confirm findings from other studies that HL in HIV-infected patients 
often presents as advanced disease with unfavourable features(78, 171). We 
observed the following rates of poor prognostic features in our HIV-HL patients: bone 
marrow involvement (37.5%), extranodal involvement (50%), poor risk IPS score 
(44%), high percentage of B-symptoms e.g. fever, night sweats and weight loss 
(75%) and stage III-IV disease (56%).  
 
When reviewing the treatment-related toxicities in our HL cohort, we observed a high 
incidence of neurotoxicity (NT). Any grade NT occurred in 50% and grade 3-4 NT 
occurred in 31% of patients. In comparison, grade 3-4 NT were only reported in 1% 
of HIV-negative patients with HL receiving ABVD chemotherapy(172). Other factors 
that may contribute to neurotoxicity are: advanced HIV-infection(173) and the use of 
older generation NRTIs e.g. stavudine and didanosine(174). However, we could only 
identify one patient with pre-treatment neuropathy in our HL cohort.  
 
When comparing treatment-related toxicities between patients on PI-based and non-
PI based cART, we observed more rates of NT in the PI group but without reaching 
statistical significance. However, the use of ritonavir was significantly associated with 
the occurrence of any grade NT and grade 3-4 NT (p=0.04 and p=0.03, Fisher’s 
exact test, respectively). It is also important to note that two patients in our HL cohort 
experienced severe autonomic neurotoxicity, presenting as severe constipation and 
faecal loading. Both patients were on ritonavir-boosted lopinavir cART. 
 
We speculate that the observed increased incidence of NT among patients in our HL 
cohort was potentially due to the PK drug-drug interaction between vinblastine in the 
ABVD regimen and ritonavir-boosted PIs. Vinblastine is mainly metabolised by the 
CYP3A4 iso-enzyme(115).  Ritonavir is a potent inhibitor of the CYPA34, which may 
lead to decreased clearance of vinblastine, and consequently increasing vinblastine-
induced neurotoxicity and myelosuppression. Another important mechanism for the 
interaction is the modulation of the P-gp efflux pump by ritonavir, which plays an 
important role in the metabolism of vinca alkaloids(115, 175). The interaction 
between ritonavir-boosted PIs and vinblastine has been described in previous 
literature reports, with life-threatening autonomic neuropathy and increased 
haematological toxicities reported(176, 177). 
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We also observed that PI-based cART significantly enhanced neutropenia induced 
by ABVD chemotherapy, evidenced by a statistically significant decrease in the 
median nadir neutrophil count in the PI-group compared to the non-PI group, this is 
despite similar rates of G-CSF prophylactic use and similar bone marrow involvement 
in both the PI and non-PI groups. Patients on PI-based regimens also experienced 
more significant grade 3-4 haematological toxicities with their ABVD treatment 
compared to patients on non-PI based regimens.  
 
Importantly, the rates of grade 3-4 infections necessitating hospitalisation and the 
administration of intravenous antibiotics were significantly higher in patients on PI-
based regimens compared to those on non-PI based regimens (22% vs. 0%, 
respectively, p=0.005).  Consequently, the median number of days on G-CSF 
prescribed for the management of febrile neutropenia was greater in the PI-group. 
(p=0.034). 
 
The potential for more profound neutropenia and myelosuppression is a concern with 
the administration of PI-based cART and ABVD. Besides inhibiting the metabolism of 
vinblastine, ritonavir can also inhibit the metabolism of other drugs in the ABVD 
regimen leading to increasing their myelosuppressive effects. Dacarbazine is 
metabolised via CYP1A2 to reactive DNA methylating metabolites(115), induction of 
CYP1A2 by ritonavir can lead to higher concentrations of the active metabolites of 
dacarbazine causing more side effects and myelosuppression. The role of CYP450 in 
the metabolism of doxorubicin is questionable, it may play a role in the free radical 
generation invitro but clinical significance is less clear(115).  Enzyme inducers of 
CYP2B6 like ritonavir may increase doxorubicin reduction to free radical, and hence 
increasing its antineoplastic properties and cardiotoxic potential. But we did not 
observe an increased risk of cardiotoxicity in our study. 
 
Another important finding from our study was that chemotherapy dose delays were 
more common in the PI-group compared to the non-PI group (20% vs. 3%, p=0.08), 
these delays were mainly due to febrile neutropenia in half the cases (see Figure 3-
2). Patients in the PI-arm were also less likely to complete their stage appropriate 
chemotherapy (50% vs. 0%, p= 0.09), with reasons ranging from nausea and 
vomiting to severe constipation and febrile neutropenia (see Table 3-7).  
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One patient in the PI-group developed severe pancreatitis, and as a result of this 
severe adverse effect the patient’s chemotherapy was stopped prematurely after 3 
cycles. The patient was on didanosine (ddI) 250mg daily as part of his cART, which 
also included tenofovir, abacavir and nelfinavir. Pancreatitis is a life-threatening 
adverse effect of ddI (68), which may be more common when co-administered with 
tenofovir due to an increase in ddI drug exposure(178). Although the interaction is 
more prominent when ddI dose is 400mg, we cannot rule out the possibility of this 
drug interaction occurring in our patient. Therefore, the co-administration of ddI and 
tenofovir during chemotherapy should be used with extreme caution. This is in order 
minimise the chances of such severe side effects occurring, leading to chemotherapy 
delays and interruptions. 
 
Patients in our HL cohort showed excellent CD4 cell count recovery post 
chemotherapy chemotherapy, with their CD4 cell counts at 1-3 months post 
chemotherapy significantly increasing to higher levels at 12-15 months post 
chemotherapy (see Table 3-8). This highlights the important role of cART in assisting 
with the immune reconstitution post chemotherapy. An interesting finding was that 
the median CD4 cell count at 1-3 months post chemotherapy found to be significantly 
lower in patients in the PI-group compared to that in the non-PI group (p=0.05), see 
Figure 3-3. This could potentially reflect the fact that PI-based regimens may have 
potentiated the myelosuppressive effects of chemotherapy, and hence CD4 cell 
count was lower in the PI-arm. However, there were no significant differences in the 
median CD4 cell count values between the two groups at 6-9 months or 12-15 
months post chemotherapy. 
 
We were pleased to observe excellent response rates and survival outcomes in our 
HL cohort. All 16 patients (100%) achieved either CR or CRu at the end of their 
treatment. At a median follow-up period of 62 (range, 32-121) months all 16 patients 
were alive (100% OS rate).  To our knowledge, these excellent clinical outcomes are 
considered to be among the best case reports published in the literature for patients 
with HIV-associated HL, especially that there were also no opportunistic infections 
observed in our HL cohort.  
 
 105 
There was no difference in DFS between the PI and the non-PI group using the 
Kaplan Meier method and the log-rank test (see figure 3-4). It is important to note 
that the two relapses in this case series were in the PI-group, and both were patients 
who did not complete their stage appropriate chemotherapy treatment due to 
potential adverse effects relating to their cART at the time of chemotherapy. 
 
The theoretical concern that patients on NNRTIs may have worse outcomes with 
chemotherapy due to the potential induction of the chemotherapy metabolism by 
NNRTIs, especially efavirenz and nevirapine, was not seen in our HL cohort. There 
was a total of 6 patients in the non-PI group, 5 patients on NNRTI-based (n=3 
efavirenz-based cART and n=2 nevirapine-based cART) and one patient on 
raltegravir-based cART. All patients in the NNRTI-based group tolerated their 
chemotherapy well and achieved CR at the end of their treatment with 100% OS. 
This may suggest that the theoretical drug interactions between NNRTI and ABVD 
chemotherapy may not be clinically significant. 
 
In our HL cohort treated with ABVD chemotherapy, PI-based cART was significantly 
associated with more treatment related toxicities compared to non-PI based cART. 
If appropriate, we believe that non-PI based cART regimens should be considered 
during ABVD chemotherapy to minimise toxicities. The concurrent use of didanosine 
and tenofovir during chemotherapy should be used with extreme caution, due to 
possible increased risk of serious side effects like pancreatitis. 
 
4.2 HIV-associated Burkitt lymphoma results  
In the cART era, it has become clear that the administration of intense treatment 
regimens for HIV-associated BL is a feasible option with excellent outcomes(54, 58, 
63, 179).  The administration of more intense regimens like CODOX-M/IVAC has 
become the main treatment option for HIV-associated BL. This was also evident from 
our BL patient cohort, where CODOX-M/IVAC was the treatment regimen used for 
the majority of patients. 
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In our study, we identified a total of 13 patients with HIV-associated BL who were on 
cART during chemotherapy. The majority of patients in the BL cohort were on a non-
PI-based cART (n=10, 77%), with only 3 patients  (23%) on PI-based cART. The 
median CD4 cell count at BL diagnosis was reasonably high at 330 cells/µL. This is 
in line with what have been reported with other HIV-associated BL studies which 
showed that the risk for HIV-BL incidence peaks at CD4 cell counts of well above 200 
cells/µL(47, 180).   
 
Most of the patients in our BL cohort had high-risk disease with high Magrath score 
(69%), high rate of B-symptoms (92%) and elevated LDH at diagnosis (77%).  Bone 
marrow (31%) and extrandal involvement (62%) were also common features in most 
patients. Three patients (23%) in our BL cohort had CNS involvement of their 
lymphoma, which is very similar to an incidence rate of 10-20% reported in the 
literature (30, 181) 
 
We observed high rates of neurotoxicity (NT) in our BL cohort, with 46% and 23% of 
patients experiencing any grade NT and grade 3-4 NT, respectively. High rates of 
grade 3-4 NT were also observed in another study that compared outcomes and 
toxicities of CODOX-M/IVAC regimen in HIV-infected patients and HIV-negative 
patients (38% vs. 14%, respectively)(58).  In our BL cohort, more rates of NT were 
reported in patients on PI-based cART compared to those on non-PI cART, but 
differences were only marginally insignificant. 
 
We speculate that the observed treatment-related neurotoxicity in the PI-group, 
including two patients presenting with severe grade 3-4 autonomic neuropathy, was 
due to the drug-drug interaction between the ritonavir-boosted lopinavir and 
vincristine in the EPOCH and the CODOX-M chemotherapy regimens. Vincristine is 
metabolised by the CYP3A4, which is inhibited by ritonavir leading to potentiating 
vincristine neurotoxicity. We also expect that this interaction was more profound 
when atazanavir was used concurrently with lopinavir/ritonavir in one patient in the 
BL cohort, due to additive CYP3A4 inhibition potential of atazanavir. Leveque et al, 
previously reported a case of severe drug interaction between vincristine and 
ritonavir-boosted lopinavir that contributed to the development of paralytic ileus in a 
patient with BL who was receiving CODOX-M chemotherapy(144).   
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The incidence of NT in the non-PI group, with the development of severe grade 3-4 
autonomic neuropathy in one patient, could be explained by the use of itraconazole 
as antifungal prophylaxis during CODOX-M chemotherapy in two out of three 
patients who developed NT. Several published reports described severe neurotoxic 
symptoms including paralytic ileus when vincristine was given concomitantly with 
itraconazole, this is possibly due the inhibition of the vincristine metabolism by 
itraconazole, and the subsequent increase in the plasma concentrations of vincristine 
(182-185). On the basis of these reports most clinicians will now avoid the concurrent 
use of itraconazole and vinca-alkaloid containing chemotherapy regimens.  
 
Grade 3-4 haematological toxicities were universal across all patients. This is similar 
to what have been reported in previous studies using CODOX-M/IVAC chemotherapy 
treatment for BL(54, 58, 60).  No differences in grade 3-4 haematological toxicities or 
grade 3-4 anaemia were observed between the PI and the non-PI groups. Another 
factor that may have contributed to high rate of haematological toxicities in our cohort 
was the high rate of bone marrow involvement in 31% of the patients. This high rate 
of haematological toxicity may have contributed to the high incidence of grade 3-4 
infections in our BL cohort. This was despite the use of G-CSF primary prophylaxis in 
all 13 patients. No difference in infection rates were observed between PI and non-PI 
group. 
 
We observed a high rate of mucositis in our BL cohort, with up to 9 patients (69%) 
experiencing any grade mucositis and 7 patients (54%) experiencing grade 3-4 
mucositis. In an attempt to reduce the rates of grade 3-4 mucositis seen with HIV-
patients with the original CODOX-M regimen, the haematology unit at SVH reduced 
the dose of methotrexate in the CODOX-M regimen from 6720mg/m2 to 1000mg/m2.  
However, in our BL cohort we did not observe any difference in the mucositis rates 
between patients receiving CODOX-M using higher MTX dose (6720mg/m2) and 
those receiving lower MTX dose (1000mg/m2).  
 
When comparing the mucositis rates among patients on PI and non-PI based 
regimens, we observed higher rate of grade 3-4 mucositis in the PI group compared 
to the non-PI group (100% vs. 40%), however the difference was not statistically 
significant.  Saparano et al have reported an increased rate of mucositis with PI-
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based regimens in a previous study.  They observed a higher incidence of grade 3-4 
mucositis in 8 of 12 patients receiving CDE chemotherapy (cyclophosphamide, 
doxorubicin and etoposide) and saquinavir based cART(145). As CODOX-M 
chemotherapy also contains cyclophosphamide, etoposide and doxorubicin, we 
speculate that PIs may have lead to higher rates of grade 3-4 mucositis as a result of 
the potentiation of the cytotoxic effects of these agents. 
 
Two patients developed grade 3-4 ALT/AST elevations during chemotherapy, both 
patients were on efavirenz-based cART at the time of chemotherapy. In both 
patients, ALT/AST returned to baseline values after the completion of chemotherapy.  
Grade 3-4 AST/ALT elevations have been reported in up to 3% of patients on 
efavirenz and in up to 8% of patients with hepatitis-B virus (HBV) or hepatitis-C virus 
(HCV) co-infection(123). It was interesting to see these grade 3-4 AST/ALT 
elevations in patients on efavirenz rather than nevirapine, especially that nevirapine 
is considered to be associated with higher risk of hepatotoxicity compared to 
efavirenz(186, 187). Other reasons for ALT/AST elevations cannot be ruled out e.g. 
chemotherapy-induced hepatotoxicity and the fact that one of the two patients also 
had HBV co-infection.  
 
One patient in our cohort experienced transient renal impairment, manifesting as 
doubling of the serum creatinine from baseline after the administration of high dose 
methotrexate. Patient’s cART regimen was tenofovir+ lamivudine and efavirenz. 
Patient’s renal function returned to baseline with administration of intravenous fluids. 
Renal tubular toxicity is common adverse effect of tenofovir(68, 118) and 
nephrotoxicity might accumulate with other nephrotoxic chemotherapy agents like 
methotrexate. Hence, close monitoring of renal function would be recommended in 
these circumstances. 
 
Only one case of treatment related death was reported in our BL patient, which was a 
patient in the PI-group. Cause of death was neutropenic sepsis in the context of 
prolonged neutropenia that lasted 14 days after the 3rd EPOCH chemotherapy cycle. 
The same patient also suffered from significant grade 3-4 NT including paralytic ileus 
and peripheral neuropathy. We believe that the PIs in the patient’s cART regimen 
(lopinavir/ritonavir+ atazanavir) may have potentiated the myelosuppressive effects 
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of the EPOCH chemotherapy. Etoposide, vincristine and prednisolone in EPOCH are 
all metabolised by the CYP3A4 and their metabolism can be inhibited by ritonavir and 
atazanavir, and thus increasing their potential myelosuppressive effects(111, 114, 
115). Cyclophosphamide is metabolised by the CY2B6 to an active metabolite and by 
the CY3A4 to inactive and possibly toxic metabolites(111, 114, 115, 188). Therefore, 
the toxicity of cyclophosphamide could be potentiated via the CYP3A4 inhibition by 
atazanavir and ritonavir, and via the CYP2B6 induction by ritonavir. As discussed 
previously, doxorubicin toxicity may also be potentiated by ritonavir via the CYP2B6 
induction. Another important factor contributing to toxicity in the above case is the low 
CD4 cell count at lymphoma diagnosis (28 cells/µL), which put the patient at high risk 
of infection. Due to the retrospective nature of our study it was difficult to fully assess 
the reason that led to the concurrent use of atazanavir with lopnavir/ritonavir, but it 
appeared that atazanavir may have been added to the cART regimen in context of 
multi-resistant HIV-virus and significantly low CD4 cell count despite multiple cART 
regimens. 
 
Chemotherapy dose reductions and/or changes were the same in the PI and non-PI 
groups, but there were more significant chemotherapy delays in the PI-arm 
compared to the non-PI arm, delays were primarily due to infections and severe 
mucositis in nearly 70% of the patients. Only one out of 3 patients in the PI-group 
completed their stage appropriate chemotherapy. On the other hand, 9 out of 10 
patients in the non-PI group completed their stage appropriate chemotherapy. This 
makes the point that non-PI regimens were generally better tolerated compared to PI 
regimens in our BL cohort. 
 
Although we observed a significant decline in the median CD4 cell count at 1-3 
months and 6-9 months post chemotherapy compared to baseline value at BL 
diagnosis, there was no significant difference between the median CD4 cell count at 
baseline and 12-15 months post chemotherapy, which indicates excellent CD4 cell 
recovery. Furthermore, 10 out of 12 patients who were alive at 12 months had 
undetectable HIV-VL of <50 copies/mL. These results are very similar to that 
reported by Montoto et al when they retrospectively reviewed 30 patients with HIV-
associated BL. The authors noted excellent immune recovery at 12 months post 
chemotherapy, manifesting as high CD4 cell count of > 200 cells/µL and 
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undetectable HIV-VL in 87 and 80% of patients, respectively(189).   
All the above highlights the significant role of cART in assisting immune recovery 
post chemotherapy, especially when intensive regimens like CODOX-M/IVAC are 
administered to HIV-infected patients. We did not observe any difference in the CD4 
cell count recovery post chemotherapy between PI and non-PI groups. 
 
We report a CR rate of 100% in all 12 patients who were evaluable at the end of 
treatment. Our excellent response rate compares favourably with other studies 
published in the literature(54, 58, 60). We also like to mention that all 6 patients who 
received reduced dose of methotrexate (1000mg/m2) as part of CODOX-M regimen 
achieved CR at the end of their treatment, and were all in remission at last follow-up. 
This may suggest that the reduced dose of methotrexate of 1000mg/m2 as part of 
CODOX-M appears equally effective to the higher dose of methotrexate of 
6720mg/m2, studies with larger sample size are needed to confirm this observation.  
 
At a median follow-up time of 53 months, the OS rate in the study cohort was 77% 
(10 patients). There was no difference in OS between the PI and non-PI groups (see 
Figure 3-7). It is important to note that the OS rate may have been influenced by the 
use of autologous stem cell transplant (ASCT) in our BL cohort, which was offered to 
4 patients who were in first remission after their chemotherapy. It was the SVH bone 
marrow transplant (BMT) unit’s policy from 2005 until 2007 to offer ASCT to high-risk 
BL patients who were in complete remission after their chemotherapy. It is important 
to point out that this practice was discontinued in 2008 because of concerns 
regarding increased toxicity associated with the ASCT procedure in the above patient 
population. 
 
In our BL cohort, patients in the PI-group had higher rates of neurotoxicity and 
mucositis compared to those in the non-PI group, but the differences were marginally 
insignificant.  We did not observe any significant differences in the other treatment-
related toxicities between the two groups. We observed more significant delays in the 
administration of chemotherapy cycles in the PI-group compared to the non-PI group. 
Patients in the non-PI group were also more likely to complete their stage appropriate 
chemotherapy compared to patients in the PI-group. The small number of patients on 
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PI-based cART in the BL cohort may have been a limiting factor in detecting more 
significant differences between the two groups.  
 
Similar to our data from the HL cohort, NNRTI-based regimens in our BL cohort were 
not associated with worse survival outcomes. All 10 patients in the non-PI group 
were on NNRTI-based cART (n= 8 on efavirenz-based cART and n=2 on nevirapine 
based-cART), all patients achieved CR at the end of their treatment, and 8 out of 10 
patients were alive at last date of contact. This may suggest that the theoretical drug 
interactions between NNRTI and chemotherapy agents used for BL management 
may not be clinically significant. 
 
4.3 HIV-associated diffuse large B-cell lymphoma results 
In this retrospective review, we identified 20 patients with HIV-associated DLBCL 
who were on cART during chemotherapy. DLBCL patients were equally distributed 
between the PI and non-PI groups (10 patients in each group). Patients in the PI and 
the non-PI groups had very similar HIV and lymphoma-related characteristics at 
DLBCL diagnosis. 
 
Different to what has been reported with HIV-associated HL, the incidence of HIV-
associated DLBCL tends to increase in patients with low CD4 cell count and 
uncontrolled HIV-VL(12, 190, 191). While the median CD4 cell count in our DLBCL 
was >200 cells/µL (208.5 cells/µL), the majority of patients in our DLBCL cohort had 
uncontrolled HIV-VL at diagnosis, which has been reported as a risk factor for 
developing HIV-associated DLBCL. 
 
Most of the patients in our cohort presented with aggressive disease and poor 
prognostic signs, including: grade III-IV disease (60%), high IPI score (45%), 
elevated LDH at diagnosis (90%). Bone marrow involvement (and CNS involvement 
were reported in 25% of the patients in our cohort. EPOCH and R-CHOP were the 
most commonly chemotherapy regimens used in our DLBCL cohort. More intense 
regimens, including CODOX-M/IVAC and hyper-CVAD were also used in 5 patients. 
(See Table 3-21). 
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Similar to what we have found with the HL and BL patients, we observed high rate of 
NT among patients in our DLBCL cohort. Any grade NT occurred in nearly half the 
patients (45%) and grade 3-4 NT occurred in 20% of patients. We observed more 
rates of grade 3-4 NT in the PI-group compared to the non-PI group, but the 
difference was marginally insignificant (40% vs. 0%, p=0.087).  We speculate that the 
increased incidence of grade 3-4 NT in the PI-group was due to the PK drug-drug 
interaction between PI-based cART and vincristine in the EPOCH regimen. Vaccher 
et al, previously reported this drug interaction in a study that compared HIV patients 
on cART and CHOP to those on CHOP alone. The authors reported more grade 3-4 
NT when CHOP was used with PIs compared to CHOP alone (p=0.002) (109). In the 
light of all the above and in addition to what we have previously reported with our HL 
and BL cohorts, we believe that the concurrent administration of PI-based cART and 
vinca-alkaloid based-chemotherapy is best avoided in order to prevent the 
development of severe neurotoxic symptoms.  
 
We observed more grade 3-4 haematological toxicities in the non-PI group compared 
to the PI-group (64% vs. 46.5%), but the difference was not significant (p=0.12). The 
higher rate of haematological toxicities in the non-PI group may have been due to the 
higher use of intense regimens in the non-PI arm e.g. CODOX-M and hyper-CVAD. 
One patient in the non-PI arm suffered from prolonged grade 3-4 neutropenia that 
lasted 4 months after finishing R-CHOP chemotherapy. Prolonged neutropenia, 
including late onset neutropenia, has been observed with rituximab in the treatment 
of DLBCL in a previous study by Dunleavy et al, but were managed without 
occurrence of any death(192). No difference in infection rates or any other treatment 
related toxicity was observed between patients in the PI and the non-PI arm.  
 
We observed grade 3-4 ALT/AST elevations in two patients in our cohort, both were 
in the non-PI group. One patient was on efavirenz-based therapy and the other 
patient was on etravirine and raltegravir based cART regimen. The patient on 
efavirenz-based cART went on to develop jaundice and liver failure. The patient was 
concomitantly receiving hyper-CVAD part B chemotherapy (methotrexate+ 
cytarabine). It was difficult, due to the retrospective nature of the review, to identify 
the main reason(s) for the development of liver failure, especially that grade 3-4 
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ALT/AST elevations have been reported in up to 12% of patients and grade 3-4 
bilirubin elevations in up to 3% of patients receiving hyper-CVAD(193). Other 
complicating factors were; HBV co-infection and hepatic lymphoma involvement at 
diagnosis in our patient. Nevertheless, this observation along with what has been 
previously observed in our BL cohort highlights the importance of close monitoring of 
hepatic functions in patients on cART and chemotherapy, especially those receiving 
more intense chemotherapy regimens. 
 
Chemotherapy dose reductions and/or changes and dose delays were very similar in 
patients in the PI and the non-PI group. Equal number of patients in both groups did 
not complete their stage appropriate their chemotherapy treatment (Table 3-23). 
 
Our DLBCL patients showed excellent CD4 cell count recovery after chemotherapy, 
demonstrated by an increase in the median CD4 cell count from 280 cells/µL at 1-3 
months after chemotherapy to a median CD4 cell count of 486 cells/µL at 12-15 
months post chemotherapy (p=0.06). This may be explained by the fact that 11 out of 
12 evaluable patients at 6-9 months post chemotherapy had undetectable HIV-VL of 
<50 copies/mL. This again highlights the important role of cART in assisting in the 
immune reconstitution post chemotherapy.  Despite the fact that more patients in the 
non-PI group had more intense chemotherapy treatment, there was no difference in 
CD4 cell recovery post chemotherapy between PI and non-PI groups (see Figure 3-
9). 
 
We observed an overall CR/CRu of 68% in our cohort, with similar response rates in 
both PI and non-PI groups (66% vs. 70%, respectively). Our OS rate was 60% at a 
median follow-up period of 26.5 months. We found no differences in OS or DFS 
between the PI and the non-PI group. Response and OS rates from our DLBCL 
cohort are comparable to what have been reported in previous studies(38, 39, 169). 
In our univariate analysis of possible factors associated with achieving CR/CRu, 
bone marrow and CNS involvement of lymphoma were significant factors associated 
with decreased OR of achieving CR/CRu, while completing stage appropriate 
chemotherapy was a significant factor associated with increased OR of achieving 
CR/CRu (see Tables 3-27 A&B for all variables tested in univariate analysis). 
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In our DLBCL cohort, we did not observe any difference in the haematological 
toxicities, or infection rates between the PI and the non-PI groups. The rate of grade 
3-4 NT was higher in the PI group. We did not observe any differences in 
chemotherapy delays, or changes and/or reductions in chemotherapy between the 
two groups. Response rates and survival outcomes were also similar in both the PI 
and the non-PI groups. All 10 patients in the non-PI group were on NNRTI-based 
cART (n= 6 on efavirenz-based cART and n=3 on nevirapine based-cART, n=1 
etravirine and raltegravir-based cART).  High complete response rates of 70% were 
reported in the non-PI group. Therefore, similar to what have been observed with the 
HL and the BL cohorts, the theoretical concern regarding the potential drug 
interactions between NNRTIs and chemotherapy agents used for DLBCL may not be 
clinically significant. Further studies with larger sample size are needed to confirm 
these results. 
 
4.4  HIV-patients with ‘other lymphomas’ 
Four patients with ‘other lymphoma’ were included in this retrospective review, two 
patients with plasmablastic lymphoma (PBL), one with anaplastic lymphoma and one 
with primary effusion lymphoma (PEL). These patients were grouped separately as 
they have different survival outcomes from DLBCL patients. Two patients were on PI-
based and two on non-PI based regimen. 
 
As mentioned previously, PBL and PEL in the setting of HIV-infection most 
commonly present in patients with severe immunosuppression i.e. with CD4 count 
<100 cells/µL and high-uncontrolled HIV-VL at diagnosis(87, 194).  Anaplastic 
lymphoma is a distinctive type of NHL of either T-cell or null-cell lineage(195). Our 
patient in the cohort had anaplastic lymphoma of null-cell lineage type.  
 
Although only one patient was cART naïve at lymphoma diagnosis, all four patients 
had uncontrolled HIV-VL. This may be explained by the sub-optimal adherence to 
cART as all three patients experienced significant cART holiday periods ranging from 
22 to 60 months. Three of the four patients had CD4 cell count < 200 cells/µL, and in 
one patient the CD4 cell count was only 21 cells/µL. EPOCH and CHOP 
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chemotherapy were used for the treatment of lymphoma in this cohort (see details of 
treatment in Table 3-21).  
 
When comparing treatment related toxicities between patients in the PI and the non-
PI groups. We observed two cases of grade 3-4 NT, one case in each of the PI and 
the non-PI group. An interesting recurring finding was the development of grade 3-4 
autonomic neuropathy, with severe bowel obstruction and anal fistula development, 
in a patient in the PI group who was on ritonavir-boosted lopinavir based cART 
concurrently with EPOCH. The other patient who developed grade 3-4 NT was on 
efavirenz-based cART, and as a result vincristine was ceased after cycle 4 of CHOP 
chemotherapy. 
 
We observed that PI-based cART in this cohort was associated with more significant 
haematological toxicities compared to patients in the non-PI group. Patients in the PI 
group also experienced more delays in their chemotherapy cycles and had more 
grade 3-4 infections compared to patients in the non-PI group. 
 
Numbers in this cohort were too small to do survival analysis, but it is important to 
note that the only death reported in this group was in the PI-group. The patient 
experienced significant myelosuppression leading to chemotherapy delays, and 
failed to complete the full course of planned treatment. The observed excessive 
myelosuppression may have been due to the PK drug-drug interaction between 
atazanavir/ritonavir in the patient’s cART and CHOP chemotherapy, leading to 
potentiating the myelotoxicity of the CHOP regimen. 
 
It was very encouraging to observe that three out of four patients in this cohort 
achieved CR at the end of their treatment, especially that these lymphoma types are 
associated with poor prognosis. One patient in the non-PI group relapsed at 7 
months post treatment. He was salvaged by autologous stem cell transplant, and 
then salvaged again after his second relapse by reduced intensity allogeneic stem 
cell transplant. To date the patient is still well, alive and in remission, which is 
remarkable as allogeneic stem cell transplant is still considered an experimental 
approach in HIV-patients with relapsed lymphoma(196). 
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4.5 Pooled-analysis discussion 
Our results confirm that presenting CD4 cell count and HIV-VL values at diagnosis 
vary by lymphoma type. In our cohort, BL occurred at higher CD4 cell counts 
compared to other lymphoma types. On the other hand, ‘other lymphoma’ diagnoses 
including PBL and PEL occurred at lower CD4 cell counts confirming that these types 
of lymphomas occur in HIV-infected patients with severe immunosuppression. HL 
patients in our cohort had the highest rate of HIV-VL suppression compared to other 
types of lymphomas. This confirms that the risk for developing HL in the cART era 
has no clear link with immunosuppression. Which is why HL has been classified as a 
non-AIDS defining cancer (NADC). 
 
Another important finding from our study cohort was the high rate of HBV co-infection 
(34%), demonstrated by being surface antigen (HBsAG) positive or the presence of 
anti-core antibody (anti-HBc). Persistent HBV infection is more common in individuals 
with HIV, with prevalence of chronic HBV infection estimated at 25%(68), with up to 
8.7% of patients (in one European study) having active HBV infection(68, 197).The 
incidence of HCV in our cohort was 9%. Australian data on rates of HCV co-
infections is limited, but one study showed that the rate of HCV co-infection was 
7.6% at an Australian tertiary referral centre(198). 
 
HIV-associated lymphomas in our cohort presented as aggressive wide spread 
disease in a significant proportion of patients (see Table 3-34), with high rates of 
grade III-IV disease, bone marrow involvement, extranodal involvement and elevated 
LDH and B-symptoms. CNS involvement, which is a poor prognostic feature(199), 
was evident in 15% of patients in our cohort (in BL and DLBCL patients only) 
 
We performed univariate and multivariate analysis to test for the association of cART 
and grade 3-4 toxicities in a pooled analysis of all patients in our study cohort. The 
multivariate analysis confirmed that PI-based cART and the use of lopinavir/ritonavir 
were independent factors significantly associated with the development of grade 3-4 
neurotoxicity and grade 3-4 infections after adjusting for other factors, including 
chemotherapy regimen used. 
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PI-based cART was also associated with decreased odds of completing stage 
appropriate chemotherapy in the univariate analysis. On the other hand, patients on 
efavirenz-based cART where more likely to complete their stage appropriate 
chemotherapy. Importantly, in our overall survival analysis of all patients with HIV-
associated lymphomas we found that the completion of stage appropriate 
chemotherapy was a significant factor associated with better OS. We also found that 
completing stage appropriate chemotherapy was associated with an increased OR of 
achieving CR/CRu in our DLBCL cohort. Therefore, although we could not detect 
differences is OS or DFS between PI and non-PI groups in our study, patients in the 
PI group were less likely to complete their full course of stage appropriate 
chemotherapy, which has been shown to be a significant factor associated with 
achieving CR and better OS in our cohort. 
 
Overall, clinical outcomes of our patient cohort compare favourably to what have 
been reported in the literature. We observed excellent outcomes in our HL patients, 
with 100% CR/CRu and OS rates. All twelve BL patients who were evaluable at the 
end of their treatment achieved CR, with 77% OS rates at last follow-up. In our 
DLBCL and ‘other lymphoma’ patients we observed OS rates of 60% and 75%, 
respectively.   
 
Improvements in the outcomes of HIV-associated lymphomas have been a success 
story. All thanks to cART, patients are now able to receive standard and dose intense 
chemotherapy with better survival outcomes. However, the issue of cART and 
chemotherapy drug-drug interactions remains a potential hazard for adverse effects. 
In our study PI-based cART was associated with more significant grade 3-4 toxicities 
compared to non-PI regimens. The increase in the chemotherapy-related toxicities in 
the PI-group is likely caused by the PK drug-drug interactions with chemotherapy 
agents via inhibition of the CYP450 enzyme system and the P-gp efflux pump. 
 
In our study, non-PI based cART was better tolerated in comparison to PI-based 
cART. Furthermore, we did not observe inferior response rates or OS among patients 
on NNRTI-based cART compared to patients in the PI-group. This was an important 
research question that we wanted to address when we undertook this study. As 
inducers of the CYP3A4, efavirenz and nevirapine are expected to induce the 
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metabolism of many chemotherapy agents and potentially leading to decreasing their 
therapeutic effect. We however, did not see that effect within our cohort. We had a 
total of 19 patients on efavirenz-based cART and 7 patients on nevirapine-based 
cART in the non-PI group, which is a reasonable sample size. Therefore, based on 
our results we think that the theoretical drug interactions between chemotherapy and 
efavirenz/nevirapine-based cART may not be clinically significant at this stage. 
Studies with larger numbers of patients are urgently needed to confirm these 
observations. Due to the small number of patients on etravirine in our cohort (one 
patient in the non-PI group), we cannot make a definite recommendation regarding 
its use with chemotherapy. Etravirine is a weak inducer of the CYP3A4 and CYP2B6 
and is expected to have minimal drug interactions with chemotherapy(126), but 
further studies are needed to confirm that it could be safely co-administered with 
chemotherapy. 
 
If appropriate from an HIV treatment point of view, we believe that PI-sparing 
regimens like NNRTIs and raltegravir should be used instead of PIs in patients 
undergoing chemotherapy for HIV-associated lymphoma. This is in order to reduce 
chemotherapy-related toxicities and improve treatment tolerability, allowing for full 
delivery of chemotherapy treatment course and maximizing treatment outcomes. 
 
Other potential regimens that could be also used during chemotherapy are 
maraviroc-based regimens. Although not studied in our cohort, maraviroc is not a 
CYP inhibitor nor inducer and is likely to have minimal drug interactions with 
chemotherapy(141). Important considerations and recommendations as suggested 
by our study results for patients undergoing chemotherapy for HIV-associated 
lymphoma will be discussed in the next section. 
 
4.6 Important considerations and recommendations for patients 
with HIV-associated lymphoma.  
4.6.1 Opportunistic infection (OI) prophylaxis 
We were pleased to observe a low rate of OIs in our cohort. Only two patients (4%) 
out of 53 patients in our study had OIs. First patient had PML infection and the 
second patient had cytomegalovirus (CMV) infection; both patients had a CD4 cell 
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count of < 200 cells/µL at diagnosis. The low rate of OIs in our study may have been 
due to the high rate of OI prophylaxis among our patients. We were able to find 
documentation for PJP prophylaxis in 50 patients (94%), herpes simplex/varicella 
zoster prophylaxis in 36 patients (68%) and fungal prophylaxis in 30 patients (56%). 
MAC prophylaxis was administered in 6 patients; all with CD4 cell count of <50 
cells/µL. CMV prophylaxis was also administered in two patients, both with CD4 cell 
count of <100 cell/µL.  
 
Prophylaxis against PJP is recommended for those who have a CD4 cell count of 
<200 cells/µL and should be considered in individuals with an AIDS diagnosis with a 
CD4 cell count above this level(200, 201). Therefore all patients with lymphoma 
diagnosis should be considered for PJP prophylaxis during chemotherapy and post 
chemotherapy until satisfactory immune reconstitution. Most of HIV-infected patients 
are at risk of reaching a CD4 cell count of < 200 cells/µL with chemotherapy. In our 
study we observed that 30% of patients still had a CD4 cell counts of <200 cells/µL at 
1-3 months post chemotherapy. Sulfamethoxazole/trimethoprim (cotrimoxazole) is 
the agent of choice for PJP prophylaxis(165). The use of cotrimoxazole also confers 
cross protection against cerebral toxoplasmosis(165, 201). Although one double 
strength cotrimoxazole tablet daily is the preferred regimen, the Australian 
therapeutic guidelines also recommend the use of single strength tablet daily or 
double strength tablet 3 times weekly(202). If cotrimoxazole is not tolerated, other 
agents like dapsone, pentamidine and atovaquone can be used for PJP prophylaxis. 
 
We recommend antifungal prophylaxis for HIV-infected patients undergoing 
chemotherapy that requires prolonged central venous access as these patients are at 
risk of developing fungal infections, especially in the context of profound neutropenia 
(163). A meta-analysis of fluconazole vs. itraconazole for fungal prophylaxis in 
patients with haematological malignancies yielded no statistical differences in 
invasive fungal infections and overall mortality(203).  Furthermore, there are 
potentially significant drug interactions between vinca alkaloids and itraconazole(182, 
183, 185), which we also observed in our patient cohort presenting as severe 
neurotoxic adverse effects. Therefore, fluconazole should be used with 
chemotherapy regimens containing vinca alkaloids to minimise the possibility of 
adverse effects due to drug interactions.   
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MAC prophylaxis should be initiated for HIV-infected patients with a CD4 cell count of 
<50 cells/µL, as well as patients who are risk of achieving a CD4 count below this 
level during chemotherapy(58, 68, 200, 201). The treatment of choice is azithromycin 
1200mg once a week.  We also recommend that close CMV monitoring should be 
initiated at least twice a week in HIV-patients with CD4 cell count of <100 cells/µL 
who are undergoing chemotherapy. Patients who are at risk of CMV infection should 
receive prophylaxis with oral valganciclovir or intravenous ganciclovir(68).  
 
4.6.2 cART interruption during chemotherapy 
As mentioned before, cART use during chemotherapy is associated with better 
response rates and survival outcomes due to the improved immune status of HIV-
infected patients undergoing chemotherapy(26, 109, 110, 204). Based on our results, 
we suggest continuation of cART during chemotherapy for HIV-associated lymphoma 
due to the favourable clinical outcomes and the excellent immune reconstitution post 
chemotherapy. 
 
However, we would like to point out that in some situations, interruption of cART 
during chemotherapy is inevitable to due significant gastrointestinal (GI) toxicities 
observed with chemotherapy e.g. severe nausea, vomiting and diarrhoea, and the 
severe mucositis that may develop with some intense chemotherapy regimens.  
 
We observed cART interruptions lasting for more than 3 days in 8 patients (15%) in 
our cohort due to GI toxicities and mucositis. Similarly, Gopal et al in a recent 
retrospective review of 65 patients with HIV-associated lymphoma, reported cART 
interruptions in up to 25% patients(205). In their study, the authors observed that 
regimens containing PIs, especially ritonavir seemed more vulnerable to interruption. 
This is perhaps because some ritonavir containing regimens needs to be 
administered with food e.g. ritonavir-boosted atazanavir and darunavir. In our study 
the rates of cART interruption was similar across the PI and the non-PI regimens.  
 
Interruption of all cART agents at once within a patient’s regimen could lead to 
potential problems, especially when using an antiretroviral agent which has long half-
life like efavirenz (40-55hrs)(123). Duration of detectable efavirenz levels after 
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discontinuation could last from less than one week to more than 3 weeks(206), which  
may lead to monotherapy and the development of drug resistance. Therefore, we 
recommend a multidisciplinary approach that involves the collaboration of HIV 
physicians and HIV/infectious diseases pharmacists to ensure the management of 
these complex situations when they arise. 
 
4.6.3 cART choice during chemotherapy  
Based on our results and the available literature regarding cART and chemotherapy 
drug interactions, we would like to put forward the following suggestions and 
recommendations regarding the choice of cART during chemotherapy for patients 
with HIV-associated lymphoma. These recommendations are made specifically for 
patients undergoing chemotherapy with ABVD, CHOP±R, EPOCH, CODOX-M/IVAC 
and hyper-CVAD. But may also be used as a guide for patients undergoing 
chemotherapy with other regimens. 
 
Nucleoside reverse transcriptase inhibitors (NRTIs) 
Zidovudine (ZDV)- should be avoided due to increased risk of haematological 
toxicity and bone marrow suppression with chemotherapy (anaemia and 
neutropenia). 
 
Didanosine (ddI)- Best avoided. Not recommended in the current HIV treatment 
guidelines; possible increased risk of peripheral neuropathy with vinca-alkaloids. Can 
be associated with life-threatening pancreatitis, especially when combined with 
tenofovir. 
 
Stavudine (d4T)- Best avoided. Not recommended in current HIV treatment 
guidelines; possible increased risk of peripheral neuropathy with vinca-alkaloids.  
If the patient presents for chemotherapy and is on one of the above 
antiretroviral agents, then we recommend consulting the HIV-team/physician to 
request change and/or substitution of the above agents. 
 
Abacavir (ABC), Lamivudine (3TC) and Emtricitabine (FTC)- No contraindication 
for use with chemotherapy. 
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Tenofovir (TDF)- Due to the potential for additive renal toxicity, tenofovir should be 
used with caution in patients receiving nephrotoxic regimens e.g. high dose 
methotrexate in CODOX-M/IVAC and hyper-CVAD regimens.  
 
If the patients presents for a chemotherapy regimen that has nephrotoxic 
potential, then consider consulting the HIV-team/physician to request 
substitution of tenofovir. If switching to another agent is not suitable, then 
consider close monitoring of renal function during treatment. Before the 
discontinuation of tenofovir, clinicians should check if tenofovir is used for the 
management of hepatitis B co-infection. If so, an alternative anti-hepatitis B 
agent should be started before the discontinuation of tenofovir. 
 
Protease inhibitors (PIs)-The use of PIs is best avoided due to the increased risk of 
neurotoxicity and the potentiation of the myelotoxicty of chemotherapy, which in turn 
may be associated with more significant infections.  
 
If the patient presents for chemotherapy and is on a PI-regimen, then we 
recommend consulting the HIV team/physician to request substitution to a 
non-PI based regimen e.g. raltegravir or NNRTI-based cART(§). If switching to a 
non-PI regimen is not suitable, then chemotherapy dose reductions according 
to emerging treatment-toxicities should be considered. 
 
(§) Clinicians should be particularly thoughtful when switching patients who are stable on 
boosted PI-regimens to raltegravir or NNRTI-based regimens. Virological failures have been 
reported when switching patients from a regimen of 2 NRTIs plus a PI to 2 NRTIs plus an 
NNRTI or 2 NRTIs plus raltegravir(207-209). These virological failures were evident in 
patients who had a history of NRTIs mutations. PIs have a high genetic barrier to resistance 
mutations compared to NNRTIs and raltegravir (210, 211). Therefore, in patients who have 
background NRTI mutations, the switch from a PI-based regimen to a non-PI based regimen 
may not be appropriate. 
 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
Efavirenz (EFV)- No increased risk of toxicity observed with chemotherapy. Monitor 
for hepatotoxicity. 
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Nevirapine (NVP)- No increased risk of toxicity observed with chemotherapy. 
Monitor for hepatotoxicity. 
 
Integrase inhibitors (INSTIs) 
Raltegravir- Appears safe to use during chemotherapy. Has a low potential for drug-
drug interactions with chemotherapy. Elvitegravir, a new integrase inhibitor has 
different PK characteristics to raltegravir. Elvitegravir is a CYP3A substrate and is co-
formulated with cobicistat, a pharmacokinetic enhancer, and thus is susceptible to PK 
drug interactions. Therefore, not all integrase inhibitors have the same PK interaction 
profile(212). 
 
In individuals who are cART naïve at lymphoma diagnosis we recommended the 
initiation of raltegravir-based regimen with tenofovir/emtricitabine (consider 
abacavir/lamivudine if nephrotoxic chemotherapy will be used) or efavirenz with 
tenofovir/emtricitabine (consider abacavir/lamivudine if nephrotoxic chemotherapy 
will be used). Check HLA-B*5701 status prior to initiating abacavir in naïve patients. 
 
4.6.4 Supportive therapy and cART during chemotherapy 
Although we did not study the drug interactions between supportive therapy and 
cART in our patient cohort, we would like to highlight the possibilities of PK and PD 
interactions between medications used for supportive care and cART.  Some 
examples include: acid suppressants commonly used as part of supportive therapy in 
patients undergoing chemotherapy can reduce the absorption of atazanavir and 
consequently lead to sub-therapeutic serum levels(213). Dexamethasone used as 
anti-emetic is a strong CYP3A4 inducer and long-term use can reduce the 
concentration of NNRTIs, PIs, maraviroc as well as the new integrase inhibitor 
elvitegravir (115).  Azole antifungal agents like itraconazole and voriconazole are 
substrates and inhibitors of the CYP3A4, which could potentially lead to two-way 
drug interactions with cART(214). 
 
Final comments: 
 All the above points mentioned highlight the complexity and the challenges 
involved in the management of HIV-patients with lymphoma. Therefore, we 
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believe that a multidisciplinary cooperation between oncologists, HIV physicians 
and clinical pharmacists with expertise in oncology and HIV would be the best 
approach to ensure that HIV patients with malignancies are suitably managed. 
 
 We are planning to disseminate information from our review by publishing our 
results in one of the haematology and/or HIV journals. Our HL data will be 
presented as a poster paper at the Conference on Retroviruses and Opportunistic 
Infections (CROI), Atlanta, USA, in March 2013. We also plan to present our 
results at the Australasian Society of HIV Medicine (ASHM) meeting in 2013. We 
aim to communicate with ASHM guidelines committee regarding the importance 
of including a section on cART and chemotherapy drug interactions when new 
guidelines are published. We hope that this will help increase awareness among 
Australian clinicians regarding such drug interactions, especially in the era of the 
increase in the incidence of non-AIDS defining cancers among HIV-infected 
patients. 
 
4.7 Study limitations 
Limitations of our study include: 
 The retrospective nature of data collection and hence it is possible that significant 
confounders were not addressed. 
 The study was conducted in a single centre and the generalization of results 
cannot be guaranteed.  
 The small number of patients included in our study.   
 The variability in chemotherapy treatment between the PI and the non-PI groups 
in the DLBCL cohort. 
 
4.8 Future directions 
Continued future research in the area of cART and chemotherapy drug-drug 
interactions is warranted in order to provide more information to clinicians and guide 
treatment decisions. Identification of large number of patients should be considered 
through multi-institutional efforts across Australia. We have already approached 
another Australian academic tertiary hospital to collect their data to allow for larger 
number of patients with HIV-associated lymphoma to be studied. Randomised 
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studies aimed at evaluating the impact of the different classes of antiretroviral agents 
on the tolerability and response to chemotherapy are needed. Prospective 
pharmacokinetic studies are also needed to measure the in-vivo therapeutic drug 
concentrations of chemotherapy agents as well as the antiretroviral agents. These 
studies should also include newer agents like rilpivirine, etravirine, maraviroc and 
elvitegravir. At the end, we would like to encourage all centres treating HIV-patients 
with malignancies and on cART to publish their case reports and case series to 
enrich the literature with much need data regarding cART and chemotherapy drug 
interactions. 
 
4.9 Conclusions 
In this retrospective study we reviewed patients with HIV-associated lymphoma who 
were on cART during chemotherapy at a single Australian academic tertiary Hospital. 
We compared the tolerability and survival outcomes of HIV-infected patients on PI-
based and non-PI based cART during chemotherapy. To our knowledge, this is the 
first Australian study, and one in very few studies ever presented, that reports on 
both the tolerability and survival outcomes of PI and non-PI cART regimens during 
chemotherapy for HIV-associated lymphoma. In our study, PI-based cART was 
significantly associated with more treatment related toxicities compared to non-PI 
based cART. Patients on non-PI based regimens were more likely to complete their 
stage appropriate chemotherapy treatment compared to those on PI-based cART, 
but there no difference in response rates, overall survival or disease free survival 
between the two groups. We conclude that, If appropriate, non-PI based cART 
should be considered during chemotherapy for HIV-associated lymphoma to 
minimise treatment-related toxicities. 
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Appendix 2  Data collection form  
Combined Antiretroviral Therapy During Chemotherapy for HIV-Patients with 
Hodgkin and Non-Hodgkin Lymphoma: A review of tolerability and survival 
outcomes 
1-Patient Details 
Study Code (initials+ D.O.B as DDMMYY) 
e.g. AB010569:  
                                                        
Date of Birth:            
 
Gender: 1 male          
                2 female  
Height:  
                                                                            
Weight:   
                              
BSA:           
 
 
BSA capped  
 1 yes, specify……… 
 2 no                                                                                                              
 
                                              2-HIV Data 
1-Date of diagnosis of Human Immunodeficiency Virus (HIV):  
 
2-When was the diagnosis of HIV infection made relative to diagnosis of lymphoma? 
1 prior to diagnosis of lymphoma, specify duration……………………….. 
 
2 at the time of diagnosis of lymphoma 
 
3 incidental detection during lymphoma workup 
 
4 unknown 
 
3- Was the lymphoma considered HIV-associated (i.e. due to the presence of the HIV 
infection? 
   1 yes    
 
   2 no 
 
4-Prior AIDS history                  
  1 yes. If yes, please specify: 1- 
                                                        2- 
                                                        3- 
                                                        4- 
                                                        5- 
                                                        6- 
 
 2 no  
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5- Was the patient on antiretroviral therapy prior to lymphoma diagnosis? 
1 yes. If yes, record duration on ART prior to lymphoma………………………… 
 
2 no, started after lymphoma diagnosis 
 
6- Did the patient experience any ART holidays prior to lymphoma diagnosis? 
1 yes, if yes, record total period of interruption prior to lymphoma……………………. 
 
2 no 
 
7-Was the subject receiving ART during chemotherapy? 
1 yes            
                           
2 no (exclude from study) 
 
8- If yes to Q7, specify ART regimen given during chemotherapy:  
 
1 protease inhibitor (PI) based-regimen 
2 non-nucleoside reverse transcriptase inhibitor (NNRTI) based-regimen  
3 integrase inhibitor based-regimen  
4 mixed regimen, specify ……………………………………………………………………………………………. 
                                                    ……………………………………………………………………………………………. 
                                                    ……………………………………………………………………………………………. 
9- List antiretroviral agents used during chemotherapy  
Antiretroviral agent Dose Date started Date stopped or 
Currently taking 
1-              
 
   
2- 
 
   
3- 
 
   
4- 
 
   
5- 
 
   
6-                
   
   
7- 
 
   
8- 
 
   
9- 
 
   
10- 
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10- Issues with ART adherence identified during chemotherapy (assess using Pharmacy 
dispensing history or Clinic progress notes) 
1 no 
 
2 yes, specify……………………………………………………………………………………….          
 
11- Was the ART changed during chemotherapy? 
1 yes, complete question 12 and specify alternate regimen(s):………………………………………….. 
                                                                                                                 ……………………………………………. 
                                                                                                                 ……………………………………………. 
 
2 no, go to question 13 
 
12- Specify reason for change in ART during chemotherapy, if applicable: 
1 undesirable adverse effect, specify……………………………………………………………………………………. 
                                                                     ……………………………………………………………………………………. 
2 virological failure  
 
3 other, please specify…………… 
 
4 Unknown  
 
13-Hep-B co-infection    1 yes, specify treatment if any:……………………………………………………… 
 
                                            2 no 
 
14-Hep-C co-infection    1 yes, specify treatment if any:……………………………………………………… 
 
                                            2 no 
 
15- CD4 counts  
Timing                                                                        Test Date CD4 % Absolute count 
1-Nadir count CD4 (lowest CD4 ever) prior to 
lymphoma diagnosis 
   
2- Count at lymphoma diagnosis  
 
   
3-Count during chemotherapy 
 
   
4-Count post chemotherapy  
 
   
5-Count 6 months post chemotherapy  
 
   
6-Count 12 months post chemotherapy  
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16- Viral load  
Timing Test date Viral load 
1-Viral load prior at HIV diagnosis   
 
  
2-Viral load prior at lymphoma diagnosis  
 
  
3-Viral load during chemotherapy  
 
  
4-Viral load post chemotherapy  
 
  
5-Viral load 6 months post chemotherapy  
 
  
6-Viral load 12 months post chemotherapy  
 
  
 
17- Opportunistic infections prophylaxis given during chemotherapy:  
1-Pneumocystis jiroveci (carinii) pneumonia prophylaxis: 
1 yes  
2 no  
If yes, specify agent and dose:…………………………………………….. 
 
2-Herpes/zoster prophylaxis: 
1 yes 
2 no  
If yes, specify agent and dose:…………………………………………….. 
 
3-Antifungal prophylaxis:  
1 yes  
2 no  
If yes, specify agent and dose:…………………………………………….. 
 
4- Toxoplasma gondii prophylaxis:  
1 yes  
2 no  
If yes, specify agent and dose:…………………………………………….. 
 
5-Mycobacterium avium complex (MAC) prophylaxis:  
1 yes  
2 no  
If yes, specify agent and dose:…………………………………………….. 
 
6-Cytomegalovirus  (CMV) prophylaxis:  
1 yes  
2 yo  
If yes, specify agent and dose:…………………………………………….. 
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3-Lymphoma Data 
1-Diagnosis: 
1 Hodgkin’s Lymphoma  
 
2 Diffuse Large B-Cell Lymphoma  
 
3 Burkitt Lymphoma  
 
4 Intermediate Lymphoma 
 
5 Other, specify……………………………………………………………….. 
 
2-Diagnosis date: 
 
3- Staging of the Lymphoma 
1- Ann Arbor score: 
 
2- B-symptoms (fever, weight loss, night sweats) 1 Yes 2 No 
 
3- International Prognostic Index (IPI) score for non-Burkitts NHL: 
 
4- Magrath risk score (for Burkitt Lymphoma): 
 
5- CNS involvement 1 yes  
                                2 no 
 
6- BM involvement 1 yes     
                               2 no 
 
 
4-Performance status (ECOG) scale prior to chemotherapy: 
 
0 fully active, able to carry on all pre-disease performance without restriction.   
1 restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g. light housework, office work.  
2 ambulatory and capable of all self-care but unable to carry out any work activities. Up 
and about >50% of waking hours.  
3 capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours. 
4 completely disabled. Cannot carry out any self-care. Totally confined to bed or chair. 
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5-Chemotherapy regimen chosen and frequency:……………………………………………………………… 
 
Cycle 1 
 (1A if ABVD) 
Cycle 2  
(1B if ABVD) 
Cycle 3  
(2A if ABVD)  
Cycle 4  
(2B if ABVD) 
Date: 
Full dose: 1 yes 
                  2 no 
If No, note reason: 
 
 
Date: 
Full dose: 1 yes 
                 2 no 
If No, note reason: 
 
 
 
 
 
 
Delayed:  1 yes 
                 2 no 
If Yes, number of 
days: 
Date: 
Full dose: 1 yes 
                 2 no 
If No, note reason: 
 
 
 
 
 
 
Delayed: 1 yes 
                2 no 
If Yes, number of 
days: 
 
Date: 
Full dose: 1 yes 
                 2 no 
If No, note reason: 
 
 
 
 
 
 
Delayed: 1 yes 
        2 no 
If Yes, number of 
days: 
 
 
 
 
Cycle 5     
(3A if ABVD)   
 N/A 
Cycle 6    
  (3B if ABVD) 
N/A 
Cycle 7    
(4A if ABVD)   
N/A 
Cycle 8   
 (4B if ABVD)  
           N/A 
Date: 
Full dose: 1 yes 
                 2 no 
If No, note reason: 
 
 
 
 
 
 
Delayed:  1 yes 
                 2 no 
If Yes, number of 
days: 
 
Date: 
Full dose: 1 yes 
                  2 no 
If No, note reason: 
 
 
 
 
 
 
Delayed:  1 yes 
                 2 no 
If Yes, number of 
days: 
 
Date: 
Full dose: 1 yes 
                 2 no 
If No, note reason: 
 
 
 
 
 
 
Delayed: 1 yes 
                2 no 
If Yes, number of 
days: 
 
Date: 
Full dose: 1yes 
                 2 no 
If No, note reason: 
 
 
 
 
 
 
Delayed: 1 yes 
                2 no 
If Yes, number of 
days: 
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6-Chemotherapy dose intensification     
1 yes, if yes, specify……………………………………………………………………………………………………….. 
                                      …………………………………………………………………………………………………………                                 
2 no 
 
7-Chemotherapy reductions due to toxicity 
1 yes, if yes, specify............................................................................................................. 
                                       ………………………………………………………………………………………………………… 
2 no 
 
8- Did the patient complete the full intended course of chemotherapy? 
1 yes 
 
2 no, if no, specify reason(s)………………………………………………………………………………………….. 
                                                      …………………………………………………………………………………………… 
9- Intrathecal chemotherapy given        
1 yes, if yes, specify……………………………………………………………………………………………………….. 
                                       ………...……………………………………………………………………………………………..              
2 no 
 
10- Radiotherapy given:                        
1 yes, if yes, specify……………………………………………………………………………………………………….. 
                                      …………………………………………………………………………………………………………. 
2 no 
 
11-Response to chemotherapy: 
At the end of 
chemotherapy 
 
Six months year 
post treatment 
One year post 
treatment 
Two years post 
treatment 
1 Complete 
response 
 
2 Unconfirmed 
complete 
response  
 
3 Partial 
response  
 
4 Stable 
disease 
 
5 Progressive 
disease  
 
6 Not 
evaluated  
1 Complete 
response 
 
2 Unconfirmed 
complete 
response  
 
3 Partial 
response  
 
4 Stable 
disease 
 
5 Progressive 
disease  
 
6 Not 
evaluated 
1 Complete 
response 
 
2 Unconfirmed 
complete 
response  
 
3 Partial 
response  
 
4 Stable 
disease 
 
5 Progressive 
disease  
 
6 Not 
evaluated 
1 Complete 
response 
 
2 Unconfirmed 
complete 
response  
 
3 Partial 
response  
 
4 Stable 
disease 
 
5 Progressive 
disease  
 
6 Not 
evaluated 
 156 
12- Treatment related toxicities:  
 Grading according to (NCI-CTCAE criteria, version 3, 2006) 
 Record the worst grade experienced during chemotherapy cycle 
Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, Grade 4 = Life-threatening 
or disabling AE, Grade 5 = Death related to AE 
Toxicities  Cycle 1 Cycle 2 Cycle 3  Cycle 4  
Haematological adverse effects 
Haemoglobin  
 
Leukocytes (total WBC)  
 
Neutrophils (ANC)  
 
Platelets 
 
 
   
    
    
 
 
   
Infection related 
Culture –ve febrile neutropenia   
 
Documented infection with neutropenia 
 
Documented infection with normal 
neutrophils 
    
    
    
Cardiac adverse effect 
Cardiac arrhythmias 
 
Cardiac other 
 
 
   
    
Metabolic/Laboratory  
ALT/AST  
 
Bilirubin  
 
 
   
    
Gastrointestinal adverse effects: 
Mucositis 
 
Nausea/Vomiting 
 
Diarrhoea  
 
 
 
   
 
 
   
    
Autonomic neurotoxicity  
 
 
    
Dermatology/skin  
 
    
Other adverse effects, specify  
1- 
2- 
3- 
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Toxicities  Cycle 5 Cycle 6 Cycle 7 Cycle 8  
Haematological adverse effects 
Haemoglobin  
 
Leukocytes (total WBC)  
 
Neutrophils (ANC)  
 
Platelets 
 
 
   
    
    
 
 
   
Infection related 
Culture –ve febrile neutropenia   
 
Documented infection with neutropenia 
 
Documented infection with normal 
neutrophils 
    
    
    
Cardiac adverse effect 
Cardiac arrhythmias 
 
Cardiac other 
 
 
   
    
Metabolic/Laboratory  
ALT/AST  
 
Bilirubin  
 
 
   
    
Gastrointestinal adverse effects: 
Mucositis 
 
Nausea/Vomiting 
 
Diarrhoea  
 
 
 
   
 
 
   
    
Autonomic neurotoxicity  
 
 
    
Dermatology/skin  
 
 
    
Other adverse effects, specify  
1- 
2- 
3- 
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12- Use of G-CSF: 
Did the patient get G-CSF prophylaxis as part of chemotherapy? 
1 yes                     1primary prophylaxis i.e. starting from first cycle 
 
                                    2 secondary prophylaxis i.e. after a prior episode of febrile neutropenia 
 
2 no, move to question 14 
 
13- G-CSF agent used for prophylaxis  
1 Filgrastim, specify dose………………………………………. 
 
2 Pegfilgrastim 
 
14- Did the patient get G-CSF as part of febrile neutropenia treatment: 
1 yes, specify number of days and doses:…………………………………………………………………… 
 
 
2 no 
 
15-Date of relapse (when applicable): 
 
16- If relapsed, other treatment offered?  
1 yes, please specify…………………………………………………………………………………………………… 
                                        ……………………………………………………………………………………………………. 
2 no 
 
 
17- Patient alive at the time of this review  
1 yes, move to question 19 
 
2 no, complete question 18 
 
 
18-Cause of death (when applicable): 
1Lymphoma. 
  
2HIV related 
 
3Other cancer  
 
4Other reason, specify 
   
5Unknown 
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19- Adverse events during chemotherapy relevant to ART therapy: 
Description Onset date Relationship with ART 
 
 
  
 
 
  
 
 
  
 
 
  
Codes for relationship with antiretroviral therapy 
0 unrelated 
 
1 unlikely to be related  
 
2 possibly related 
 
3 probable or definitely related  
 
 
20- Other concomitant medications  (apart from ART) taken during chemotherapy: 
 
Drug name/dose  Indication 
1- 
 
 
2- 
 
 
3- 
 
 
4- 
 
 
5- 
 
 
6- 
 
 
7- 
 
 
8- 
 
 
9- 
 
 
10- 
 
 
 
 
 
 
 
